Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2019

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)
www.gastro.org

* Information contained in this report is current as of April 22, 2019.
AGA Oral Presentations
DURING PROGRESSION OF CHRONIC SYSTEMIC INFLAMMATION, GUT HUMAN PANCREAS LOCALIZES TO THE (18 MONTHS AFTER) Pharmaceuticals (5)

GASTRIC Pharmaceuticals 9

ANALYSIS DEFINES THE... (4*)

MICROBIOTA-DEPENDENT BEHAVIORAL ABNORMALITIES IN THE ZONULIN... (2*)

INTESTINAL MICROBIAL FUNCTIONAL CONTENT BETTER DEFINES... (4*) (2)

THE ICON STUDY: INFLAMMATORY BOWEL DISEASE... (6*) (2)

POPULATION-SCALE MICROBIOME ANALYSIS DEFINES A NEW... (2*)

PREVALENCE AND PREDICTORS OF GERD AND... (3*) (Ironwood Pharmaceuticals)

EFFECT OF RECENTLY DESCRIBED ADVERSE EVENTS... (5*)

THE EFFECT OF REBAMIPIDE IN PATIENTS... (3*) (Korea Otsuka Pharmaceutical Co., Ltd.)

IMPACT OF IW-3718, A NOVEL GASTRIC-RETENTIVE... (3*) (Ironwood Pharmaceuticals)

ANTIREFLUX SURGERY WITHIN SIX MONTHS AFTER... (5*)

PANCREATIC AND HEMATOPOIETIC CALCINEURIN INDEPENDENTLY MEDIATE... (2*)

SOLUTE TRANSPORTER SLC26A9 LOCALIZES TO THE... (2*)

IMMUNE PROFILING OF THE HUMAN PANCREAS... (2*)

DYNAMIC ASSOCIATION OF SYSTEMIC INFLAMMATION, GUT... (2*)

ROLE OF SONIC HEDGEHOG PATHWAY IN... (2*) (5)

KRÜPELL-LIKE FACTOR 5 PLAYS AN IMPORTANT... (4*)

TRANSCRIPTOME ANALYSIS DURING PROGRESSION OF CHRONIC... (4*) (Nil)

EFFICACY AND SAFETY OF URSODEOXYCHOLIC ACID... (3*) (Daewoong Pharmaceutical Co., Ltd.)

CAN CHOLECYSTITIS BE AN ADVERSE EVENT... (5*)

BILIARY DILATATION IN PATIENTS WITH NORMAL... (2*) (4)

TIMING OF CHOLECYSTECTOMY AFTER ACUTE BILIARY... (5*)

UNDERLYING EATING DISORDER PATHOLOGY IN CHRONIC... (5*)

THE EFFECT OF RECREATIONAL MARIJUANA USE... (7*) (2)

TRANSPLUMBOSACRAL NEUROMODULATION THERAPY FOR FECAL INCONTINENCE... (2*)

DEFECATORY FUNCTION TESTING IN FI PATIENTS... (2*)

RESTORATION OF FECAL CONTINENCE IN A... (6*)

NORMAL VALUES FOR ANORECTAL PRESSURES MEASURED... (2*) (Medspira Inc)

ENDOSOMAL SNX17 SETS THE PLASMA MEMBRANE... (2*)

UNIQUE REGULATION OF INTESTINAL EPITHELIAL CELL... (2*)

GLP-2 INCREASES ELECTROGENIC ANION SECRETION AND... (2*) (3) (Shire Pharmaceuticals)

E.COLI HEAT STABLE ENTEROTOXIN (ST) INHIBITION... (2*) (6)

SHIGELLA GASTROENTERITIS TARGETS INTESTINAL URATE TRANSPORTER... (2*)

GLUCOCORTICOIDS AND SGK1-POTENT REGULATORS OF... (2*)

METHYLATION CHANGES AT THE GNAS IMPRINTED... (7*)

ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE BIOPSY HAS... (5*)

AGE, OBESITY, DIABETES AND INITIAL CYST... (5*)

TRIACYLGLYCEROLS AS A MARKER FOR CHARACTERIZATION... (2*)

THE DUTCH AMERICAN RISK STRATIFICATION TOOL... (5*)

TIOPURINE METABOLITE LEVELS IN PREGNANT IBD... (4*) (6)

PREGNANCY OUTCOMES IN INFLAMMATORY BOWEL DISEASE... (5*)

INFLIXIMAB CLEARANCE IS DECREASED DURING 2ND... (1*)

LONG-TERM OUTCOMES OF IN-UTERO EXPOSURE TO... (6*)

SAFETY OF FLEXIBLE SIGMOIDOSCOPY IN PREGNANT... (5*)

SIRT2 REGULATES INTESTINAL CELL PROLIFERATION AND... (2*)

HEAT SHOCK PROTEIN GP96 IS ESSENTIAL... (4*)

MIR-181A-5P CONTRIBUTES TO INTESTINAL CELL DIFFERENTIATION... (2*)

MULTITARGET STOOL DNA TESTING AS ALTERNATIVE... (6*)

POST-COLONOSCOPY MORTALITY IN A FIT BASED COLORECTAL... (2*)

INTERVAL CANCERS AFTER A NEGATIVE FAECAL... (2*)

COMPARING THE COST-EFFECTIVENESS OF NEW COLORECTAL... (2*)

FACTORS ASSOCIATED WITH THE PROGRESSION OF... (7*) (4)

SYSTEMATIC SCREENING PROTOCOL FOR THE STOMACH... (2*)

SERUM PROTEOMIC PROFILING IN ULCERATIVE COLITIS... (4*)

INCREASED INTESTINAL PERMEABILITY IS A PREDICTOR... (6*) (2)

INCREASED RISK OF ULCERATIVE COLITIS IN... (5*)

HORMONE THERAPY FOR CANCER IS A... (6*) (The Chemotherapy Foundation, philanthropic organization)

COLORECTAL CANCER IS AN...

INFLAMMATORY BOWEL DISEASE IN UK PRIMARY... (6*)

LONGITUDINAL CHANGES IN THE DIRECT COSTS... (6*) (Crohn’s and Colitis Cada)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
101. . . . INCREASED EXPRESSION OF MELATONIN IN THE... (2*)
102. . . . PHYSIOLOGICAL AND PROTEOMIC CHARACTERIZATION OF CAMPYLOBACTER... (2*) (NIH K23 DK103911)
103. . . . BENEFICIAL EFFECTS OF A LOCALLY ADMINISTERED... (2*) (4)
104. . . . ASSOCIATIONS BETWEEN FECAL SHORT CHAIN FATTY... (4*)
105. . . . SACCHAROMYCES BOULARDII, A YEAST PROBIOTIC, REGulates... (5*)
106. . . . ALTERED GENDER DIFFERENCE IN BRAIN HISTAMINE... (2*)
107. . . . DISCONTINUITY OF CARE AMONG INFLAMMATORY BOWEL... (5*)
108. . . . THE PREVALENCE AND USE OF CANNABIS... (5*)
109. . . . ORAL VANCOMYCIN INDUCES AND MAINTAINS REMISSION... (5*)
110. . . . STOPPING S-AMINOSALICYLATES IN CROHN'S DISEASE PATIENTS... (6*)
111. . . . INCREASING VACCINATION RATES WITH A PATIENT... (5*)
112. . . . TELEPHONE STRAIGHT-TO-TEST (TSST) IMPROVES EARLY DIAGNOSIS... (5*)
113. . . . HIGHER RESILIENCE IS ASSOCIATED WITH DECREASED... (5*)
114. . . . TISSUE-ENGINEERED INTESTINES CAN NEO-INNERVATE EXPERIMENTALLY DENERVATED... (2*)
115. . . . TRANSCUTANEOUS AURICULAR VAGAL NERVE STIMULATION IMPROVES... (5*)
116. . . . ELECTROGASTROGRAPHY AT BASELINE AND RESPONSE TO... (5*)
117. . . . SYNDAPIN 2 IS REQUIRED FOR MICROVILLUS... (2*)
118. . . . ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE... (2*)
119. . . . RNA-BINDING PROTEIN HUR REGULATES AUTOHAPY ACTIVITY... (2*)
120. . . . MITOCHONDRIAL IMPAIRMENT IN CROHN'S DISEASE-LIKE INFLAMMATION... (2*)
121. . . . HIGH CONTENT MORPHOLOGICAL ANALYSES OF ESOPHAGEAL... (2*) (4)
122. . . . CALPONIN-HOMOLOGY AND MICROTUBULE-ASSOCIATED PROTEIN INTERACTS WITH... (2*)
123. . . . POSTOPERATIVE ENDOSCOPIC AND CLINICAL RECURRENCE AFTER... (6*) (7)
124. . . . INFLAMMATORY POTENTIAL OF DIET IS NOT... (2*)
125. . . . GUT MICROBIAL DYSBIOSIS CONTRIBUTES TO FATIGUE... (6*) (3)
126. . . . SLC7A5 IS CRUCIAL FOR MAINTENANCE OF... (2*)
127. . . . IN-DEPTH CHARACTERIZATION OF HOST-GENETICS AND GUT... (4*) (2)
128. . . . SINGLE-CELL ANALYSIS OF T CELL PATHOGENESIS... (4*)
129. . . . USING DEEPLARNNING AND GENETIC BIGDATA TO... (2*) (6)
130. . . . PRIMARY AND PLURIPOTENT STEM CELL DERIVED... (2*) (4)
131. . . . H. PYLORI INDUCES GASTRIC EPITHELIAL CELL... (2*)
132. . . . CORONIN 1 IS NECESSARY FOR M... (2*)
133. . . . GUT MICROBE-PRODUCED SHORT CHAIN FATTY ACIDS... (2*) (4)
134. . . . PRIMARY AND PLURIPOTENT STEM CELL DERIVED... (2*) (4)
135. . . . H. PYLORI INDUCES GASTRIC EPITHELIAL CELL... (2*)
136. . . . THE INTESTINAL MICROENVIRONMENT INDUCES A TRANSCRIPTION... (4*)
137. . . . LEVERAGING HUMAN INTESTINAL ORGANOIDS TO ADVANCE... (3*) (AbbVie)
138. . . . INHIBITORS (VERAPAMIL AND... (4*)
139. . . . THE MICROBIAL METABOLITE BUTYRATE PROMOTES GOBLET... (2*)
140. . . . COLONIC MESENCHYAL STROMAL CELL MYDB8-MEDIATED SIGNALING... (2*)
141. . . . SURGERY IN VERY EARLY ONSET INFLAMMATORY... (6*)
142. . . . COLLEGE ADJUSTMENT IN IBD STUDENTS: AGE... (3*) (AbbVie Inc.)
143. . . . INCREASED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS... (2*) (6)
144. . . . INCREASED INCIDENCE OF MALIGNANCY IN PATIENTS... (2*) (6)
145. . . . SAFETY AND EFFICACY OF ANTI-TNF THERAPY... (5*)
146. . . . EARLY COMBINED IMMUNOSUPPRESSION IS EFFECTIVE AND... (2*)
147. . . . EARLY INFILXIMAB PHARMACOKINETICS AND WEEK ONE... (6*) (2) (Prometheus Laboratories, Inc.provided study assay.)
148. . . . ADOLESCENTS' AND YOUNG ADULTS' SATISFACTION WITH... (4*)
149. . . . GEOGRAPHIC ANALYSIS OF PEDIATRIC INFLAMMATORY BOWEL... (5*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
ASSOCIATED WITH INTACTNESS OF INTEGRITY OF PROSPECTIVE THERMOGENESIS IN BROWN ADIPOSE TISSUE DURING EARLY LIFE AND SYMPTOM ANXIETY ARE... *(2)*

ENDOSCOPIST-RELATED FACTORS INFLUENCING POLYPS DETECTION RATE... *(5)* *(The first author completed this research during a Newman Fellowship programme, sponsored by Boston Scientific)*

A PROSPECTIVE RANDOMIZED TANDEM COLONOSCOPY STUDY... *(4)* *(Nil)*

THE POLYP-BASED RESECTION AND DISCARD STRATEGY: A PROSPECTIVE... *(5)*

VALIDATION OF BLUE LIGHT IMAGING (BLI)... *(5)*

ARTIFICIAL INTELLIGENCE IMAGE CLASSIFIER BASED ON... *(4)*

ARTIFICIAL INTELLIGENCE FOR REAL-TIME MULTIPLE POLYP... *(5)*

HIGHER ABUNDANCE OF BILE ACID-METABOLIZING MICROBIOTA... *(5)*

INTEGRATED METABOLOMIC AND MICROBIOME APPROACH REVEALED... *(6)*

INCREASED BACTERIOPHAGE ABUNDANCE AND LOSS OF... *(2)* *(4)*

IDENTIFICATION OF PATHOGENIC BACTERIA IN SEVERE... *(2)*

PROTEUS IS A KEY CANDIDATE IN... *(6)*

DIETARY SERINE REGULATE THE INTEGRITY OF... *(2)* *(4)*

GUT MICROBIOTA PROFILING IN A PROSPECTIVE... *(4)*

DIETARY EMULSIFIERS REDUCE THERMOGENESIS IN BROWN... *(2)*

NEUROTENSIN (NT)-α-DEFENSINS AXIS MEDIATES THE INFLUENCE... *(2)*

DIETARY INTERVENTIONS AMELIORATE INFECTIOUS COLITIS THROUGH... *(2)*

EXCLUSIVE ENTERAL NUTRITION (EEN) AND CROHN’S... *(2)* *(3)*

GUT MICROBIOTA MATURATION DURING EARLY LIFE... *(2)* *(4)*

COLONIC EOSINOPHILIA IS ASSOCIATED WITH CURRENT... *(4)*

ESOPHAGEAL HYPERVIGILANCE AND SYMPTOM ANXIETY ARE... *(2)*

MANAGEMENT OF SUPRAGASTRIC BELCHING WITH COGNITIVE... *(1)*

AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER AMONG ADULT... *(5)*

A MULTIDISCIPLINARY INTEGRATED TREATMENT APPROACH IS... *(2)*

VARIATION IN ADENOMA DETECTION RATE AND... *(2)*

DETERMINATION OF BENCHMARKS FOR SERRATED POLYP... *(5)*

EFFICACY AND SAFETY OF HOT AND... *(5)*

RAPID DEVELOPMENT OF FELLOWS’ COGNITIVE AND... *(5)*

SIMULATION BASED TRAINING IMPROVES CONFIDENCE LEVELS... *(5)*

VALIDATION OF A NATURAL LANGUAGE PROCESSING... *(2)*

INHIBITORY SMAD6 REDuces SOX9 EXPRESSION IN... *(2)*

ROLE OF ENDOGENOUS AND EXOGENOUS CARBON... *(4)* *(Jagiellonian University Medical College, Faculty of Medicine, statutory grant No. 007716)*

EXPOSURE OF BARRETT’S AND ESOPHAGEAL ADENOCARCINOMA... *(2)* *(4)*

THE ROLE OF STEGAL-I, A GLYCOSYLTRANSFERASE... *(4)* *(2)*

TRANSGENIC MOUSE MODEL BASED ON VSG110L... *(2)*

DEEP LEARNING ALGORITHM FOR CHARACTERIZATION OF... *(5)*

ARTIFICIAL INTELLIGENCE FOR DETECTING GASTRIC CANCER... *(5)*

VIDEO VALIDATION OF SMALL BOWEL CONVOLUTATIONAL... *(5)*

DIFFERENTIATION BETWEEN PANCREATIC CANCER AND NORMAL... *(2)*

CROHN’S DISEASE EXCLUSION DIET IS EQUALLY... *(2)* *(3)* *(Nestlé Health Sciences)*

EARLY CHANGE IN FECAL CALPROTECTIN PREDICTS... *(2)* *(4)*

EFFECT OF A PRACTICE-WIDE ANTI-TNF THERAPEUTIC... *(2)* *(4)*

NEW KEY PLAYERS IN IMPAIRED ANGIOGENESIS... *(2)*

GENERATION OF STRATIFIED ESOPHAGEAL EPITHELium FROM... *(6)*

CELLS LINEAGE TRACED FROM LGR5+ CELLS... *(2)*

PROTEOMIC ANALYSIS OF INTESTINAL BRUSH BORDER... *(2)*

TEDUGLUTIDE IN A REAL WORLD SETTING... *(5)*

A NOVEL R-SPOUNDIN 1/POMC NEUROCIRCUIT IN... *(2)*

PREVENTION OF RECURRENT IDIOPATHIC GASTRODUODENAL ULCER... *(2)*

RIVAROXYBAN IS ASSOCIATED WITH HIGHER RATES... *(1)*

FAK ACTIVATORS PROMOTE INTESTINAL MUCOSAL HEALING... *(5)*

PRECLINICAL DRUG EVALUATION REVEALS INHIBITION OF... *(2)*

TNFAIP8 IS A CRITICAL REGULATOR OF... *(2)*

PHARMACOLOGICAL INHIBITION OF THE APICAL SODIUM-DEPENDENT... *(2)*

THE LONG NON-CODING RNA, IFNG-AS1/NEST, IS... *(6)* *(4)*

TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES... *(2)* *(6)*

TREM1, THE FIRST ANTI-TNF SPECIFIC BIOMARKER... *(4)*

DEVELOPMENT AND VALIDATION OF A CLINICAL... *(3)* *(Takeda Pharmaceuticals U.S.A., Inc.)*

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
335. . . VEDOLIZUMAB TARGETS LYMPHOID AGGREGATES IN THE... (2*1)[3]|) (Takeda Pharmaceuticals)
336. . . USING DEEP LEARNING FOR AUTOMATED GRADING... (2*)
337. . . COMPLETE HISTOLOGIC NORMALIZATION IS ASSOCIATED WITH... (5*)
338. . . LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS... (5*)
347. . . IS SUCROSE THE SIXTH FODMAP IN... (4*)
348. . . BMI RATHER THAN SYMPTOMS IS ASSOCIATED... (5*)
349. . . BASELINE GLP-1 LEVEL CORRELATES WITH DEGREE... (5*)
350. . . GWAS-IDENTIFIED METABOLIC SYNDROME GENES ARE TIGHTLY... (2*1)[3] (Pathway Genomics)
357. . . PROSPECTIVE EVALUATION OF A NOVEL, ENDOSCOPIC... (2*)[(6]
358. . . CLOSE FOLLOW-UP IS ASSOCIATED WITH FEWER... (2*)
359. . . EOSINOPHILIC ESOPHAGITIS-LIKE DISEASE WITH LACK OF... (2*)
360. . . ORAL VISCUOUS Budesonide VERSUS SWALLOWED FLUTICASONE... (2*)
361. . . FUNCTIONAL LUMINAL IMAGING PROBE PROVIDES AN... (6*)[1)(2]
362. . . IBD EPIDEMIOLOGY: WHAT IS GOING ON... (5*)
363. . . DOES RIFAXIMIN OFFER ANY PROMISE IN... (5*)
364. . . EARLY USE OF AZATHIOPRINE ASSOCIATED WITH... (5*)
365. . . EFFICACY AND SAFETY OF INFliximab RETREATMENT... (5*)
366. . . SURVEILLANCE COLONOSCOPIES IN ULCERATIVE COLITIS: DOES... (4*)
367. . . VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY... (3*1)(SetPoint Medical)
369. . . TARGETED DELETION OF THE ATP-BINDING CASSETTE... (2*)
370. . . PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
371. . . USING A MACHINE LEARNING PROGRAM -... (2*)
372. . . ELMO1, A MICROBIAL SENSOR, REGULATES BACTERIAL... (2*)
373. . . ROLE OF SURFACE POLYSACCHARIDES OF ADHERENT- INVASIVE... (6*)
374. . . MICRONRNA-125A PROTECTS INTESTINAL MUCOSAL INFLAMMATION THROUGH... (2*)[The tio ral Science Foundation of Chi (81630017)]
375. . . HELMINTH EXPOSURE ALTERS TH17 SUBPOPULATION PLASTICITY... (2*)
377. . . PROTECTIVE AND POTENTIALLY AGGRESSIVE BACTERIAL SPECIES... (2*)
401. . . EFFICACY AND SAFETY OF COMBINED CCP-1X/SULINDAC... (3*1)(Cancer Prevention Pharmaceuticals, Inc.)
414. . . A ROLE FOR THE STOMACH IN... (4*)
415. . . COMBINED BLOCKADE OF α4β7 AND 8β7... (3*1)(Genentech Inc., South San Francisco, CA)
416. . . THE ORAL α4β7 INTEGRIN SPECIFIC ANTAGONIST... (3*1)(Protagonist Therapeutics, Inc.)
417. . . FUNCTIONAL CHARACTERIZATION OF ENTEROCHROMAFFIN CELLS USING... (2*)
418. . . DEFECTIVE CFTR FUNCTION IN PANCREATIC DUCTAL... (4*)[1)(2]
419. . . LACTOBACILLUS REUTERI SECRETES γ-GLUTAMYLGLYCINE TO SUPPRESS... (2*)
421. . . PATHOLOGICAL ACTIVATION OF PIEZO1 IS THE... (2*)
422. . . EPITHELIAL IDO1 MODULATES AHR AND NOTCH... (2*)[6]
423. . . IDENTIFYING THE MOST COST-EFFECTIVE TREATMENT ALGORITHM... (5*)
424. . . A PROSPECTIVE, LONGITUDINAL STUDY OF METABOLOMIC... (2*)
425. . . DURABLE TRANSFER OF CANDIDATE PROCARCINOGENIC BACTERIA... (2*)
426. . . MARKED ALTERATIONS IN THE FECAL VIROME... (4*)
427. . . FECAL MICROBIOTA TRANSPLANTATION REGULATES CIRCULATING MICRONNA... (4*)
428. . . SOLUTE CARRIER FAMILY 26 MEMBER 3... (3*1)[2][Funding: Merck & Company sponsored this study. HWK was supported by NIH R03 DK103964 grant. CP was supported by NIH U01 DK110003-01 and P30 DK 43101-26.]
429. . . AUTOIMMUNE ANTIBODIES AND SYMPTOMS OF AUTOIMMUNE... (2*)
430. . . A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF... (3*)[1](Lyrical Pharmaceuticals, South San Francisco, CA, USA)
431. . . ACTIVATION OF Nrf2 ATTENUATES DELAYED GASTRIC... (2*)
432. . . PROTEOMICS IN GASTROPARESIS: UNIQUE AND OVERLAPPING... (2*)[Study funded by NIDDK grants: U01DK112193, U01DK112194, U01DK073983, U01DK073975, U01DK074035, U01DK074007, U01DK073974, U24DK074008)
433. . . LOSS OF CX3CR1-POSITIVE GASTRIC MUSCULARIS MACROPHAGES... (2*)
434. . . CHARACTERIZATION OF PYLORIC TONIC AND PHASIC... (5*)
435. . . DUAL THERAPY WITH ESOMEPRAZOLE AND AMOXICILLIN... (2*1)[3][This study was funded by ‘12th Five-Year’ tio Science and Technology Support Plan project (2012BAI06802) and AstraZeneca Investment (Ch) Co., Ltd.)
436. . . THE Efficacy OF FOURTEEN-DAYS ESOMEPRAZOLE AND... (4*)
437. . . AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, SUPERIORITY TRIAL... (5*)
438. . . HISTOLOGICAL GASTRITIS IN A COMMUNITY POPULATION... (3*1)[The study was supported by Olympus Sverige AB (Box 1816, 171 23 Sol, Sweden), who supplied study equipment.)
439. . . RESIDUAL RISK OF GASTRIC CANCER FOLLOWING... (5*)
440. . . ROBUSTNESS OF ELUXADOLINE FOR THE TREATMENT... (3*1)[This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
441. . . PSYCHOLOGICAL FACTORS HAVE A VARYING EFFECT... (6*)

442. . . SAFETY PROFILE OF ELUXADOLINE IN PATIENTS... (3*) (This study was supported by Allergan plc, Dublin, Ireland. Writing assistance by Complete HealthVizion, Inc., Chicago, IL, USA with funding by Allergan plc, Dublin, Ireland.)

443. . . INTESTINAL BIOFILMS ARE AN ENDOSCOPIC FEATURE... (2*)

444. . . RIFAXIMIN FOR IMPROVING ABDOMINAL PAIN AND... (3*) ( Funded by Salix Pharmaceuticals.)

445. . . NT-NTR1 SIGNALING POSITIVELY REGULATES INTESTINAL FATTY... (2*)

446. . . MODULATION OF BILE ACIDS PATHWAY IN... (2*) (Fund and product provided by Satiogen Pharmaceuticals.)

447. . . DIFFERENCES IN PREVALENCE OF METABOLIC CONDITIONS... (5*)

448. . . CHOLECYSTECTOMY ALTERS GASTROINTESTINAL HEALTH INDICES AND... (4*)

449. . . HIGH FAT KETOCARD DIET DECREASES SERUM... (4*)

450. . . EFFECT OF FARNESOID X RECEPTOR ACTIVATION... (2*)

451. . . FUNCTIONAL GENOMIC SCREENING USING CRISPR/CAS9 IDENTIFIES... (4*)

452. . . TRIM67 PREVENTS COLORECTAL TUMORIGENESIS IN MICE BY... (2*)

453. . . THERAPEUTIC DOSE OF PELVIC RADIATION SLOWS... (2*)

454. . . PD-L1 EXPRESSION REGULATES TUMOR CELL APOPTOSIS... (2*) (4)

455. . . DIFFERENTIAL POST-TRANSLATIONAL MODIFICATION OF POLYMORPHIC MSH3... (2*) (4)

456. . . DCLK1 MONOCLONAL ANTIBODY-BASED CAR-T CELLS AS... (2*)

457. . . ON DEMAND VS CONTINUOUS USE OF... (4*)

458. . . SUCCESSFUL REDUCTION OF OVERALL AND INAPPROPRIATE... (5*)

459. . . TRENDS IN PRESCRIBING OF ACID-REDUCING THERAPIES... (1*)

460. . . EFFECTS OF PROTON-PUMP INHIBITORS IN PATIENTS... (5*)

461. . . ANOTHER FALSE ALARM: NO GOOD EVIDENCE... (5*)

462. . . CIRCULATING EXTRACELLULAR VESICLES AND SPHINGOLIPIDS CARGO... (2*)

463. . . SIGNIFICANTLY WORSE FUNCTIONAL STATUS AT TIME... (5*)

464. . . SIGNIFICANT INCREASES IN ALCOHOL CIRRHOSIS RELATED... (5*)

465. . . INFLAMMATION-INDUCED LOSS OF SPROUTY2 IN THE... (2*) (6) (NIH R01DK95004 (MRF) Crohn’s & Colitis Foundation Career Development Award (MAS))

509. . . WOMEN GASTROENTEROLOGISTS ARE UNDERREPRESENTED IN RECOGNITION... (5*)

510. . . STRATEGIES TO ACCOUNT FOR COLONOSCOPY VOLUME... (6*)

511. . . ENDOSCOPIC HISTORY POTENTIALLY EXPLAINS SURVIVAL DIFFERENCES... (4*)

512. . . DONOR HEALTH SCREENING FOR FECAL MICROBIOTA... (5*)

513. . . MORTALITY IN MICROSCOPIC COLITIS - RESULTS... (5*)

514. . . BEVERAGE INTAKE AND THE INCIDENCE OF... (2*)

515. . . COLONOSCOPY AFTER HOLIDAYS IS AN INDEPENDENT... (5*)

516. . . RACIAL DISPARITIES IN THE CARE OF... (4*)

517. . . RACIAL AND ETHNIC TRENDS IN ESOPHAGEAL... (5*)

518. . . RACIAL DISPARITIES IN RATES OF SURGERY... (5*)

519. . . THE AGE TO STOP ENDOSCOPIC SURVEILLANCE... (2*)

520. . . OVERUSE OF SURVEILLANCE ENDOSCOPY FOR BARRETT’S... (2*)

521. . . NUMBER OF SESSIONS TO ACHIEVE COMPLETE... (7*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
568. . . . HIGHER INFlixIMAB AND
ADAlUMIMAB TROUGH LEVELS... (5*)
569. . . . ADAlUMIMAB FOR PATIENTS
WITH CroHN’S DISEASE... (3*) (AbBvie)
570. . . . EARLY ENDOscopic RETROGRADE
CHOLANGIOGRAPHY WITH BILIARY...
(2*) (4)
571. . . . THE PREDICTIVE EFFECT OF A
HIGH-QUALITY... (5*)
574. . . . EFFICACY AND SAFETY OF
RIFAXIMIN TREATMENT... (3*) (Fundied by
Salix Pharmaceuticals.)
575. . . . EFFECT OF THROMBOPOIETIN
RECEPTOR AGONIST IS... (5*)
576. . . . BALLOON-OCCCLUDED
RETROGRADE TRANSVENOUS
OB LITERATION (BRT0) VERSUS... (5*)
577. . . . PENTADECAPEPTIDE BPC 157
THERAPY IN BILE... (4*)
578. . . . COMPLICATIONS ASSOCIATED
WITH ANESTHESIA SERVICES IN...
(2*)
579. . . . QUALITATIVE DERIVATION AND
QUANTITATIVE PREDICTION OF...
(7*)
580. . . . HIGH DIAGNOSTIC YIELD USING
ADVANCED ARTIFICIAL... (5*)
581. . . . DERIVATION AND VALIDATION OF
QUANTITATIVE PARAMETERS... (7*)
582. . . . SEQUENTIAL DIAGNOSIS OF LIVER
METASTASIS FROM... (5*)
583. . . . DEVELOPMENT, VALIDATION OF A
POST-ERC P PANCREATITIS... (5*)
584. . . . ENDOscopic ULTRASOUND-
GUIDED TREATMENT OF GASTRIC
VARICES... (5*)
585. . . . UTILITY OF SYMPTOM SEVERITY,
FREQUENCY, AND... (3*) (The original study
was funded by Alvine Pharmaceuticals. The
data was then acquired by ImmunogenX.
This is a post hoc alysis of the lead in data
from that trial and shared with us from
ImmunogenX. No funding for this current
post hoc alysis was used from t)
586. . . . REAL LIFE PATTERNS OF GLUTEN-
FREE DIET... (5*)
587. . . . A THEORY-BASED, BEHAVIORALLY
FOCUSED COOKING INTERVENTION... (4*)
588. . . . IDENTIFICATION OF
IMMUNOTOXIC PEPTIDES FROM DIETARY...
(2*) (4)
589. . . . EFFECT OF BIFIDOBACTERIUM
INFANTIS NSL SUPER... (5*)
600. . . . CONCORDANCE OF BULB AND
DISTAL DUODENAL... (5*)
601. . . . THE EFFECT OF ESOMEPRAZOLE
ON THE... (2*) (tural Science Fund of Chi
(U1702281 and 81670551))
602. . . . THROMBOEMBOLIC EVENTS IN
ACUTE PANCREATITIS... (5*)
603. . . . NATURAL HISTORY OF LOW
OUTPUT EXTERNAL... (5*)
604. . . . IMPACT OF STATIN USE ON
CLINICAL... (5*)
605. . . . THE CLINICAL COURSE AND
DIAGNOSTIC WORK-UP... (5*)
606. . . . CLINICAL FEATURES OF
HYPERTRIGLYCERIDEMIA-INDUCED ACUTE
PANCREATITIS... (5*)
607. . . . DYNAMIC ANALYSIS OF PATIENTS
WITH ACUTE... (3*) (This was not a funded
study but it was performed in part by Ariel
Precision Medicine, a commercial entity.
We performed a cohort alysis that was
agreed upon a priori by the investigators as
a collaboration.)
608. . . . PAIN MODULATORY PHENOTYPES
DIFFERENTIATE CHRONIC PANCREATITIS...
(7*)
609. . . . RESULTS FROM A MULTICENTER,
PHASE II,... (3*)
610. . . . CHRONIC PANCREATITIS IS
ASSOCIATED WITH INCREASED... (5*)
611. . . . A NOVEL METHOD FOR
ASSESSMENT AND... (7*)
612. . . . PANCREATIC ATROPHY DOES NOT
CORRELATE WITH... (5*)
613. . . . PANCREATIC CANCER INCIDENCE
IN A LARGE... (7*)
614. . . . PAIN “BURN-OUT” DURING THE
NATURAL COURSE... (2*)
615. . . . ACCELERATED ONSET OF
SPONTANEOUS PROXIMAL COLONIC...
(2*)
616. . . . LOSS OF GLUTATHIONE
PEROXIDASE 1 PROTECS... (2*)
617. . . . SIMULTANEOUS LOSS OF BOTH
ATYPICAL PROTEIN... (2*) (7)
618. . . . ROLE OF LGRS IN DCLK1+ CELL-
DERIVED... (7*) (4)
619. . . . MYELOID CALCINEURIN IN THE
CONTROL OF... (4*)
620. . . . NEUTROPHILS RESTRICT TUMOR-
ASSOCIATED MICROBIOTA TO DAMPEN...
(2*)
621. . . . FECAL MICROBIOTA
TRANSPLANTATION FOR THE
TREATMENT... (3*) (4) (This study was an
Investigator Initiated Study funded by Finch
Therapeutics.)
622. . . . DOUBLE-BLIND RANDOMIZED
PLACEBO-CONTROLLED TRIAL OF WEEKLY...
(3*) (2) (SERES THERAPEUTICS NIH Grant
P30 DK40561 Massachusetts General
Hospital Claflin Distinguished Scholar
Award)
623. . . . SER-287, AN INVESTIGATIONAL
MICROBIOME THERAPEUTIC, INDUCES...
(3*) (Seres Therapeutics)
624. . . . COMPARISON OF TWO OPEN-
LABEL TRIALS DEMONSTRATES...
(3*) (This alysis was funded by Rebiotix Inc.,
Roseville, MN, USA.)
625. . . . DONOR FUNGI AND BACTERIA
ENCEMATTER AFTER... (4*)
626. . . . GUT MICROBIOTA FROM
COLORECTAL CANCER PATIENTS... (2*)
627. . . . DYSREGULATION OF EPITHELIAL
TLR4 SELECTS FOR... (2*) (6)
628. . . . IDENTIFICATION OF CROSSTALK
BETWEEN GUT MICROBIOTA..., (2*)
629. . . . COLORECTAL CANCER-
ASSOCIATED BACTERIA INDUCE TH1 AND...
(6*)
630. . . . GUT MICROBIOTA MODULATES
THE CHEMOPREVENTIVE EFFICACY... (2*)
631. . . . DIETARY INTAKE, H2S-PRODUCING
MICROBES, AND RISK... (2*) (6)
632. . . . DEVELOPMENT OF A NOVEL
MINRA-BASED SIGNATURE... (5*)
633. . . . GA-68 DOTATATE PET IN GASTRO-
ENTERO-PANCREATIC NEOENDOCRINE...
(5*)
635. . . . THE UTILITY OF COMPUTED
TOMOGRAPHY (CT)... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
636. . . DUODENAL NEUROENDOCRINE TUMORS EXHIBIT DISTINCT SOMATIC... (2*)

637. . . DELINEATION OF THE PATHOGENESIS OF MESENTERIC... (4*)

649. . . ECONOMIC BURDEN OF CELIAC DISEASE IN... (3*)[(Takeda Pharmaceuticals Intertiol Co.)

650. . . PREVALENCE OF CELIAC DISEASE AUTOIMMUNITY AND... (5*)

651. . . INTERNATIONAL STUDY GROUP OF PEDIATRIC PANCREATITIS... (2*)

652. . . CLINICAL OUTCOMES IN AUSTRALIAN CHILDREN WITH... (5*)

653. . . EXTENSIVE GENE TESTING AND GENETIC INVOLVEMENT... (2*)[(Conflicts of Interests: Dr. C. Alexander Valencia worked at Cincinti Children’s when the study was conducted, he currently works at PerkinElmer genomics, Pittsburgh, PA, and this company has not provided any fincial support for the study. Dr. Abu-El-Hal)]

654. . . THE STOOL MICROBIOME MAY PREDICT OUTCOMES... (6*)[(4)]

655. . . STANDARDIZING THE CARE OF ACUTE SEVERE... (5*)

656. . . MULTI-SYSTEM APPROACH TO DECREASING PROTON PUMP... (POSTER PRESENTATION)... (5*)

657. . . FENTANYL WASTE WAS REDUCED BY CONSERVATION... (POSTER PRESENTATION)... (5*)

658. . . IMPROVING FIRST-CASE START DELAYS IN A... (POSTER PRESENTATION)... (5*)

659. . . NEW PATIENT ACCESS IN A GASTROENTEROLOGY... (POSTER PRESENTATION)... (5*)

660. . . IMPROVING VACCINATION ADHERENCE IN INFLAMMATORY BOWEL... (POSTER PRESENTATION)... (2*)[(7)]

661. . . USE OF A SIMPLE 6-ITEM QUESTIONNAIRE... (POSTER PRESENTATION)... (5*)

662. . . QUALITY GAPS IN PREVENTATIVE CARE PROVIDED... (POSTER PRESENTATION)... (5*)

663. . . LET’S MAKE YOUR CLINIC VISIT A LITTLE SIMPLER - DEVELOPMENT OF A QUESTION... (POSTER PRESENTATION)... (5*)

664. . . HEPATOCELLULAR CARCINOMA SCREENING RATES IN A... (POSTER PRESENTATION)... (5*)

665. . . EVALUATING THE IMPACT OF A NOVEL... (POSTER PRESENTATION)... (5*)

666. . . THE IMPACT OF DELAY BETWEEN BIOLOGIC... (POSTER PRESENTATION)... (5*)

667. . . OPTIMIZING OUTPATIENT COLORRECTAL CANCER SCREENING AND... (POSTER PRESENTATION)... (5*)

668. . . RATE OF INAPPROPRIATE FIT TESTING AT... (POSTER PRESENTATION)... (5*)

669. . . PROACTIVE MANAGEMENT OF IRON DEFICIENCY AND... (POSTER PRESENTATION)... (5*)

670. . . UTILIZING A TIME SERIES STUDY TO... (POSTER PRESENTATION)... (5*)

671. . . IMPLEMENTATION OF AN ACUTE CARE CLINICAL... (POSTER PRESENTATION)... (5*)

672. . . HEMATOMECHEIA DECREASES USE OF VENOUS THROMBOEMBOLISM... (POSTER PRESENTATION)... (5*)

673. . . STANDARDIZING INPATIENT BOWEL PREPARATION ORDERS IMPROVES... (POSTER PRESENTATION)... (5*)

674. . . PATIENTS’ SELF-IDENTIFIED STOOL COLOR IS COMPARABLE... (POSTER PRESENTATION)... (5*)

675. . . REDUCING INAPPROPRIATE FECAL IMMUNOHISTOCHEMICAL TEST (FIT)... (POSTER PRESENTATION)... (5*)

676. . . ENDOCSID MANAGEMENT OF ACHALASIA: TIME FOR... (POSTER PRESENTATION)... (5*)

677. . . ESOPHAGEAL MANOMETRY STANDARDIZATION - A COMMUNITY... (POSTER PRESENTATION)... (5*)

678. . . IMPACT OF GUIDED RELAXATION AND MUSIC... (POSTER PRESENTATION)... (5*)

679. . . DISCREPANCY BETWEEN SELF-REPORTED PREFERENCES ON POLYPECTOMY... (POSTER PRESENTATION)... (5*)

680. . . RISK OF METACHRONOUS COLORRECTAL CANCER AMONG... (4*)

681. . . LONG-TERM RISK OF COLORRECTAL CANCER AFTER... (2*)

682. . . BASELINE FINDINGS ON SCREENING COLONOSCOPY IN... (2*)

683. . . RISK OF COLORRECTAL CANCER AND RELATED-MORTALITY... (2*)[(7)]

684. . . COMPLICATIONS OF SCREENING COLONOSCOPY IN A... (2*)

685. . . INCREASING PHYSICIAN ADENOMA DETECTION RATE IS... (2*)

686. . . ESCHERICHA COLI HEAT-STABLE TOXIN IMPAIRS COLORONIC... (2*)

687. . . ATYPICAL PKC¢ ACTIVITY AND RECRUITMENT TO... (2*)

688. . . THE IBD CANDIDATE GENE, PTPN2, REGULATES... (2*)[(6)]

689. . . TTC7A-DEFICIENCT HUMAN COLORONIC ENTEROIDS EXHIBIT ALTERED... (4*)

690. . . TEDUGLUTIDE INCREASES ADAPTATION IN A MURINE... (3*)[(4)][(Shire, Lexington, USA - Investigator Initiated Research Grant)]

691. . . INTESTINAL PERMEABILITY IS AN IMPORTANT FACTOR... (2*)

692. . . DISTINCTIVE SUBPOPULATION OF INNATE LYMPHOID CELLS... (5*)

693. . . HUMAN MONOCYTES ENHANCE INTESTINAL STEM CELL... (2*)

694. . . SEMAPHORIN-3E REGULATES APOPTOSIS DURING THE DEVELOPMENT... (7*)

695. . . DIETARY INTAKE OF WALNUT TO MITIGATE... (4*)

696. . . MOLECULAR CHARACTERIZATION OF MOUSE MODELS OF... (5*)

697. . . TYPE 2 CYTOKINES PROMOTE HYPERPLASIA AND... (2*)

698. . . PREOPERATIVE SERUM VEDOLIZUMAB LEVELS DO NOT... (5*)

699. . . PRE-OPERATIVE BIOLOGICS SIGNIFICANTLY REDUCE POST-OPERATIVE LEAKS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
706. . . . A PROMINENT ROLE FOR CHEMOKINES, IN... (2*)

707. . . . RISK OF VENOUS THROMBOEMBOLISM ACCORDING TO... (5*)

708. . . . A SIGNIFICANT DECREASE IN THE RATE... [6]*

709. . . . COLECTOMY RATES ARE SIGNIFICANTLY HIGHER AMONG... (4*)

710. . . . FUNCTIONAL LUMINAL IMAGING PROBE (FLIP) ASSESSMENT... (2*)

711. . . . FUNCTIONAL GASTROINTESTINAL DISORDERS AND BEHAVIORAL PROBLEMS... (5*)

712. . . . LONG-TERM OUTCOMES OF GASTRIC ELECTRICAL STIMULATION... (5*)

713. . . . SIGNIFICANT VARIANTS IN MONOGENIC INFLAMMATORY BOWEL... (6*)

714. . . . MUTATIONS IN X-LINKED INHIBITOR OF APOPTOSIS... (2*) (4)

715. . . . CYSTEIN/GLUTAMATE ANTIPORTER (XCT) IS REQUIRED FOR... (2*)

716. . . . ROLE OF CELL CYCLE INHIBITOR P21WAF1/CIP1... (2*)

717. . . . EXOGENOUS STIFFNESS RESULTS IN NUCLEAR TRANSLLOCATION... (4*) (7)

718. . . . LOSS OF TGF-β SIGNALING PROMOTES PROLIFERATION... (2*) (4)

719. . . . NCX1/CA SIGNAL PATHWAY CONTRIBUTES TO THE... (2*)

720. . . . USE OF NON-ASPIRIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS... (5*)

721. . . . INNOVATIVE SYSTEM FOR SELECTIVE ERADICATION OF... (5*)

722. . . . QUANTIFYING EVOLUTION OF EARLY DYSPLASTIC LESIONS... (2*) (6)

723. . . . PATIENT-MATCHED STEM CELLS OF THE BARRETT’S-DYSPLASIA-ADENOCARCINOMA... (2*)

724. . . . LONG-TERM PROTON PUMP INHIBITOR USE AND... (3*) [Investigator initiated research grant from Pfizer]

725. . . . VELUSETRAG IMPROVES GASTOPARESIS BOTH IN SYMPTOMS... (7*)

(3*) (Theravance Biopharma R&D, Inc. Alfasigma S.P.A.)

814. . . . HELICOBACTER PYLORI INDUCES ABBRENT LRG1 STEM... (2*)

815. . . . LONG-TERM CHANGES OF GUT MICROBIOTA, ANTIMICROBIAL... (2*) (4)

816. . . . EFFECTS OF ANTIHELICOBACTER PYLORI THERAPY ON... (2*) (4)

817. . . . EFFICACY OF 1-FOOD AND 4-FOOD ELIMINATION... (2*) (4)

818. . . . CYTOKINE EXPRESSSion ILLUSTRATES HETEROGENEITY OF ACTIV... (2*) (6)

819. . . . METABOLISM OF WHEAT AMYLASE TRYPSIN INHIBITORS... (2*)

820. . . . PROSPECTIVE LONGITUDINAL GUT METAGENOMIC ANALYSIS SUGGESTS... (2*)

821. . . . A RANDOMIZED, PLACEBO-CONTROLLED EVALUATION OF THE... (3*) (ImmunsanT, Inc.)

822. . . . FURTHER DEVELOPMENT OF A NOVEL IN... (4*)

823. . . . BENEFITS AND BARRIERS OF A HANDHELD... (2*) (Nima Labs supplied 30 Nima devices (the capsules were purchased separately by the above-acknowledged grant support). Nima labs was not privy to the study design, results, or composition of the abstract.)

824. . . . ACUTE GLUTEN-INDUCED SYMPTOMS IN CELIAC DISEASE... (3*) (ImmunsanT, Inc.)

825. . . . AN ACUTE RISE IN SERUM IL-2... (6*) (4) (Nestle Research Center/Society for the Study of Celiac Disease)

826. . . . POLYGENIC RISK SCORE, FAMILY HISTORY, AND... (2*)

827. . . . OPTIMAL TIMING OF TOTAL GASTRECTOMY TO... (5*)

828. . . . WHAT’S MY RISK OF CANCER DOCTOR?... (3*)

829. . . . THE IDENTIFICATION OF DNA MISMATCH REPAIR... (2*) (4)

830. . . . SCREENING UPPER ENDOSCOPY IS USEFUL FOR... (5*)

831. . . . AN EVALUATION OF THE RISKS AND... (5*)

832. . . . DASHBOARD DRIVEN DOSING OF INFILXIMAB IS... (5*)
833. . . Efficacy and Safety of Ustekinumab in Ulcerative Colitis (UC) (3*) ([This study was funded by Janssen Research & Development, LLC])

834. . . withdrawal of thiopurines in Crohn’s disease (2*) ([Grant from the Ministry of Health, Labour and Welfare of Japan (“Investigation and research for intractable inflammatory bowel disease”).)]

835. . . long-term safety of vedoluzumab in ulcerative colitis (UC) (3*) (Takeda)

836. . . ImmunoLogic Predictors of Response to Vedoluzumab (UC) (3*) ([The study was supported by Takeda (ISRS-2014-100922)]).

837. . . pilot study of early screening in... (4*)

838. . . Is 45 the new 50? Adenoma... (5*)

839. . . Disparities in colorectal cancer screening: The... (5*)

840. . . colorectal cancer screening among Hispanics in... (4*)

841. . . Patient-directed messaging to increase colorectal cancer... (5*)

842. . . Sequential or active choice for colorectal... (2*)

843. . . Impact of mailed outreach and inreach... (2*)

844. . . Identification of putative cancer stem cells... (5*)

845. . . Genomewide transcriptomic profiling identifies a novel... (4*)

847. . . Mir130b expressed by Slfn4+ mdscs stimulates epithelial... (2*)

848. . . loss of human epithidymis protein (HE4)... (2*) (3)

849. . . loss of SLC26A9 results in the... (2*)

850. . . induction of double strand breaks (dsb)... (2*) (4)

851. . . zinc finger protein 545 suppresses colorectal... (2*)

852. . . overexpression of rage and its ligands... (2*) (4)

853. . . Cholangiocarcinoma (CCA) derived extracellular vesicles reprogram... (7*) (4)

855. . . SLC25A22 drives oncometabolite succinate to promote... (2*)

856. . . assessment of the impact of introducing... (5*)

857. . . medication utilization and satisfaction in irritable... (5*)

858. . . therapeutic response to small intestinal bacterial... (5*)

859. . . identification of bile acid diarrhea in... (4*)

860. . . low FODMAP diet in the long... (5*)

861. . . effect of ketotifen on abdominal symptoms... (2*)

862. . . intestinal acidification sensed by pH-sensing receptor... (4*)

863. . . induction of autophagy in CX3CR1+ mononuclear... (2*) (4)

864. . . platelets and their interaction with primary... (4*)

865. . . circulating fibrocytes are increased in patients... (2*)

866. . . orally active elafin-eudragit inhibits colitis-associated intestinal... (2*) (6)

867. . . the Bcl-2 inhibitor ABT-263 attenuates intestinal... (3*) (Abbvie)

868. . . the role of nuclear factor NFIB-mediated... (5*)

870. . . plasma biomarkers of insulin and the... (2*)

871. . . transcriptional signatures of western-style and prudent... (4*)

872. . . yogurt consumption and risk of conventional... (2*)

873. . . cognitive behavioral therapy-induced changes in resting... (2*)

874. . . gut dysbiosis characterized by overabundance of... (2*)

875. . . fecal microbiota from IBS patient induces... (4*)

876. . . stress-induced disruption of intestinal barrier and... (7*) ([This study proposal received AGA Student Research Fellowship award.])

877. . . microbiota plays a key role in... (4*)

878. . . gut microbiome biomarkers before and during... (2*)

879. . . switching from infliximab originator to a... (5*)

880. . . delineating the phenotype of pediatric PSC-IBD... (5*)

881. . . pilot study of eosinophilic biomarker measured... (5*)

882. . . normalization of fecal calprotectin requires higher... (5*)

883. . . integration of clinical, immunologic and genomic... (2*)

884. . . prospective comparison of sacral nerve stimulation... (5*)

945. . . Gluten avoidance and self-reported non-celiac wheat... (3*) ([This study was supported by a grant from Prometheus laboratories.])

946. . . a high rate of iGE-negative food... (6*) (2)

947. . . priming and maturation of the human... (4*)

948. . . nuclear receptor liver receptor homolog-1 promotes... (2*) (6)

949. . . development of coordinated electrical activity in... (6*)

950. . . maternal milk enhances intestinal mucosal barrier... (2*) (6)

969. . . primary cilium transduce inflammatory and hedgehog... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
1076. . . FORKHEAD BOX K2 (FOXK2) PROMOTES HUMAN... (2*)}}[This study was supported by combined grants from the tional Science Foundation of Chi (No.81522031, No. 81772623, No. 81627807, No.81430072 and No. 81421003), tional Key Research and Development Program of Chi (2018YFC1312103) and tional Center for Clinic)

1077. . . A NOVEL GENE EXPRESSION SIGNATURE FOR... (4*)

1078. . . METHYLATED DNA MARKERS DETECT ESOPHAGEAL SQUAMOUS... (3*)|[|Exact Sciences, Madison, Wl.)

1079. . . A NOVEL GENE EXPRESSION SIGNATURE FOR... (5*)

1080. . . CHARACTERIZATION OF SONIC HEDGEHOG IN ESOPHAGEAL... (2*)

1081. . . GENOME-WIDE TRANSCRIPTOMIC PROFILING FOR THE IDENTIFICATION... (4*)

1082. . . ‘TURNING-OFF’ STRESS-INDUCED VISCERAL PAIN VIA OPTOGENTIC... (2*)|[|6)

1083. . . GUT SENSING OF NUTRIENT CALORIC CONTENT... (2*)|[|4)

1084. . . ENTERIC ALPHA-SYNUCLEIN INCLUSIONS, COLONIC INFLAMMATION, INCREASED... (5*)

1085. . . NEURONAL SEROTONIN AS A LINK BETWEEN... (2*)|[|6)

1086. . . BILATERAL BRAIN-GUT INTERACTIONS AND ANORECTAL SENSATION... (7*)

1087. . . ENTERIC INFLAMMATION AND ALTERED COLONIC CHOLINERGIC... (4*)

1088. . . META-ANALYSIS: THE RISK OF DEVELOPING NEW... (5*)

1089. . . GASTROINTESTINAL SYMPTOMS OBSERVED AFTER CHIMERIC ANTIGEN... (5*)

1091. . . EARLY INTRODUCTION OF NON-STEROIDAL IMMUNOSUPPRESSIVE THERAPY... (5*)

1092. . . IMPORTANCE OF ENDOSCOPIC AND HISTOLOGICAL EVALUATION... (5*)

1093. . . A NOVEL ROLE OF S-ACYLATION IN... (2*)

1094. . . ROLE OF HISTONE ACETYLATION IN UPREGULATION... (2*)

1095. . . TRANSMEMBRANE PROTEIN 237 (TMEM237) INTERACTS WITH... (2*)

1096. . . REGULATION OF NA-Glutamine CO-TRANSPORT BOAT1 IN... (2*)

1097. . . LINACLOTIDE STIMULATES DUODENAL BICARBONATE SECRETION VIA... (4*)

1098. . . INCREASED DIVALENT METAL TRANSPORTER 1 (DMT1)... (2*)

1099. . . THE MICROBIOME IN IRRITABLE BOWEL SYNDROME... (2*)

1100. . . REDUCED BACTERIA-DERIVED BILE SALT HYDROLYSE ENZYMATIC... (3*)|[The study was sponsored by Nestle Institute of Health (NIHS.).]

1101. . . FMT WITH OR WITHOUT ANTIBIOTIC PRETREATMENT... (3*)|[FMT capsules provided by OpenBiome)

1102. . . EFFICACY OF HUMAN MILK OLIGOSACCHARIDES ON... (3*)

1103. . . DAILY INTAKE OF SULFORAPHANE-RICH BROCCOLI SPROUTS... (3*)|[Murakami Nohen Co. Ltd.)

1104. . . INTEGRATED MULTI-OMICS ANALYSIS OF THE FAECAL... (2*)

1105. . . IMPACT OF CONCURRENT PHARMACOTHERAPY WITH INTRAGASTRIC... (5*)

1106. . . AN ANALYSIS OF LEPTIN AND INSULIN-GLUCOSE... (5*)

1107. . . OBESITY IS AN INDEPENDENT RISK FACTOR... (5*)

1108. . . TRANSPYLORIC SHUTTLE TREATMENT IMPROVES CARDIOMETABOLIC RISK... (3*)|[BaroNova)

1109. . . ENDOSCOPIC MANAGEMENT OF LATE DUMPING SYNDROME... (5*)

1110. . . OUTCOMES OF A NOVEL BARIATRIC STENT... (5*)

1111. . . LONG-TERM MULTIDONOR FECAL MICROBIOTA TRANSFER (FMT)... (5*)

1112. . . THE MACROPHAGE REVERSE TRANSSULFURATION PATHWAY MEDIATES... (2*)

1113. . . ααINDUCTION OF GASTRIC DYSBIOSES BY CARCINOGENIC... (2*)

1114. . . POSTTRANSCRIPTIONAL CONTROL OF VDR EXPRESSION BY... (2*)

1115. . . 5-HT3 RECEPTOR ACTIVATION INCREASES ANION SECRETION... (2*)

1116. . . FUSOBACTERIUM NUCLEATUM INITIATES COLORECTAL CANCER BY... (2*)

1117. . . FORWARD GENETICS IDENTIFIES HOST LOCUS RESPONSIBLE... (2*)

1118. . . SHORT-CHAIN FATTY ACIDS POSTPONE THE PROGRESSION... (2*)

1119. . . THE INTESTINAL VIROME IN CHILDREN WITH... (7*)|[2)

1120. . . SYN-007, AN ORAL BETA-LACTAMASE PREVENTS GUT... (3*)|[Synthetic Biologics, Inc.)

1121. . . TOWARDS HEALTH: RECURRENT CLOSTRIDIUM DIFFICILE INFECTION... (3*)|[This alysis was funded by Rebiotix Inc., Roseville, MN, USA.)

1122. . . THE EFFECTS OF HUMAN MILK OLIGOSACCHARIDES... (4*)|[Supported by an unrestricted grant from Glycom A/S

1123. . . FUNCTIONAL LUMEN IMAGING PROBE DEMONSTRATES REDUCED... (5*)

1124. . . ABNORMALITIES OF ESOPHAGEAL DISTENSION-CONTRACTION PROFILE DURING... (2*)

1125. . . DISTENSION-INDUCED CONTRACTILITY IS FREQUENTLY PRESENT, BUT... (2*)

1126. . . ESOPHAGEAL HYPERCONTRACTILITY IS ABOLISHED BY CHOLINERGIC... (4*)

1127. . . PROSPECTIVE EVALUATION OF RISK FACTORS FOR... (5*)

1128. . . CHARACTERIZATION AND MECHANISM OF THE ESOPHAGO-ESOPHAGEAL... (2*)

1129. . . MICROBIAL SEQUENCING OF THE APPENDICEAL MICROBIOME... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
INTRA-PERSONAL GUT MICROBIAL VARIATIONS IN PATIENTS... (6*)

CD8+ T CELL-SPECIFIC TUMOR NECROSIS FACTOR... (2*) (6)

A HEALTHY HUMAN FECAL SPECIMEN INCLUDES... (3*) (6) [Janssen Research Development]

CRITICAL ROLE OF TOLL-LIKE RECEPTOR 2... (2*)

LACK OF VITAMIN D RECEPTOR IN... (2*)

COMPARATIVE IN-VIVO DIAGNOSTIC PERFORMANCE OF CURRENT... (5*)

INTELLIGENT REAL-TIME IMAGE SEGMENTATION (IRIS) IMPROVES... (3*) (NinePoint Medical, Inc.)

GOBLET CELL METAPLASIA VARIATIONS IN TARGETED... (3*)

RISK STRATIFICATION OF BARRETT'S ESOPHAGUS WITH... (5*)

RELIABILITY OF VIDEOCONFERENCING PATHOLOGY IN THE... (5*)

INTERLEUKIN-33 PROMOTES REG3G EXPRESSION IN INTESTINAL... (2*)

CATHARTOCYTOSIS, A NOVEL CELLULAR PROCESS ESSENTIAL... (4*) (2)

THE ROLE OF TUFT CELL SPECIFICATION... (2*)

GENOME ANALYSIS OF DUODENAL GASTRINOMAS AND... (2*)

EFFICACY IN BIOLOGIC-FAILURE AND NONBIOLOGIC-FAILURE POPULATIONS... (3*) [This study was funded by Janssen Research & Development, LLC]

INTERLEUKIN-27-PRODUCING IMMUNE CELLS IN THE GASTRIC... (2*)

RNA BINDING PROTEIN IMP1 PROMOTES EXOSOME... (2*) (7)

A NOVEL ROLE FOR γδ INTRAEPITHELIAL... (2*) (4)

TRENDS IN YOUNG-ONSET COLORECTAL CANCER INCIDENCE... (2*)

DELETION OF CLAUDIN-7 LEADS TO THE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
AGA Poster Presentations
INAPPROPRIATE PROPHYLACTIC RATES IN A
OF GUIDELINE ADHERENCE

HEPATITIS C AND CHARACTERISTICS IN LEFT
AFTER AN ACUTE

ON THE MANAGEMENT OF
INTERNATIONAL GUIDELINES
ADHERENCE TO GUIDELINES
INTERNATIONAL GUIDELINES
ADHERENCE TO GUIDELINES
UND
POOR KNOWLEDGE OF
PERSONAL AND FAMILIAL

A NATIONAL SURVEY OF
INTERNISTS’ PERCEPTIONS

STRONG RECOMMENDATIONS
BASED ON LOWER QUALITY

UNDERUTILIZATION OF
ASPIRIN IN PATIENTS WITH...

POOR KNOWLEDGE OF
PERSONAL AND FAMILIAL

UNDISCLOSED PAYMENTS BY
PHARMACEUTICAL AND MEDICAL

UTILITY OF AND COMPLIANCE
WITH RECOMMENDED...

ADHERENCE TO GUIDELINES
AND BEST PRACTICES

INTERNATIONAL GUIDELINES
ON THE MANAGEMENT OF...

INTERNATIONAL GUIDELINES
ON THE MANAGEMENT OF...

IS COLONOSCOPY NECESSARY
AFTER AN ACUTE...

LACK OF RECOMMENDED
PNEUMOCOCCAL CONJUGATE VACCINE...

This study was sponsored by Pfizer Inc. All authors are employees of Pfizer Inc.

A COMPARISON OF
CHARACTERISTICS IN LEFT...

TARGETED SCREENING FOR
HEPATITIS C AND...

A MULTICENTER STUDY ON
GUIDELINE ADHERENCE...

PREVALENCE AND RELEVANCE
OF FINANCIAL CONFLICTS...

HIGH SMOKING CESSATION
RATES IN A...

CHARACTERIZING
INAPPROPRIATE PROPHYLACTIC
TRANSFUSION OF BLOOD...

COLONIC BiPSY APRACTICE IN
PATIENTS WITH...

WNT/β-CATENIN SIGNALING THROUGH
DEGRADATION...

Sa1018. . . WOMEN WITH HEPATITIS C
VIRUS (HCV)... (3*)[Abbvie - investigator
initiated research grant support]

Sa1019. . . IS ETHNICITY ASSOCIATED
WITH RATES OF... (5*)

Sa1020. . . RACIAL DISPARITIES IN TIME
FROM ADMISSION... (5*)

Sa1021. . . HISPANICS UNDER-UTILIZE
BARIATRIC SURGERY... (5*)

Sa1022. . . RACIAL DISPARITIES IN
COLORECTAL CANCER MORTALITY...
(2*)

Sa1023. . . PATIENT AND PROVIDER
REPORTED BARRIERS TO...

Sa1024. . . RACIAL DISPARITIES IN THE
EVALUATION AND...

Sa1025. . . A QUESTIONNAIRE STUDY TO
ASSESS THE...

(Takeda (Chi) Intertiol
Trade Co., Ltd.)

Sa1026. . . DEVELOPING A STUDY OF
COLORECTAL CANCER...

Sa1027. . . BEYOND AVAILABILITY:
EVALUATING ACCEPTABILITY OF HIGH...

(2*)

Sa1028. . . COST SAVINGS FROM GENERIC
PROTON PUMP...

Sa1029. . . COST-EFFECTIVENESS OF FIRST-
LINE BIOLOGICS FOR THE...

Sa1030. . . PATIENT OUTCOMES BASED
ON REFERRAL PATTERNS...

Sa1031. . . WHAT IS THE NATURAL
HISTORY OF...

(Janssen Cada)

Sa1032. . . SUBSTANTIAL INCREASE IN
ANESTHESIA ASSISTANCE FOR...

Sa1033. . . HEALTHCARE RESOURCE USE
AND DIRECT MEDICAL...

(The funding for this study was provided by Allergan plc.
Writing assistance by Complete
HealthVizion, funded by Allergan plc.)

Sa1034. . . CAN ALBUMIN-BILIRUBIN
GRADE (ALBI) PREDICT PRESENCE...

(5*)[Non]

Sa1035. . . IN-HOSPITAL MORTALITY OF
TOXIC MEGACOLON HAS...

Sa1036. . . VELODIZUMAB CLINICAL
DECISION SUPPORT TOOL PREDICTS...

(Takeda Pharmaceuticals U.S.A., Inc.)

Sa1037. . . TRENDS AND HEALTHCARE
DISPARITIES IN CIRRHOTICS...

Sa1082. . . DEVELOPMENT AND
VALIDATION OF A MACHINE-LEARNING...

Sa1083. . . AUTOMATED TIME-RELEASED
REMINDERS IMPROVES PATIENT ACCESS...

Sa1084. . . MOBILE APPLICATION USE
IMPROVES NO-SHOW RATES...

(Mobile app (MageMySurgery) is a
product of Higgs Boson Health and use of
app was doted. No direct study funding was
provided.)

Sa1085. . . COLONOSCOPY VOLUME OF
COLONIC IRRIGATION (VOC)... (5*)

Sa1086. . . DIGITAL RECTAL EXAMS ARE
RARELY PERFORMED...

Sa1087. . . A NOVEL ELECTRONIC
MEDICAL RECORD-BASED WORKFLOW...

Sa1088. . . CORRELATION BETWEEN
SURROGATE QUALITY INDICATORS FOR...

Sa1089. . . A RETROSPECTIVE REVIEW OF
INTRAVENTRICAL IRON...

Sa1090. . . ANEMIA IN PEDIATRIC
INFLAMMATORY BOWEL DISEASE...

Sa1091. . . APPLICATION OF BAYESIAN
MODELING WITH INFliximAB...

(5*)[(1)

Sa1092. . . LUMINAL NITRIC OXIDE AND
PLASMA NITRITE/NITRATE...

(1*)

Sa1093. . . HEALTH CARE COSTS OF
ENDOSCOPY AND...

Sa1094. . . FACTORS INFLUENCING
TIMING OF PARACENTESIS AFTER...

Sa1095. . . UNDERSTANDING THE ROLE OF
PHYSICIAN ATTIRE...

Sa1096. . . A PERSONALIZED MODEL TO
ASSESS INTESTINAL...

Sa1097. . . HUMAN COLON ORGANOID
MODEL OF SESSILE...

Sa1098. . . MOLECULAR RESPONSE OF
CANINE INTESTINAL ORGANIODS...

Sa1099. . . ESTABLISHMENT OF LONG-
TERM NORMAL HUMAN INTESTINAL...

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
PLASMACYTOID DENDRITIC CELL
LYMPHOCYTE MIGRATION TO GALLBLADDER CANCER
REGULATED THROUGH AUTOPHAGY AND ACCELERATES THE MUCINIPHILA. AND DECREASED AKKERMANSIA medical science
MICROBIAL TRANSGLUTAMINASE BY (DEGRADATION OF DGAT1: A P ORGANIDS IN A MULTI CYSTIC FIBROSIS PANCREATIC CANCER CELLS AND SIGNALING PREVENTS THE... (1) = Clinical Practice Funds
(2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
INCIDENCE AND OUTCOMES

PANCREATIC CANCER LEADS TO INCREASED MEDIUM-TERM RISK OF PANCREATIC CANCER... (5*)
PANCREATIC DUCTAL ADENOCARCINOMA... (5*)
HALF OF SPORADIC PANCREATIC DUCTAL ADENOCARCINOMA... (5*)

PANCREATIC DUCTAL ADENOCARCINOMA DETECTED AFTER ACUTE... (5*)
IMPACT OF ABO BLOOD TYPE... (5*)

THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)
THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)
THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)
THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)
THE QUALITY OF EARLY ACUTE PANCREATITIS... (5*)

**Abstract Funding Source Key**

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds   (5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds

(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
FOR Sa1709 . . . TARGETING DRS IN BOTH MDSCS AND... (2*) (The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).

Sa1710 . . . TRPV1 INHIBITS GASTRIC CANCER DEVELOPMENT VIA... (2*) ([t] (2016YFC1002200) and tial tural Science Foundation of Chi (No. 81570477))

Sa1711 . . . BONE MARROW-DERIVED MYOFIBROBLASTS PROMOTES GASTRIC CANCER... (2*) (The project was supported by NSFC81472727,NSFC81272403,NSFC81773259; Science and Technology Commission of Shanghai Municipality (15JC1403100)).

Sa1712 . . . THE EXPRESSION OF CIRCULAR RNA, CDRI-AS,... (2*)

Sa1713 . . . MIR-143 SUPPRESSES TUMORIGENESIS AND PROGRESSION OF... (2*)

Sa1714 . . . OXALIPLATIN INHIBITS DIFFERENTIATION OF M-MDSCS INTO... (2*)

Sa1715 . . . DECREASED P62 PROTEIN EXPRESSION IS ASSOCIATED... (5*)

Sa1716 . . . STATE SIGNALING IN COLON CANCER CELLS... (4*)

Sa1717 . . . DEVELOPMENT OF A SWALLOWABLE DIGANOSTIC CAPSULE... (3*) (Progenity Inc.)

Sa1718 . . . A NEAR-INFRARED PROBE FOR IN VIVO... (6*)

Sa1719 . . . COMPARISON OF TWO CUT-OFF VALUES OF... (2*)

Sa1720 . . . EFFECT OF COLONOSCOPY ASSISTED DEVICES ON... (5*)

Sa1721 . . . MORE LESIONS PER PATIENT DETECTED WITH... (3*) (Norgine)

Sa1722 . . . ASSESSMENT OF COLONOSCOPY QUALITY IN NON-ACADEMIC... (5*)

Sa1723 . . . MUCOSAL HEALING DEFINED BY ADVANCED ELECTRONIC... (5*)

Sa1724 . . . MOXIFLOXACIN PROMOTES MULTIPHOTON MICROSCOPIC IMAGING FOR... (5*)

Sa1725 . . . LEOPARD STUDY - ITALIAN MULTICENTER PROSPECTIVE... (1*)

Sa1726 . . . IN VIVO AND EX VIVO MICROSTRUCTURE... (5*)

Sa1727 . . . OUTCOMES OF GI POLYPS REJECTED USING... (5*)

Sa1728 . . . THE PROGNOSTIC VALUE OF A NEW... (1*)

Sa1729 . . . RISK FACTORS FOR COLONIC DIVERTICULOSIS: A... (1*)

Sa1730 . . . THE HISTOLOGICAL HEALING IN ULCERATIVE COLITIS... (5*)

Sa1731 . . . A TRANS-NASAL, IMAGE-GUIDED APPROACH FOR BRUSH... (6*)

Sa1732 . . . PREDICTORS OF 30 DAYS READMISSIONS AFTER... (5*)

Sa1733 . . . ETIOLOGIES AND TRENDS OF 30 DAYS... (5*)

Sa1734 . . . EVALUATING THE EFFICACY OF HEMOSTATIC NANOPOWDER... (5*)

Sa1735 . . . BASELINE BOWEL STIFFNESS ON REAL-TIME SHEAR... (5*)

Sa1736 . . . THE ROLE OF “ROSE” FOR ERCP-GUIDED... (5*)

Sa1737 . . . FXR AGONIST M480, EXHIBITS EFFICACY IN... (3*) (Metacrine)

Sa1738 . . . OLORINAB (FORMERLY APD371), A PERIPHERALLY RESTRICTED,... (3*) (Are Pharmaceuticals Inc. and NHMRC Australia.)

Sa1739 . . . USING THE ZONULIN TRANSGENIC MOUSE MODEL... (2*)

Sa1740 . . . SPONTANEOUS MOUSE COLITIS PRODUCED BY DELETION... (2*)

Sa1741 . . . IDENTIFICATION AND CHARACTERIZATION OF THE FIRST... (2*)

Sa1742 . . . INTERLEUKIN-10 KNOCKOUT MICE DO NOT EXHIBIT... (6*)

Sa1743 . . . INVESTIGATION OF THE RELATIONSHIP BETWEEN ASPRIN-INDUCED... (1*)

Sa1744 . . . A NOVEL PORCINE MODEL OF CROHN’S... (2*)

Sa1745 . . . GLACIAL ACETIC ACID-INDUCED ULCERATIVE COLITIS LESIONS... (4*)

Sa1746 . . . ORAL CALCIUM NANOPIRICLE THERAPY AIDS IN... (4*)

Sa1747 . . . FXR AGONISTS WITH SUSTAINED ACTIVITY EXHIBIT... (3*) (Metacrine)

Sa1748 . . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN):... (3*) (received arm-length funding from Pendopharm Inc.)

Sa1749 . . . GASTROENTEROLOGY-RELATED HASHTAG UTILIZATION ON INSTAGRAM AND... (5*)

Sa1750 . . . PREVALENCE AND OUTCOMES OF PORTOMESENTERIC VEIN... (5*)

Sa1751 . . . OUTCOME, COMPLICATION AND LONG-TERM FOLLOW UP... (5*)

Sa1752 . . . VALIDATION OF A FECAL INCONTINENCE BOWEL... (2*) (Medspira Scientific provided software and physiological recorders at discounted prices.)

Sa1753 . . . IBD NURSE INTERVENTION FOR PATIENTS ASSIGNED... (3*) (This work was supported by the Pfizer independent grants for learning & change)

Sa1754 . . . SLEEP DISTURBANCE AND TRAVEL INTERRUPTION WITH... (3*) (Pendopharm)

Sa1755 . . . PRESENTING SYMPTOM SEVERITY AND HEALTH-RELATED QUALITY... (5*)

Sa1756 . . . EFFECTS OF PHARMACEUTICAL DIRECT-TO-CONSUMER ADVERTISING (DTCA)... (5*)

Sa1757 . . . IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED... (5*)

Sa1758 . . . THE RELATIONSHIP BETWEEN SERUM BILIRUBIN AND... (2*)

Sa1759 . . . TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN... (5*)

Sa1760 . . . RISK FACTORS FOR POST-OPERATIVE CROHN’S DISEASE... (5*)

Sa1761 . . . CHITINASE 3-LIKE-1 PROTEIN: A NOVEL BIOMARKER... (6*)

Sa1762 . . . LARGE-SCALE PROTEOMICS IDENTIFIES ANTI-TNF RESPONSE SIGNATURE... (2*)
BOWEL DISEASE

THROUGHOUT THE WORLD:

and Colitis Foundation (Grant Number ...

UTERINE CANCER ARE

IN THE

INFLAMMATORY BOWEL DISEASE AFTER BARIATRIC

OLDER

Pennsylvania Commonwealth Universal Tobacco Formula grant is under the

INFLAMMATORY BOWEL DISEASE IN UK PRIMARY...

NONALCOHOLIC LIVER DISEASE

INFLAMMATORY BOWEL DISEASE AFTER BARIATRIC

RELATIONSHIP BETWEEN CIGARETTE

INFLAMMATORY BOWEL DISEASE

EXPOSURES IN DECIDUOUS...

THE PROGRESSION OF

THE INCIDENCE OF

EVALUATION OF THE 10-YEAR

A SIGNIFICANT...

THE GLOBAL BURDEN OF

SEXUAL FUNCTION IN

THE IMPACT OF OPIOID

THE INTESTINAL MICROBIOME IN INFLAMMATORY BOWEL...

DE-NOVO INFLAMMATORY BOWEL DISEASE AFTER BARIATRIC...

THE GLOBAL BURDEN OF INFLAMMATORY BOWEL...

PREVALENCE OF CERVICAL DYSPLASIA IN WOMEN...

NONALCOHOLIC LIVER DISEASE SIGNIFICANTLY MORE PREVALENT...

INCERNEL COMORBIDITIES...

THE 30-YEAR TREND ANALYSIS IN THE...

THE 30-YEAR TREND ANALYSIS IN THE...

CROHN’S DISEASE AND ULCERATIVE COLITIS WAS...

THE 30-YEAR TREND ANALYSIS IN THE...

THE 30-YEAR TREND ANALYSIS IN THE...

CROHN’S AND COLITIS FOUNDATION (GRANT NUMBER 568735 TO BK)

HOSPITALIZATIONS FOR IBD THROUGHOUT THE WORLD...

REVISITING THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL...

THE RISK OF INFLAMMATORY BOWEL DISEASE...

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
OUTCOMES OF PATIENTS WITH IMMUNOSUPPRESSANT OR ILEAL IMMUNOGLOBULIN G4 FAILS TO FAT AND SUGAR WITH IBD: TRIGGER FOODS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS IN INFLAMMATORY DISEASE ONSET ULCERATIVE COLITIS: A BURNOUT OVER (INJECTABLE BIOLOGIC MEDICATION IN INCIDENCE RATES OF 3920. Prometheus by Janssen Pharmaceuticals and (5) 3

NUTRITIONAL STATUS EFFECT CHARACTERISTICS AND MUCOSAL EOSINOPHILIA IS AN INSTABILITY IN SATURATED FAT STABILITY IN PERSONS CONSUMPTION OF DIETARY THE NATURAL COURSE OF INFLAMMATORY BOWEL... INFLAMMATORY DISEASE... CONSUMPTION OF DIETARY TRIGGER FOODS AMONG... DIET STABILITY IN PERSONS WITH IBD... INSTABILITY IN SATURATED FAT AND SUGAR... ELEVATED SERUM IMMUNOGLOBULIN G4 FAILS TO... CROHN’S LIKE DISEASE OF THE ILEAL... MUCOSAL EOSINOPHILIA IS AN INDEPENDENT PREDICTOR... OUTCOME AFTER DISCONTINUATION OF IMMUNOSUPPRESSANT OR... CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH... NUTRITIONAL STATUS EFFECT ON HEALTH CARE... EVALUATION AND MANAGEMENT OF POUCHITIS IN... NONALCOHOLIC FATTY LIVER DISEASE WITH ADVANCED... THE DILEMMA IN COMPLICATED ILEAL POUCH... PREDICTIVE FACTORS OF A SUBSEQUENT ANO-PERINEAL... PREGNANCY COUNSELING BENEFICIAL IN PATIENTS WITH... CLINICAL SIGNIFICANCE OF GRANULOMAS IN CROHN’S... FOLLOW-UP OF ULCERATIVE COLITIS PATIENTS WITH... ADVERSE ANTEPARTUM OUTCOMES IN PREGNANT WOMEN... TEMPORAL TREND IN DISEASE CHARACTERISTIC, TREATMENT... ASSOCIATION OF SEROLOGIC MARKERS AND SURGERY... FAMILIAL MEDITERRANEAN FEVER IN THE UNITED... WESTERN VERSUS MEDITERRANEAN DIETARY MARKERS DIFFER... HOW DO DIETARY PATTERNS FOR INFLAMMATORY... PSEUDOPYLPS IN INFLAMMATORY BOWEL DISEASE: HISTOLOGIC... IMPACT OF BARIATRIC SURGERY ON THE... ANALYSIS OF THE CLINICAL, GASTROSCOPIC, AND... RISK FACTORS ASSOCIATED WITH PROXIMAL DISEASE... UPPER GASTROINTESTINAL TRACT PHENOTYPE OF CROHN’S... RATE AND RISK FACTORS ASSOCIATED WITH... THE IMPACT OF TOBACCO SMOKING ON... RISK FACTORS FOR REPEATED VISITS TO... REAL WORLD USE OF THE IBD... PATIENT EMPOWERMENT THROUGH AN EDUCATIONAL INTERVENTION... GUT-BRAIN-AXIS REVISITED: SHEDDING LIGHT ON THE... THERE IS MORE THAN PHARMACOLOGY: COMPREHENSIVE... ASSOCIATION OF PSYCHIATRIC COMORBIDITIES WITH OPIOID... SEXUAL QUALITY OF LIFE IN INFLAMMATORY... FERTILITY IMPACT OF INITIAL SURGICAL MODALITY... PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE TO... THE USE OF AN EMR PATIENT... HIGH INFlixIMAB TROUGH LEVELS HAVE NO... MEASURING THE MEDIATING EFFECTS OF TOFACITINIB... MEASURING THE MEDIATING EFFECTS OF MAYO... THE VISCERAL SENSITIVITY INDEX: A NOVEL... DISEASE-RELATED WORRIES AND CONCERNS IN PATIENTS...
Sa1876. . . . BODY IMAGE
DISSATISFACTION IS INCREASED IN... (5*)

Sa1877. . . . INDIVIDUALISED,
UNSUPERVISED EXERCISE PROGRAM
ACHIEVES HIGH... (4*)

Sa1878. . . . EFFECTS OF SUBCUTANEOUS
VEDOZIUMAB ON HEALTH-RELATED...
(3*)|(Takeda)

Sa1879. . . . DISABILITY IN PATIENTS WITH
ILEAL POUCH... (5*)

Sa1880. . . . LONGITUDINAL
PSYCHOLOGICAL HEALTH IN VETERANS
WITH... (5*)

Sa1881. . . . EFFECTS OF INTRAVENOUS
VEDOZIUMAB ON HEALTH-RELATED...
(3*)|(Takeda)

Sa1882. . . . PSYCHIATRIC OUTCOMES ARE
SIGNIFICANTLY IMPACTED WITH... (4*)

Sa1883. . . . ALTERATIONS IN FUNCTIONAL
AND MICROSTRUCTURAL DEFAULT... (2*)

Sa1884. . . . UNMET NEED OF
INFLAMMATORY BOWEL DISEASE...
(3*)|(Janssen Inc. provided an educational grant to the Gastrointestinal Society. The doctors were not paid for their participation.)

Sa1885. . . . PERCEIVED DISEASE SEVERITY
AND TREATMENT SATISFACTION...
(3*)|Pfizer Inc)

Sa1886. . . . SEXUAL DYSFUNCTION IN
PATIENTS WITH INFLAMMATORY... (5*)

Sa1887. . . . GENERAL HEALTH STATUS IN
PATIENTS WITH... (3*)|This study was funded by Janssen Research & Development, LLC)

Sa1888. . . . USTEKINUMAB THERAPY
INDUCED CLINICALLY MEANINGFUL
IMPROVEMENT... (3*)|This study was funded by Janssen Research & Development, LLC)

Sa1889. . . . DOES PREGNANCY ADVERSELY
IMPACT THE HEALTH... (4*)

Sa1890. . . . THE ASSESSMENT OF
INDIVIDUAL PATIENT PREFERENCES... (6*)

Sa1891. . . . A SURVEY OF DISCLOSURE
PREFERENCES IN... (5*)

Sa1892. . . . NUTRITIONAL STATUS
CORRELATES WITH QUALITY OF... (5*)

Sa1893. . . . A SINGLE CELL SURVEY OF
LARGE... (3*)

Sa1894. . . . ENTERIC GLIAL MHC II
CONTRIBUTES TO... (2*)

Sa1895. . . . CHARACTERIZATION AND
MODELING OF THE CREEPING... (3*)

Sa1896. . . . SERUM BIOMARKERS OF
DEGRADATION AND FORMATION... (5*)

Sa1897. . . . HDAC INHIBITORS DRIVE TGF-
β1-MEDIATED STRENGTHENING AND... (2*)

Sa1898. . . . LIPIDOMIC PROFILING REVEALS
ALTERED LIPID COMPOSITION... (5*)

Sa1899. . . . FIBROSIS IN PATIENTS WITH ULCERATIVE... (2*)

Sa1900. . . . INTEROBSERVER AGREEMENT
AMONG ENDOSCOPISTS IN EVALUATING...
(6*)|(Kenneth-Rainin Foundation)

Sa1901. . . . EXPRESSION OF INTEGRIN
A4B7 AND MADCAM1... (3*)|Takeda Pharmaceuticals

Sa1902. . . . A COMPARISON OF
DIVERTICULITIS IN CROHN'S... (5*)

Sa1903. . . . THE ROLE OF SUB-MUCOSAL
COLLAGEN DEPOSITION... (5*)

Sa1904. . . . LONG-TERM SAFETY AND
OUTCOMES OF COLONOSCOPIE... (5*)

Sa1905. . . . A PHASE I RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED...
(3*)|(Study funded by 4D Pharma. RH and RKR supported by Career Researcher Fellowships from NHS Research Scotland.)

Sa1906. . . . DOSE ESCALATION WITH
ORIGINATOR INFLEXIMAB IS... (3*)|Janssen Scientific Affairs, LLC supported this study)

Sa1907. . . . ANTIBIOTICS WORSEN
VISERAL BUT NOT SOMATIC... (6*)

Sa1908. . . . ABERRANT ENTERIC
NEUROMUSCULAR SYSTEM AND
DYBSOSIS... (2*)

Sa1909. . . . DEEP SEQUENCING OF THE
ENTIRE HUMAN... (4*)

Sa1910. . . . LIFE COURSE ANTIBIOTIC USE
AND ALTERATIONS... (2*)

Sa1911. . . . ANALYSIS OF THE SMALL
INTESTINAL MICROBIOME... (4*)

Sa1912. . . . REVEALING THE ENTIRE
INTESTINAL MICROBIOTA AND... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1931. . . PHYSICOCHEMISTRY, PROTEOMICS AND IN VIVO COMPARATIVE... (5*)

Sa1932. . . EFFECT OF SACCHAROMYCES BOULARDI CCM I-745... (3*) [(The current project was partially funded by a Biocodex grant, however they were not involved neither in the study design, patients recruitment nor data analysis. USFQ, UTE and UDLA (Private Universities in Ecuador) also funded partially the current research)

Sa1933. . . GUT MICROBIOME CROSS-TALK: PLAUSIBLE OR JUST... (5*)

Sa1934. . . THE FECAL-ANTI CANDIDA ACTIVITY CAN BE... (5*)

Sa1935. . . COMPARING FAECAL VOLATILE ORGANIC COMPOUNDS FOLLOWING... (5*)

Sa1936. . . EFFICACY AND SAFETY OF SACCHAROMYCES BOULARDI... (4*)

Sa1937. . . FIVE CASES OF BACILLUS LICHENIFORMIS BACTEREMIA... (1*)

Sa1938. . . ENTEROBACTERIACEAE ARE ESSENTIAL FOR THE MODULATION... (3*)

Sa1939. . . THE GUT MICROBIOME AS A NOVEL... (7*)

Sa1940. . . FECAL AND MUCOSAL MICROBIOTA PROFILING IN... (2*)

Sa1941. . . STRUCTURED PATIENT GROUP EDUCATION VERSUS STRUCTURED... (2*)

Sa1942. . . REAL-WORLD IMPLEMENTATION OF THE LOW FODMAP... (2*)

Sa1943. . . IMPACT OF IRRITABLE BOWEL SYNDROME ON... (5*)

Sa1944. . . DIFFERENCES OF GASTROINTESTINAL (GI) SYMPTOMS BETWEEN... (5*)

Sa1945. . . FECAL MICROBIOTA TRANSPLANTATION IN IRRITABLE BOWEL... (5*)

Sa1946. . . THE MOST BOTHERSOME SYMPTOM IN FUNCTIONAL... (4*)

Sa1947. . . RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COLESEVELAM... (5*)

Sa1948. . . NEEDLELESS TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION IMPROVES IRRITABLE... (5*)

Sa1949. . . POSTMENOPAUSAL WOMEN WITH IRRITABLE BOWEL SYNDROME... (5*)

Sa1950. . . EFFECT OF SYMPTOM SEVERITY AND GENDER... (5*)

Sa1951. . . VALIDITY AND SAFETY OF SYMPTOM IMPROVEMENT... (2*)

Sa1952. . . ROLE OF LOW-GRADE INFLAMMATION IN THE... (5*)

Sa1953. . . PICTOGRAMS ARE HIGHLY EFFECTIVE FOR DIAGNOSING... (4*)

Sa1954. . . POST INFECTION IBS (PI-IBS) IS VERY... (4*)

Sa1955. . . IS ROME IV CRITERIA FOR IBS... (5*)

Sa1956. . . ANXIETY, DEPRESSION AND STRUCTURAL FACTORS IMPACT... (2*)

Sa1957. . . INCIDENCE, PREVALENCE AND RISK FACTORS ASSOCIATED... (3*) [(This project was supported by a grant from Prometheus laboratories.)

Sa1958. . . MEASURING DIET INTAKE AND GASTROINTESTINAL SYMPTOMS... (2*)

Sa1959. . . EVALUATION OF THE PSYCHOSOCIAL FEATURES OF... (2*)

Sa1960. . . A SURVEY-BASED STUDY OF IRRITABLE BOWEL... (5*)

Sa2000. . . HIGH METHYL DIET IMPAIRS E.COLI OVERGROWTH... (4*)

Sa2001. . . EXPERT CONSENSUS ON MANAGING IRON DEFICIENCY... (3*) [(Vifor Pharma)

Sa2002. . . MODERATE ETHANOL CONSUMPTION INHIBITS VILLUS CELL... (2*)

Sa2007. . . ASPIRIN/NSAID USE GREATER THAN 4 YEARS... (2*)

Sa2008. . . RISK OF METACHRONOUS SESSILE SERRATED ADENOMAS... (5*)

Sa2009. . . COMBINATORIAL BLOCKADE OF DE NOVO CHOLESTEROL... (2*)

Sa2010. . . LIPOPHILIC STATINS INHIBIT YAP NUCLEAR LOCALIZATION... (2*)

Sa2011. . . USEFULNESS OF TRACE ACETALDEHYDE/ETHANOL MEASUREMENTS IN... (5*)

Sa2012. . . REGULATION OF COLON CARCINOGENESIS BY THE... (5*)

Sa2013. . . ASPIRIN IS PROTECTIVE AGAINST GASTRIC CANCER... (2*)

Sa2014. . . ASPIRIN USE AND THE INCIDENCE OF... (2*)

Sa2015. . . . S-AMINOSALICYLIC ACID INHIBITS XENOBIOTIC METABOLISM IN...

Sa2016. . . TRANSCRIPTIONAL AND POST-TRANSLATIONAL IMPLICATIONS OF COHESIN... (2*)

Sa2017. . . PREEMPTIVE ADAлимУМАб AMELIORATED CACHExIA THROUGH CONCERTED... (4*)

Sa2018. . . COLORECTAL NEOPLASMS IN NEW USERS OF... (4*)

Sa2019. . . CHEMOPREVENTION OF COLORECTAL CANCER IN THE... (5*)

Sa2020. . . TARGETING CYCLOOXYGENASE 2 (COX-2) WITH EXERCISE-INDUCED... (2*)

Sa2021. . . A MULTICENTER STUDY OF THE SAFETY... (3*) [(Covidien/Medtronic)

Sa2022. . . EXPLORING RELATIONSHIPS BETWEEN HANDGRIP STRENGTH, MID-UPPER... (3*) [(Baxter Cada)

Sa2023. . . 13C-CAFFEINE BREATH TEST FOR THE IDENTIFICATION... (4*)

Sa2024. . . ASSOCIATION BETWEEN MALNUTRITION, NUTRITIONAL ASSESSMENT TOOLS,... (4*)

Sa2025. . . DISREGULATION OF LIVER MITOCHONDRIAL FUNCTION AND... (3*) [(Tsumura & Co.)

Sa2026. . . IMPROVEMENT IN NUTRITION STATUS IS ASSOCIATED... (4*)

Sa2027. . . VALIDATION OF THE MODIFIED NUTRITIONAL SCORE... (5*)

Sa2028. . . DIETARY FIBER IS ESSENTIAL TO MAINTAIN... (6*)

Sa2029. . . HABITUAL DIETARY INTAKE OF DUTCH IBD... (5*)

Sa2030. . . RANDOMIZED CLINICAL TRIAL TO COMPARE TWO... (5*)

Sa2031. . . HIGH PREVALENCE OF FOOD AVOIDANCE DIETS... (4*)
Sa1013. ALCOHOL CONSUMPTION AND THE COLONIC MUCOSA-ASSOCIATED BASEOPHIL... (2*)

Sa1032. SHORT- AND LONG-TERM ALCOHOL INTAKE AND... (2*)

Sa1034. INTRAPERITONEAL TREATMENT WITH KISSPEPTIN MODIFIES FEEDING... (4*)

Sa1035. DIETARY INTERVENTIONS RAPIDLY ALTER METABOLOMICS PROFILE... (6*)

Sa1036. AN EVALUATION OF DIETARY INTAKE, MACRO... (4*)| (5)

Sa1037. EFFECT OF CALCIUM AND VITAMIN D... (2*)

Sa1038. LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL... (2*)

Sa1039. UNDERSTANDING HOW DIFFERENCES IN SOCIOECONOMIC STATUS... (5*)

Sa1040. VITAMIN B12 MALABSORPTION AND DEFICIENCY FOLLOWING... (5*)

Sa1041. DIETARY ADHERENCE IN FUNCTIONAL GASTROINTESTINAL DISORDERS... (5*)

Su1006. INTERACTION BETWEEN LONG NONCODING RNA UC173... (2*)

Su1007. NLRP3 INFLAMMASOME-MEDIATED IL-1B ACTIVATION ENHANCES 5-FU... (4*)

Su1008. MIR874-3P IS INVERSELY CORRELATED WITH ITS... (7*)| (We like to acknowledge the International Organization for the study of Inflammatory Bowel Disease (IOIBD), and the tiol Institute of Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium [NIDDK IBDGC] for their financial support.)

Su1009. LOSS OF RAB25S AGGRAVATES A HYPERTROPHIC... (2*)

Su1010. ABNORMAL ACTIVATION OF HNRNPAO INHIBITS CANCER... (2*)

Su1011. HUMAN LAMINA PROPRIA LYMPHATIC CELLS AS... (5*)

Su1012. MECHANICAL STIMULI AFFECT ENTEROTOXIGENIC E. COLI... (2*)| (Emulate Inc.)

Su1013. INCREASED BASEOPHIL RECRUITMENT TO THE COLON... (4*)

Su1014. IMMUNE PROFILING OF THE HUMAN GASTRIC... (4*)

Su1015. WNT SIGNALING REGULATES SIRT2 EXPRESSION IN... (2*)

Su1016. PROTEIN KINASE D REGULATES THE NUCLEAR... (2*)

Su1017. ESTABLISHMENT AND CHARACTERIZATION OF A LEAKY... (3*)| (Innovate Biopharmaceuticals Inc, Raleigh NC)

Su1018. INTESTINAL BARRIER DYSFUNCTION ORCHESTRATES THE ONSET... (6*)| (Primary Source: International Foundation for Ethical Research Additioal Source 1: Bio & Medical Technology Development Program of the tiol Research Foundation funded by the Ministry of Science and ICT Additioal Source 2: Cancer Research Institute Additioal Source)

Su1019. LARAZOTIDE PROTECTS THE INTESTINAL TIGHT JUNCTION... (3*)| (Innovate Biopharmaceuticals Inc., Raleigh, NC, USA)

Su1020. NAFAMOSTAT MESYLATE, A BROAD SPECTRUM SERINE... (4*)

Su1021. PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN... (5*)

Su1022. INTERLEUKIN 4 RECEPTOR α DEFICIENCY ALLEVIATES... (5*)

Su1028. WHOLE-GENOME SEQUENCING OF AFRICAN AMERICANS IDENTIFIES... (6*)

Su1029. TI02 NANO PARTICLES ABROGATE THE PROTECTIVE EFFECT... (2*)

Su1030. UTILITY OF TARGETED NEXT-GENERATION SEQUENCING PANEL... (2*)

Su1031. PREVALENCE OF GERMLINE MUTATIONS AND VARIABLE... (2*)

Su1032. MIST+ ISTMUS STEM CELLS CONTRIBUTE TO... (2*)

Su1034. REBAMIPIDE REDUCES GASTRIC EPITHELIAL CELL APOPTOSIS... (4*)

Su1035. SCREENING ANTI-FIBROTIC AGENTS: EXPLORATION OF PROMISING... (4*)

Su1036. SULFORAFANE ALLEVIATES DEXTRAN SODIUM SULFATE (DSS)-INDUCED... (2*)

Su1037. HEPATOCARCINOMAGENESIS WITHOUT CIRRHOSIS IN THE ELDERLY... (4*)

Su1038. NOD1 DEFICIENT GASTRIC STEM CELLS FAIL... (4*)

Su1039. HUMAN DIFFERENTIATED ENTEROID MONOLAYERS EXHIBIT EGF/R/MEK... (2*)

Su1040. EARLY ACTIVATION OF SOX9-POSITIVE CELLS IN... (2*)

Su1041. NEW DIAGNOSTIC APPROACH FOR BILIARY TRACT... (2*)| (Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science)

Su1042. HUMAN CYTOKINE PRODUCTION BY THE INTACT... (2*)

Su1043. EXPLORING GLP2 ACTIVITY AND CELLULAR TARGETS... (4*)

Su1044. OPTIMIZATION OF CULTURE CONDITIONS FOR IMPROVED... (3*)| (AbbVie)

Su1045. MINIMUM ESSENTIAL ORGANOIDS CULTURE MEDIA (MEOM)... (2*)

Su1046. CRISPR/CAS9-MEDIATED GENOME EDITING OF MULTI-DRUG RESISTANCE... (4*)

Su1047. THE CHARACTERIZATION OF THE FUNCTION OF... (2*)| (JSPS KAKENHI Grandts Numbers 15K10124 (KY and YIK) and grants from the tiol Center for Global Health and Medicine (26-117 and 29-1019).)

Su1048. INTESTINAL EPITHELIAL BARRIER ABNORMALITIES AND CHANGES... (2*)

Su1049. MULTIPLEX NANOSCALE HIGH RESOLUTION FLOW CYTOMETRY... (4*)

Su1050. COMPARISON OF FISH VERSUS DDPCR-BASED GENE... (4*)

Su1051. CONSTRUCTION OF COLORECTAL CANCER SUBTYPES BASED... (5*)

Su1052. A NOVEL MICRORNA PANEL FOR NON-INVASIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1053. . . . HIGH RISK POPULATION SCREENING FOR COLORECTAL... (5*)
Su1054. . . . PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1) UPREGULATION CONTRIBUTES TO... (2*)
Su1055. . . . REPRIMO-LIKE: A POTENTIAL TUMOR SUPPRESSOR AND... (2*)
Su1056. . . . A CHEMORADIOTHERAPY TREATMENT RESPONSE MRNA SIGNATURE... (7*)
Su1057. . . . INCREASED EXPRESSION OF THE LONG NONCODING... (2*)
Su1058. . . . POTENTIAL OF URINARY CYSTEINE-RICH PROTEIN 61... (3*) (the Kobayashi Foundation for Cancer Research)
Su1059. . . . IMMUNE CELL INFILTRATION AND TUMOUR LOCATION... (5*)
Su1060. . . . CLINICAL UTILITY OF THE QUANTITATIVE MONITORING... (2*)
Su1061. . . . IDENTIFICATION OF A ROBUST MICRONA SIGNATURE... (2*)
Su1062. . . . MOLECULAR DEPENDENCIES IN ESOPHAGEAL ADENOCARCINOMA: A... (2*)
Su1063. . . . MIR-4715-3P MODULATES AURKA AND INDUCES FERROPTOSIS... (2*)
Su1065. . . . CANCER-DERIVED EXOSOMES ACTIVATE FIBROBLASTS THROUGH SUPPRESSION... (5*)
Su1066. . . . NOVEL METABOLOMIC PREDICTORS OF INCIDENT COLORECTAL... (2*)
Su1067. . . . GENETIC COLORECTAL CANCER RISK VARIANTS ASSOCIATED... (2*)
Su1068. . . . MUTATIONAL LANDSCAPE OF EARLY-ONSET COLORECTAL CANCER... (2*)
Su1069. . . . THE ROLE OF RARE VARIANTS IN... (2*)
Su1070. . . . MORPHOLOGICAL AND MOLECULAR RISK MARKERS FOR... (5*)
Su1071. . . . NOVEL LONG NON-CODING RNA MOLECULAR SUBTYPES... (4*)
Su1072. . . . HELICOBACTER PYLORI-RELATED DNA METHYLATION IN PRIMARY... (2*)
Su1073. . . . GENE NETWORK DIFFERENCES OF COLON CANCER... (5*)

Su1074. . . . ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN... (2*)
Su1096. . . . CALCIUM SIGNALING IN THE REGULATION OF... (2*)
Su1097. . . . NCK1/CA/NF-KB SIGNAL PATHWAY COULD BE A... (2*)
Su1098. . . . TUMOR-DERIVED EXOSOMES PROMOTE TUMOR GROWTH AND... (4*)
Su1099. . . . MYOARCHITECTURE OF THE SLING FIBERS OF... (2*)
Su1100. . . . MUCOSAL BARRIER DYSFUNCTION OF ATROPHIC MUCOSA... (5*)
Su1101. . . . CAN NSAID-INDUCED INJURY OF GASTRIC EPITHELIAL... (2*)
Su1102. . . . CARBON MONOXIDE RELEASED FROM ITS PHARMACOLOGICAL... (4*) (Grant from tel Science Centre, Poland (UMO-2016/23/N/NZ4/01890).)
Su1103. . . . DOES PPI PLAY A PROTECTIVE ROLE... (5*)
Su1104. . . . A RANDOMIZED CONTROLLED STUDY ON THE... (5*)
Su1105. . . . ESOPHAGEAL MUCOSAL IMMUNE RESPONSE TO CANDIDA... (5*)
Su1106. . . . TACROLIMUS-INDUCED PAN-ESOPHAGEAL AND DUODENAL ULCERATION: A... (5*)
Su1107. . . . CLINICAL SIGNIFICANCE OF SERUM MARKERS IN... (5*)
Su1108. . . . COLLAGENOUS GASTRITIS: A RARE CAUSE OF... (5*)
Su1109. . . . DEVELOPMENT OF NEOQUAMOUS EPITHELIUM IN THE... (5*)
Su1110. . . . EVALUATION OF SMALL BOWEL INJURY IN... (5*)
Su1111. . . . GRADING OF ACUTE ESOPHAGEAL GRAFT VERSUS... (5*)
Su1112. . . . ESOPHAGEAL PEMPHIGUS: THE EXPERIENCE FROM A... (5*)
Su1113. . . . RISK FACTORS, ENDOSCOPIC FEATURES, AND CLINICAL... (5*)
Su1114. . . . SWOLLEN STIMULANTS OF ORAL CAVITY MAY... (5*)

Su1115. . . . ACTIVATION OF EGFR-DNA-PK PATHWAY BY IGFBP2... (4*)
Su1116. . . . EOSINOPHILS ARE PRESENT IN HUMAN AND... (5*)
Su1117. . . . APURINIC/APYRIMIDINIC ENDONUCLEASE-1 IS ASSOCIATED WITH ANGIogenesis... (1*)
Su1118. . . . MEDICATION EFFECTS ON METHYLATION-RELATED BIOLOGICAL AGING... (2*)
Su1119. . . . IS THE AGE OF DIAGNOSIS OF... (5*)
Su1120. . . . HAS ACCURACY OF CLINICAL STAGING OF... (5*)
Su1121. . . . M1A DISEASE SHOULD BE RECONSIDERED IN... (5*)
Su1122. . . . COMPREHENSIVE MUTATIONAL ANALYSIS OF BACKGROUND MUCOSA... (5*)
Su1123. . . . ADDED VALUE OF MRI TO ENDOSONIC... (5*)
Su1124. . . . LONG TERM RESULTS OF ENDOSONIC TREATMENT... (4*)
Su1125. . . . ESOPHAGEAL STENT PLACEMENT FOR POST-OPERATIVE COMPLICATIONS... (5*)
Su1126. . . . CLINICAL PREDICTORS OF LOCALLYADVANCED ESOPHAGEAL ADENOCARCINOMA... (5*)
Su1127. . . . INCREASED SOX2 EXPRESSION IN THE EARLY... (2*)
Su1128. . . . CLINICAL EPIDEMIOLOGY OF ESOPHAGEAL CANCER: NATIONWIDE... (7*) (Korean College of Helicobacter and Upper Gastrointestinal Research)
Su1129. . . . PREDICTIVE SIGNIFICANCE OF ENDOSONOGRAPHIC (EUS) STAGING... (1*)
Su1130. . . . OUTCOMES AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER... (5*)
Su1131. . . . HIGH CHOLESTEROL AND HEMOGLOBIN ALC LEVELS... (4*)
Su1132. . . . NOVEL APPLICATION OF IMPEDEANCE-PH TECHNOLOGY SHOWS... (5*)
Su1133. . . . ACID SUPPRESSION DOES NOT IMPROVE LARYNGOMALACIA... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1146. . . . USE OF FECAL OCCULT BLOOD TESTING... (2*)
Su1147. . . . BLEEDING AND THROMBOSIS RISK IN CRITICALLY... (5*)
Su1148. . . . RISK OF ADVANCED METACHRONOUS NEOPLASIA IS... (5*)
Su1149. . . . ARE PPIs ASSOCIATED WITH DEMENTIA? ... (5*)
Su1150. . . . RISK OF TUBERCULOSIS IN PATIENTS WITH... (5*)
Su1151. . . . EARLY VS DELAYED ERCP IN ACUTE... (5*)
Su1152. . . . IMPACT OF NURSE OR TRAINEE PARTICIPATION... (5*)
Su11247. . . . SCREENING FOR GASTRIC INTESTINAL METAPLASIA: WHAT... (4*)
Su11248. . . . COMBINATION OF HELICOBACTER PYLORI STATUS AND... (5*)
Su11249. . . . DEMOGRAPHIC, LIFESTYLE AND DIETARY RISK FACTORS... (5*)
Su11250. . . . FEASIBILITY OF GASTRIC INTESTINAL METAPLASIA SURVEILLANCE... (5*)
Su11251. . . . CLINICOPATHOLOGICAL FEATURES OF SPORADIC NON-AMPULLARY DUODENAL... (5*)
Su11252. . . . INCIDENT DIAGNOSES OF GASTRIC INTESTINAL METAPLASIA... (5*)
Su11253. . . . EVALUATION OF DNA AND RNA EXTRACTION... (4*)
Su11254. . . . OLGA AND OLGIM STAGE DISTRIBUTION ACCORDING... (5*)
Su11255. . . . AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS (AMAG) ... (5*)
Su11257. . . . CHARACTERISTICS OF GASTROINTESTINAL STROMAL TUMORS USING... (5*)
Su11258. . . . MISSED OPPORTUNITIES FOR SCREENING OR SURVEILLANCE... (5*)
Su11259. . . . THE INCIDENCE OF GASTRIC CANCER IN... (5*)
Su11260. . . . LOW PREVALENCE OF HELICOBACTER PYLORI-POSITIVE PEPTIC... (5*)
Su11261. . . . SMOKING, HELICOBACTER PYLORI SEROLOGY, AND GASTRIC... (2*)

Su1262. . . . PREVALENCE OF HELICOBACTER PYLORI INFECTION IN... (5*)
Su1263. . . . ASSESSMENT OF GASTRIC PREMALIGNANT LESIONS BY... (2*)
Su1264. . . . HELICOBACTER PYLORI ANTIBODY PREVALENCE BY YEAR... (2*)
Su1265. . . . PROSPECTIVE COMPARISON VALIDATION STUDY OF 13C-UREA... (5*)
Su1266. . . . HELICOBACTER PYLORI TESTING AND TREATMENT IN... (3*)||Otsuka Pharmaceutical Development and Commercialization, Inc. (Rockville, MD)
Su1267. . . . MANAGEMENT OF HELICOBACTER PYLORI INFECTION AT... (5*)
Su1268. . . . HELICOBACTER PYLORI INFECTION: PRACTICE PATTERNS IN... (5*)
Su1269. . . . HELICOBACTER PYLORI INFECTION AND IRON DEFICIENCY... (5*)
Su1270. . . . CLINICAL PERFORMANCE OF THE H. PYLORI... (3*)
Su1271. . . . CHANGES IN GUT MICROBIOTA AFTER HELICOBACTER... (5*)
Su1272. . . . THE RATIO OF PEPSONGEN I TO... (4*)
Su1273. . . . HELICOBACTER PYLORI ERADICATION CANNOT RESTORE THE... (2*)||This work was supported by the tiol Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2017R1C1B5075233)
Su1274. . . . HELICOBACTER PYLORI INFECTION AMONG YOUNG PEOPLE... (5*)
Su1275. . . . HELICOBACTER PYLORI IN SOUTH TEXAS: ERADICATION... (5*)
Su1276. . . . LONG-TERM FOLLOW UP OF ENDOSCOPIC/HISTOLOGICAL ATROPHY,... (5*)
Su1277. . . . THE MANAGEMENT OF H. PYLORI IS... (5*)
Su1278. . . . ASSOCIATION OF HELICOBACTER PYLORI INFECTION AND... (4*)
Su1279. . . . IMPACT OF PRIOR EXPOSURE TO MACROLIDE... (5*)
Su1280. . . . EFFICACIES OF TAILORED THERAPY VERSUS GUIDELINE-RECOMMENDED... (4*)
Su1281. . . . TETRACYCLINE-LEVOFLOXACIN QUADRUPLE THERAPY ACHIEVES A HIGHER... (4*)
Su1282. . . . ERADICATION RATES OF TRIPLE, TRIPLE WITH... (5*)
Su1283. . . . TEN-DAY CONCOMITANT, 10-DAY SEQUENTIAL, AND 7-DAY... (2*)||Ministry of Health and Welfare, Republic of Korea)
Su1284. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN... (5*)
Su1285. . . . SYNERGISTIC INHIBITORY EFFECTS OF NANOPARTICLE HEATING... (2*)
Su1286. . . . A POTASSIUM-COMPETITIVE ACID BLOCKER-BASED REGIMEN AS... (5*)
Su1287. . . . A PHASE 1, RANDOMIZED, DOUBLE-BLIND STUDY... (3*)||Takeda Pharmaceutical Company Limited
Su1288. . . . FIRST LINE HELICOBACTER PYLORI ERADICATION IN PATIENTS... (5*)
Su1289. . . . INFLUENCE OF CLOSTRIDIUM BUTYRICUM AS PROBIOTICS... (5*)
Su1290. . . . EFFICACY AND SAFETY OF LACTOBACILLUS REUTERI... (5*)
Su1291. . . . EFFECTIVENESS OF HIGH DOSE DUAL THERAPY... (1*)
Su1292. . . . TRIPLE-DRUG BLISTER-PACKAGED DRUG WITH VONOPRAZAN IMPROVES... (5*)
Su1293. . . . LONG-TERM EFFET FOR LIPID METABOLISM BY... (5*)
Su1294. . . . ERADICATION RATIO AND ADVERSE EVENTS INCIDENCE... (1*)
Su1295. . . . SUSCEPTIBILITY-BASED THIRD LINE RESCUE THERAPY FOR... (4*)
Su1296. . . . SUPERBUG OR SOMETHING ELSE: FACTORS CONTRIBUTING... (5*)
Su1297. . . . GENETIC AND BACTERIAL FACTORS FOR OUTCOME... (5*)
Su1298. . . . CLARITHROMYCIN VERSUS METRONIDAZOLE CONTAINING FIRST-LINE VONOPRAZAN... (5*)

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIB, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1603. . . . WHEN ANTEGRADE ENEMAS GO RETROGRADE: SIGNIFICANCE... (5*)
Su1604. . . . A PRELIMINARY STUDY OF THE IMPACT... (5*)
Su1605. . . . ALTERATIONS IN BRAIN FUNCTIONAL CONNECTIVITY IN... (2*)
Su1606. . . . AUTONOMIC NERVOUS SYSTEM RESPONSE IN IRITABLE... (2*)
Su1607. . . . SOCIAL STRAIN AND LOW SOCIAL SUPPORT... (4*)
Su1608. . . . VAGUS NERVES PROVIDE A ROBUST AFFERENT... (2*)
Su1609. . . . NEUROMODULATION AND COLON MOTILITY MAPPING IN... (2*)
Su1610. . . . DYSREGULATION OF PARKINSON’S DISEASE RELATED GENES... (2*)
Su1611. . . . COLORECTAL DISTENSION MODULATES THE PAG FUNCTIONAL... (2*)
Su1612. . . . EFFECT OF VISCERO-VISCERAL INTERACTION ON FMRI... (2*)
Su1613. . . . THE ASSOCIATION OF VISCERAL ADIPOSY WITH... (2*)
Su1614. . . . HYPOGLYCEMIC EFFECTS OF CHRONIC VAGAL NERVE... (5*)
Su1615. . . . PROMOTING EFFECTS AND AUTONOMIC MECHANISMS OF... (5*)
Su1616. . . . ANTI-INFLAMMATORY EFFECTS AND MECHANISMS OF SACRAL... (2*)
Su1617. . . . NEUROANATOMICAL AND CONNECTIVITY ABNORMALITIES IDENTIFIED IN... (4*)
Su1618. . . . SEXUALLY DIMORPHIC BRAIN SIGNATURES IN STIMULUS... (2*)
Su1619. . . . RIKKUNSHITO IMPROVES CCK AND STRESS-INDUCED ANOREXIA... (4*)
Su1620. . . . NERVE FIBER SPROUTING AND NEURO-IMMUNE INTERACTIONS... (4*)
Su1621. . . . AMELIORATING EFFECTS OF SACRAL NERVE STIMULATION... (2*)
Su1622. . . . DETERMINE GINGER CONSTITUENT 6-SHOGAOL-INDUCED EFFECT ON... (5*)
Su1623. . . . ABNORMAL PERIPHERAL AUTONOMIC AND CENTRAL AUTONOMIC... (2*)
Su1624. . . . GENETIC ETHNICITY AFFECTS RESPONSE VARIABILITY IN... (4*)
Su1625. . . . IN VIVO AND IN VITRO EFFECTS... (2*) (NIH/NIDDK)
Su1626. . . . POST-STROKE CONSTIPATION IS ASSOCIATED WITH IMPAIRED... (5*)
Su1627. . . . OPIOID USAGE IS SIGNIFICANTLY ASSOCIATED WITH... (5*)
Su1628. . . . INVASIVE AND NONINVASIVE VAGAL NERVE STIMULATION... (5*)
Su1629. . . . THE AGEING GUT: SYMPTOMS COMPATIBLE WITH... (4*)
Su1630. . . . SENSORY DOMAINS, NOT STOOL FREQUENCY, PREDICT... (5*)
Su1631. . . . MACHINE LEARNING WITH PAIN MEASURES ALONE... (5*)
Su1632. . . . PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: RESULTS... (5*)
Su1633. . . . LACTOBACILLUS RHAMNOSUS GG SUPERNATANT IMPROVES DEFECTION... (5*)
Su1634. . . . IRRITABLE BOWEL SYNDROME AND STRUCTURAL ABNORMALITIES... (5*)
Su1635. . . . ORAL IRON SUPPLEMENTATION, MICROBIOME RELATED METHANOGENESIS... (5*)
Su1636. . . . THE PLACEBO RESPONSE IN CHRONIC IDIOPATHIC... (5*)
Su1637. . . . THE RELATIONSHIPS AMONG FECAL MICROBIOTA AND... (2*) ([This study was supported by Dalian municipal science and technology plan project (NO. 2015F11GH098).]
Su1638. . . . CSP01, A NOVEL SUPERABSORBENT HYDROGEL, REDUCES... (3*) (Gelesis Inc.)
Su1639. . . . DAIKENCHUTO (TU-100), A TRADITIONAL JAPANESE HERBAL... (3*) (Tsumura & Co.)
Su1640. . . . PERSISTENT IMPROVEMENT IN CHRONIC CONSTIPATION WITH... (5*)
Su1641. . . . RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL TO... (3*) (Study sponsored by Bustar Alimentos S.A.P.I de C.V)
Su1642. . . . SUPERIOR PERFORMANCE OF GASTROINTESTINAL ULTRASOUND OVER... (5*)
Su1643. . . . DEVELOPMENT OF VALIDATED QUESTIONNAIRE EVALUATING PARENT-PERCEIVED... (4*)
Su1644. . . . INTEROBSERVER ANALYSIS TRIAL ON COLONIC MOTOR... (4*)
Su1645. . . . NALOXEGOL RESTORES CODEINE-INDUCED INHIBITION OF HIGH-AMPLITUDE... (4*) ([No industry or commercial source funding was received for this study.])
Su1646. . . . THE INFLUENCE OF BRAIN METASTASES ON... (3*) ([This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.])
Su1647. . . . THE INFLUENCE OF AGE ON CENTRAL... (3*) ([This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.])
Su1648. . . . EFFICACY VARIABLES IN CANCER VERSUS NONCANCER... (3*) ([This work was supported by Salix Pharmaceuticals, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.])
Su1649. . . . WHY PATIENTS WITH CHRONIC CONSTIPATION OR... (5*)
Su1650. . . . SACRAL NERVE STIMULATION FOR SLOW TRANSIT... (2*)
Su1651. . . . A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON... (5*)
Su1652. . . . CONSTIPATION MANAGEMENT STRATEGIES: CONSUMER PREFERENCES AND... (3*) (Sanofi)
Su1653. . . . THE STUDY ON HEALTH-RELATED QUALITY OF... (5*)
Su1654. . . . THE PREVALENCE OF HLA-DQ GENES, CELIAC... (5*)
Su1655. . . . ADMINISTRATION OF NEOSTIGMINE AND GLYCOPYRROLATE BY... (4*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1657. . . . FECAL MICROBIAL MARKERS IN COLORECTAL CANCER... (5*)
Su1658. . . . MACHINE LEARNING ENABLES DETECTION OF EARLY-STAGE... (5*)
Su1659. . . . POSITIVE Fecal OCCULT BLOOD TEST AFTER... (5*)
Su1660. . . . COLORECTAL CANCER SCREENING: COMPLIANCE WITH MULTI-TARGET... (3*) (Exact Sciences)
Su1661. . . . A FAVORABLE SURVIVAL OF THE SCREENING-DETECTED... (5*)
Su1662. . . . TIME TO DIAGNOSIS OF EARLY-ONSET VS.... (2*)
Su1663. . . . WATER EXCHANGE (WE) ENHANCED DETECTION OF... (2*)
Su1664. . . . HIGH YIELD OF TOTAL AND RIGHT-SIDED... (4*)
Su1665. . . . USE OF SCREENING COLONOSCOPY IN AFRICAN... (5*)
Su1666. . . . PREDICTORS OF MODIFIABLE FAILURES TO SCREEN... (2*)
Su1667. . . . INCREASING UPTAKE OF COLON CANCER SCREENING... (5*)
Su1668. . . . THE CORRELATION OF FIT LEVELS WITH... (5*) (The first author completed this research as part of a Newman Fellowship, which was funded by Boston Scientific.)
Su1754. . . . OVERESTIMATION OF THE PREVALENCE OF EOSINOPHILIC... (2*)
Su1771. . . . SYSTEMS GENOMICS OF ULCERATIVE COLITIS: COMBINING... (6*)
Su1772. . . . INFLAMMATION-DEPENDENT TRANSCRIPTIONAL RE-PROGRAMMING OF THE HIF... (2*)
Su1773. . . . INTESTINAL ORGANOIDS DERIVED FROM HUMAN INDUCED... (5*)
Su1774. . . . AN INTERPLAY OF PAK1 AND NRF2... (2*)
Su1775. . . . ARTIFICIAL SWEETENER ACESULFAMEPOTASSIUMENHANCED LYMPHOCYTE MIGRATION TO... (4*)
Su1776. . . . ASSOCIATION OF BIOLOGIC PRESCRIBING FOR INFLAMMATORY... (5*)
Su1777. . . . RECEIPT OF PREVENTIVE CARE SERVICES AMONG... (5*)
Su1778. . . . THE TORONTO IBD GLOBAL ENDOSCOPIC REPORTING... (5*)
Su1779. . . . TEXT MESSAGE-BASED TELEMEDICINE DOES NOT IMPROVE... (2*)
Su1800. . . . EFFECT OF ADDITION OF AN IMMUNOMODULATOR... (5*)
Su1798. . . . THE INFLUENZA VACCINATION AND PEDIATRIC INFLAMMATORY... (5*)
Su1799. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND... (3*)
Su1801. . . . A NOVEL SALT OF RESOLVIN E1... (2*) (This work was funded in part by Thetis Pharmaceuticals.)
Su1802. . . . SLCO2A1 DEFICIENCY EXACERBATES EXPERIMENTAL COLITIS VIA... (5*)
Su1803. . . . TWEAK/FN14 AMELIORATES EXPERIMENTAL ILEITIS BY REGULATING... (2*)
Su1804. . . . THE COMMON IBD COMPLICATIONS IRON DEFICIENCY... (2*)
Su1805. . . . WHEAT AMYLASE/TRYPsin INHIBITORS AGGRAVATE EOSINOPHILIC ESOPHAGITIS... (2*)
Su1806. . . . BERBERINE REGULATES LYPOSIPHATIDYLCOLINE TO PROTECT DSS-INDUCED... (2*) (This work was kindly funded by grants from tional Science Foundation of Chi (Project No. 81560676), Logan Charitable Foundation, Hong Kong Baptist University Research Grant (No. LUVE/15-16/01-CLNC) and Shenzhen Science and Technology Innovation Commi)
Su1807. . . . POST-OPERATIVE RECURRENCE AFTER Ileo-caecal RESECTION FOR... (5*) (Lesaffre Intertiol, Lesaffre Group, Marcq-en-Baroeul, France)
Su1808. . . . DOWNREGULATION OF RALGTPASE-ACTIVATING PROTEIN LEADS TO... (2*) (Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI))
Su1809. . . . A COMPARISON STUDY OF SYSTEMIC VERSUS... (3*) (Progenity Inc.)
Su1810. . . . COMBINATORIAL TREATMENT WITH A HIF-HYDROXYLASE INHIBITOR... (2*) (Sigmoid Pharma)
Su1811. . . . NOVEL INSIGHT INTO MECHANISM OF PROTECTIVE... (4*) (tional Science Centre, Poland (grant number UMO-2015/19/B/NZ4/03130)).
Su1812. . . . TREATMENT WITH HYDROLYZED DIET SUPPLEMENTED WITH... (3*) (Bioberic SAU)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds     (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)     (3) = Industry or Commercial Entity     (4) = Institutional Funds
(5) = No Study Funding     (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)     (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1919. . . MONITORING VITAMIN D METABOLISM IN INFLAMMATORY... (3*) [(Immundiagnostik AG, Bensheim, Germany)
Su1920. . . PHENOTYPE CLASSIFYING CROHN'S DISEASE INTO ILEAL... (2*)
Su1921. . . VALIDATION OF SCORING SYSTEMS FOR DIFFERENTIATING... (5*]
Su1922. . . PERFORMANCE OF A NOVEL FECAL CALPROTECTIN... (3*)
Su1923. . . NOVEL ASSOCIATIONS OF PLATELETS WITH CLINICAL... (2*)
Su1924. . . THE USE OF ALVIMOPAN AS PROPHYLAXIS... (5*)
Su1925. . . NON-ADHERENCE TO MAINTENANCE MEDICATIONS IS COMMON... (2*)
Su1926. . . RISK OF INFECTIONS AND HOSPITALISATIONS IN... (5*)
Su1927. . . CONTINUING 5-ASA THERAPY IN MODERATE-TO-SEVERE ULCERATIVE... (4*)
Su1928. . . TOFACITINIB IMPROVES CLINICAL DISEASE ACTIVITY IN... (5*)
Su1929. . . OUTCOMES FOLLOWING INTRAVENOUS STEROID USE IN... (5*)
Su1930. . . SAFETY AND EFFICACY OF OLORINAB, A... (3*) [(Are Pharmaceuticals, Inc.)
Su1931. . . DOES CORTICOSTEROID THERAPY AFFECT PROGNOSIS IN... (5*)
Su1932. . . SAFETY OF RECOMBINANT ZOSTER VACCINE (RZV-SHINGRIX)... (5*)
Su1933. . . ANTI-MYCOBACTERIUM PARATUBERCULOUS THERAPY IN CROHN'S DISEASE... (5*)
Su1934. . . SAFETY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE... (3*)
Su1935. . . SAFETY AND EFFECTIVENESS OF GRANULOCYTE AND... (3*)
Su1936. . . ENDOSCOPIC EVALUATION FOR GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE... (5*)
Su1937. . . THE MANITOBA LIVING WITH IBD STUDY... (2*)
Su1941. . . HELICOBACTER PYLORI CAGA PROTEIN NEGATIVELY REGULATES... (5*)
Su1942. . . CRYPTOSPORIDIUM PARVUM INFECTION INDUCES AUTOPHAGY IN... (2*)
Su1943. . . LONG-TERM EHEC INFECTION STIMULATES MUCUS PRODUCTION... (5*)
Su1944. . . METASTATIC ASSOCIATED COLON CANCER 1 (MACC1)... (2*)
Su1945. . . DIFFERENTIAL RESPONSE OF INTESTINAL EPITHELIAL CELLS... (6*)
Su1946. . . DISRUPTION OF INTESTINAL EPITHELUM WITH THE... (2*)
Su1947. . . HYA, A METABOLITE OF LINOLEIC ACID... (5*)
Su1948. . . CHARACTERISTICS AND INFLUENCING FACTORS OF GUT... (5*)
Su1949. . . SMALL INTESTINAL ASPIRATES REQUIRE SPECIFIC TREATMENT... (4*)
Su1950. . . RISK FACTORS FOR CENTRAL LINE-ASSOCIATED BLOODSTREAM... (5*)
Su1951. . . GLOBAL DISPARITIES AND NEW INDICATIONS IN... (5*)
Su1952. . . PATIENTS' PERSPECTIVE AND COMPLIANCE AFFECT THE... (1*)
Su1953. . . PATIENT PERCEPTIONS OF FECAL MICROBIOTA TRANSPLANTATION... (5*)
Su1954. . . LONG-TERM EFFICACY OF RIFAXIMIN TO MANAGE... (1*)
Su1955. . . CLOSTRIDIUM DIFFICILE-ASSOCIATED OUTCOMES AMONG HOSPITALIZED INFLAMMATORY... (5*)
Su1956. . . IS DIARRHEA THE ONLY SYMPTOM OF... (5*)
Su1957. . . CLOSTRIDIUM DIFFICILE SCREENING IN HOSPITALIZED PATIENTS... (5*)
Su1958. . . GEOSPATIAL DISTRIBUTION AND TRENDS IN COMMUNITY... (5*)
Su1959. . . TRENDS IN INCIDENCE, MORTALITY, AND COSTS... (5*)
Su1960. . . ASSESSMENT OF CLOSTRIDIUM DIFFICILE EPIDEMIOLOGY AMONG... (7*) [(Merck Cada)
Su1961. . . COST-EFFECTIVENESS OF TREATMENT REGIMENS FOR CLOSTRIDIUM... (2*)
Su1962. . . DOES HIGHER SERUM PROCALCITONIN LEVELS PREDICT... (5*)
Su1963. . . AMINO ACID SENSING IS AN ESSENTIAL... (2*)
Su1964. . . THE FOOD ADDITIVE EDTA INCREASES INTESTINAL... (7*)
Su1965. . . CROHN'S LIKE LYMPHOID REACTION IS ASSOCIATED... (5*)
Su1966. . . NOVEL EVIDENCE FOR SERUM MIR-203 LEVELS... (4*)
Su1967. . . HIGH RIBOFLAVIN INTAKE PROTECTS AGAINST SESSEILE... (2*)
Su1968. . . INCREASED PREVALENCE OF TYPE 2 DIABETES... (2*)
Su1969. . . PSOSA MUSCLE INDEX AFFECTS THE LONG-TERM... (5*)
Su1970. . . THE ASSOCIATION OF LACTOSE INTOLERANCE WITH... (5*)
Su1971. . . ASSOCIATION BETWEEN SARCOPENIA AND GASTRIC CARCINOGENESIS... (5*)
Su1972. . . GASTRIC MICROBIOME IN PATIENTS WITH INTESTINAL... (2*)
Su1973. . . CAN INTRAGASTRIC BALLOON THERAPY normalize the... (5*)
Su1974. . . FECAL MICROBIOTA TRANSPLANT IN GRAFT VERSUS... (5*)
Su1975. . . GERM-FREE C57BL/6 MICE ARE SUSCEPTIBLE TO... (4*)
Su1976. . . IMPACTS OF ADDITIVE FOOD E171 (TITANIUM... (4*)
Su1977. . . THE SAFETY AND EFFICACY OF FECAL... (5*)
Su1978. . . ASSOCIATION OF FUSOBACTERIUM NUCLEATUM IN COLORECTAL... (2*)
Su1979. . . UPREGULATED CLAUDIN-1 EXPRESSION INDUCES GUT DYSBIOSIS... (2*)
Su1980. . . THE NETWORK CONSTRUCTION AND MODULE ORGANIZATION... (2*)
Su1981. . . INDUCTION OF SPECIFIC CARCINOGENIC MICRO-RNAS EXPRESSION... (2*)
Su1982. . . MUCOSA-ASSOCIATED MICROBIOTA IN THE UPPER GUT... (1*)
Su1983. . . LACK OF PREVENTIVE DENTAL CARE IS... (2*)
Su1984. . . THE DIFFERENCE OF GUT MICROBIOME... (5*)
Su1985. . . PRELIMINARY DATA ON ORAL AND FECAL... (5*)
Su1986. . . GUT DYSBIOSIS INDUCED ABNORMAL BILE ACIDS... (5*)
Su1987. . . THE CHANGE OF THE GUT MICROBIOTA... (5*)
Su1988. . . MUCOSA-ASSOCIATED MICROBIOTA DIVERSITY SIGNIFICANTLY DIFFERS IN... (5*)
Su1989. . . ASSOCIATIONS BETWEEN GASTROESOPHAGEAL HISTOPATHOLOGY AND THE... (5*)
Su1990. . . FUSOBACTERIUM NUCLEATUM INFECTION ASSOCIATES WITH TWO... (2*)
Su1991. . . DIFFERENCES IN THE GASTROESOPHAGEAL MICROBIOME AND... (2*)
Su1992. . . INFECTION BY PATHOGENIC E. COLI INDUCES... (2*)
Su1993. . . DIET AND OBESITY RATHER THAN ETHNICITY... (4*)
Su1994. . . THE COMMON FOOD ADDITIVES SODIUM SULFITE... (6*)
Su1995. . . HIGH-FAT DIET-INDUCED GUT MICROBIOTA DYSBIOSIS PROMOTE... (2*)
Su1996. . . ALTERED GUT MICROBIOTA INDUCED BY A... (2*)
Su1997. . . COCONUT OIL DIET AS ADJUVANT FOR... (2*)
Su1998. . . EARLY LIFE SOLID FOOD INGESTION REMODELS... (5*)
Su1999. . . THE EFFECT OF DIETARY FIBER INTAKE... (2*)
Su2000. . . CROHN’S DISEASE PATIENTS IN REMISSION CONSUMING... (6*)
Su2001. . . EFFECT OF A MODIFIED AMERICAN DIET... (2*)
Su2002. . . ALTERATIONS IN THE SMALL BOWEL MICROBIOTA... (4*)
Su2003. . . MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE... (4*)
Su2004. . . DISRUPTION OF CIRCADIAN RHYTHM REDUCES THERMOGENESIS... (2*)
Su2005. . . AGE-RELATED DYSMETABOLISM IS ASSOCIATED WITH CHANGES... (2*)
Su2006. . . FUSOBACTERIUM NUCLEATUM MAY PROMOTE GLYCOLYSIS VIA... (2*)
Su2008. . . MECHANISM OF INHIBITION OF VILLUS CELL... (2*)
Su2009. . . NUTRITIONAL ASSESSMENT IN PATIENTS UNDERGOING GASTRIC... (5*)
Su2010. . . MORTALITY AND OUTCOMES IN PATIENTS WITH... (3*) [(Study funding provided by Shire)]
Su2011. . . SHORT BOWEL SYNDROME PATIENTS WITH RESIDUAL... (2*)
Su2012. . . ETIOLOGY OF AND PREDICTIVE FACTORS FOR... (5*)
Su2013. . . EFFECTS OF GLIEPAGLUTIDE, A NOVEL LONG-ACTING... (3*) [(The trial was sponsored by Zealand Pharma, Denmark.)]
Su2014. . . HOME PARENTERAL NUTRITION PATIENTS WITH SEVERE... (5*)
Su2015. . . EFFECT OF APRAGLUTIDE, A NOVEL LONG-ACTING... (3*)
Su2016. . . ADIPOSE-DERIVED SECRETOME (ADS) MEDIATES THE STIMULATION... (2*)
Su2018. . . LONG NON-CODING RNA ZFAS1 PROMOTES PROLIFERATION... (2*)
Su2019. . . INTESTINAL GROWTH IN GLUCAGON RECEPTOR KNOCKOUT... (6*)
Su2020. . . NUTRITIONAL CARE PATHWAYS OF PATIENTS WITH... (3*) [[This research was funded by CALEA, Fresenius Kabi, UK.]]
Su2022. . . TOLERANCE AND OUTCOME OF NUTRITION SUPPORT... (5*)
Su2023. . . A RETROSPECTIVE STUDY ON ICU ADMISSION... (5*)
Su2024. . . USE OF PREOPERATIVE TOTAL PARENTERAL NUTRITION... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1009. . . USE OF COMMUNITY HEALTH WORKERS IN... (6*)
Mo1010. . . INCREASING INCIDENCE OF STAGE I PANCREATIC... (5*)
Mo1011. . . UTILIZING SOCIAL MEDIA TO SHARE SCIENTIFIC... (4*) (5)
Mo1100. . . HYPERURICEMIA AMELIORATES INTESTINAL INFLAMMATION ALONG WITH... (4*)
Mo1101. . . SUPERIOR MESENTERIC VEIN OCCLUSION IN RATS... (4*)
Mo1102. . . ASPIRIN AND ISCHEMIA IN THE MURINE... (4*)
Mo1103. . . RESTRICTIVE EXPRESSION OF METALLOENDOPEPTIDASE ADAM-LIKE DECYSIN... (2*)
Mo1104. . . THE TRANS-GOLGI NETWORK PROTEIN APFITHILIN REGULATES... (2*)
Mo1106. . . IMMUNOLOGIC DISSECTION OF COLITIS RELATED TO... (2*)
Mo1107. . . IRON PREVENTS HYPOXIA-INDUCED INFLAMMATION IN THE... (2*)
Mo1108. . . RESCUE OF RESTITUTION DEFECT IN A... (2*)
Mo1109. . . SEVERE WOUND CONTRACTION PROMOTES BARRETT'S ESOPHAGUS... (1*)
Mo1110. . . ER STRESS PATHWAY ACTIVATION AFTER DOXORUBICIN... (2*)
Mo1111. . . THE METFORMIN INHIBITS MDSC AND M2... (5*)
Mo1112. . . MICRorna-24 IS OVEREXPRESSED IN ULCERATIVE COLITIS... (2*)
Mo1113. . . 3-Oxo-C12:2 N-Acyl Homoserine Lactone, A Quorum... (4*)
Mo1114. . . DOXORUBICIN EXPOSURE DECREASES INTESTINAL EPITHELIAL BARRIER... (2*)
Mo1115. . . PRO-INFLAMMATORY AND PRO-FIBROTIC STEM CELL VARIANTS... (2*)
Mo1116. . . MOLECULAR CHARACTERIZATION OF COLONIC MAIT CELLS... (4*)
Mo1117. . . GAVAGE AS-MIR-214-3P REDUCES INFLAMMATION IN EXPERIMENTAL... (2*)
Mo1118. . . PRESERVATION OF JEJUNAL ACTIVE INTESTINAL STEM... (2*)
Mo1119. . . THE ROLE OF EXTRACELLULAR DNA IN... (2*)
Mo1120. . . A TRIAL FOR THE ADMINISTRATION OF... (5*)
Mo1121. . . PH-DEPENDENT G PROTEIN-COUPLED RECEPTOR GPR68 (OGR1)... (2*)
Mo1122. . . GENE EXPRESSION PROFILING AND FLOW CYTOMETRY... (4*)
Mo1126. . . RAPID RECURRENT OF SYMPTOMS, ENDOSCOPIC FINDINGS,... (2*)
Mo1127. . . MAST CELLS IN ADDITION TO EOSINOPHILS... (3*) (Allakos, Inc. This work was also funded in part by the Division of Intramural Research, NIAID, NIH)
Mo1128. . . VONOPRAZAN SHOWS EFFICACY SIMILAR TO THAT... (5*)
Mo1129. . . EFFICACY OF BUDENOSIDE ORODISPERSIBLE TABLETS FOR... (3*) (This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany)
Mo1130. . . BUDENOSIDE ORODISPERSIBLE TABLETS CAN EFFECTIVELY INDUCE... (3*) (This study was funded by Dr. Falk Pharma GmbH, Freiburg, Germany)
Mo1131. . . CLINICAL AND ENDOSCOPIC CHARACTERISTICS ACCURATELY PREDICT... (2*)
Mo1132. . . DIETARY ELIMINATION THERAPY IS EFFECTIVE FOR... (2*)
Mo1133. . . HIGH PATIENT-REPORTED DISEASE BURDEN FOR EOSINOPHILIC... (2*)
Mo1134. . . ESOPHAGEAL LICHEN PLANUS: DIAGNOSTIC CRITERIA AND... (5*)
Mo1135. . . ROLE OF REFLUX IN THE PATHOGENESIS... (5*)
Mo1136. . . EOSINOPHIL COUNT ON BASELINE ENDOSCOPY PREDICTS... (5*)
Mo1137. . . QUALITY IMPROVEMENT IN THE MANAGEMENT OF... (5*)
Mo1138. . . A COMPREHENSIVE ASSESSMENT OF EOSINOPHILIC OESOPHAGITIS... (5*)

Abstract Funding Source Key

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
... CAN IGG4 BE USED AS AN...
(5*)
Mo1140. . . EOSINOPHILIC OESOPHAGITIS IN CHILDREN AND ADULTS... (5*)
Mo1141. . . FECAL EOSINOPHIL CATIONIC PROTEIN AS POTENTIAL... (5*)
Mo1142. . . ACHALASIA IS A COMMON FINDING IN... (5*)
Mo1143. . . ESOPHAGEAL MOTILITY DISORDERS IN EOSINOPHILIC OESOPHAGITIS... (5*)
Mo1144. . . EOSINOPHILIC GASTROINTESTINAL DISEASE FOLLOWING INTESTINAL TRANSPLANT... (5*)
Mo1145. . . EOSINOPHILIC ESOPHAGITIS IS ASSOCIATED WITH A... (5*)
Mo1146. . . CLINICAL MANIFESTATION, COURSE OF DISEASE AND... (5*)
Mo1147. . . ASSOCIATION OF ALLERGENIC HOUSING COMPONENTS AND... (2*)
Mo1148. . . ESOPHAGEAL LAMINA PROPIA FIBROSI S OCCURS IN... (4*)
Mo1149. . . PREDOMINANCE OF EOSINOPHILIC ESOPHAGITIS IN CROHN’S... (5*)
Mo1150. . . SUBSTANTIAL BURDEN OF PSYCHIATRIC COMORBIDITIES AND... (5*)
Mo1151. . . PSYCHIATRIC COMORBIDITY IS ASSOCIATED WITH DEMOGRAPHIC... (5*)
Mo1152. . . VALIDATION OF A MODEL TO PREDICT... (2*)
Mo1153. . . BIOMARKERS OF DISEASE ACTIVITY AND TREATMENT... (5*)
Mo1154. . . PREVALENCE AND CHARACTERISTICS OF EOSINOPHILIC ESOPHAGITIS... (3*) (This study was funded by Shire Human Genetic Therapies, Inc.)
Mo1155. . . PATTERNS OF CARE IN THE MANAGEMENT... (5*)
Mo1156. . . ENDOscopic FEATURES OF GERD PREDICT PERSISTENCE... (2*)
Mo1157. . . THE ASSOCIATION OF EOSINOPHILIC ESOPHAGITIS AND... (5*)
Mo1158. . . CLINICAL FEATURES AND TREATMENT OUTCOMES ACCORDING... (5*)
Mo1159. . . LYMPHOcytic ESOPHAGITIS: A CASE SERIES OF... (5*)
Mo1160. . . EATING BEHAVIOR IN PATIENTS WITH EOSINOPHILIC... (6*)
Mo1161. . . THE ENDOSCOPIC BURDEN OF EOSINOPHILIC ESOPHAGITIS... (5*)
Mo1162. . . THE ENDOSCOPICALLY NORMAL ESOPHAGUS IN EOSINOPHILIC... (2*)
Mo1163. . . EG AND EOE PATIENT BIOPSI ES HAVE... (3*) (Allakos, Inc.)
Mo1164. . . THE UTILITY OF EPITHELIAL EOSINOPHILIC DERIVED... (1*)
Mo1165. . . THE THIAZOLIDINEDIONES AS POTENTIAL THERAPEUTIC AGENTS... (2*)
Mo1166. . . DISRUPTION OF ESOPHAGEAL EPITHELIAL BARRIER FUNCTION... (5*)
Mo1167. . . EFFECT OF VARYING TIME INTERVALS ON... (4*)
Mo1168. . . SERUM MILK-SPECIFIC IGG4 LEVELS ARE ASSOCIATED... (2*)
Mo1169. . . AUTOMATED ANALYSIS OF EOSINOPHIL PEROXIDASE FOR... (2*)
Mo1170. . . EVOLVING FROM DE TREATED, H.... (5*)
Mo1171. . . THE INFLUENCE OF H. PYLORI INFECTION... (5*)
Mo1172. . . SHORT-TERM EFFECTS OF AMBIENT FINE PARTICULATE... (2*)
Mo1173. . . A SYSTEMATIC REVIEW AND META-ANALYSIS. ANALYSING... (5*)
Mo1174. . . NON-VITAMIN K ORAL ANTICOAGULANTS HAVE LOWER... (1*)
Mo1175. . . THE EFFECT OF LOW-DOSE ASPIRIN ON... (3*) (This study was funded by Bayer AG)
Mo1176. . . NO DIFFERENCES IN GI BLEEDING RISK... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds    (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)    (3) = Industry or Commercial Entity    (4) = Institutional Funds
(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1565. . . . CONFOCAL LASER ENDOMICROSCOPY IN PATIENTS WITH... (2*) [Study supported by Michigan Institute for Clinical and Health Research (MICHR) grant number UL1TR000433]

Mo1566. . . . CHARACTERISTICS OF THE HOT-WATER BATHING PATTERN... (4*)

Mo1567. . . . IMPACT OF GENETIC VARIATION IN GLP-1... (2*)

Mo1568. . . . CORRELATION BETWEEN SLEEP DISTURBANCE IN FUNCTIONAL... (5*)

Mo1569. . . . EXOSOMAL HSA-MIR-933 IN GASTRIC JUICE AS... (2*) [Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP16K09252]

Mo1570. . . . A NOVEL COMBINED NONINVASIVE MULTIPLE GASTRIC... (5*)

Mo1571. . . . COMPARISON OF GASTRIC SLOW WAVES AND... (5*)

Mo1572. . . . DELAYED GASTRIC EMPTYING BY WIRELESS MOTILITY... (3*) [This study was supported by a grant from Medtronic.]

Mo1573. . . . 3D MRI IMAGING OF THE STOMACH... (2*)

Mo1574. . . . GASTRIC ELECTRICAL NEUROSTIMULATION COMBINED WITH PYLOROPLASTY... (5*)

Mo1575. . . . ASSESSMENT OF GASTRIC EMPTYING MOTILITY UTILIZING... (5*)

Mo1576. . . . GASTRIC EMPTYING RESULTS FROM WIRELESS MOTILITY... (5*)

Mo1577. . . . ADVANCED GASTRIC EMPTYING SCINTIGRAPHY TO EVALUATE... (4*)

Mo1578. . . . SURGICAL INTERVENTIONS FOR REFRACTORY GASTROPARESIS: GASTRIC... (5*)

Mo1579. . . . CLINICAL AND GASTRIC MOTILITY FEATURES IN... (5*)

Mo1580. . . . EFFECT OF DIETARY INTERVENTION ON PATIENTS... (4*)

Mo1581. . . . EVALUATION OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC... (3*) [The study was funded by Theravance Biopharma US, Inc., while medical writing assistance was provided by Colin Glen of Oxford PharmaGenesis, Oxford, UK and supported by Takeda Pharmaceutical Company Ltd.]

Mo1582. . . . TRANSCUTANEOUS VAGAL NERVE STIMULATION IMPROVES SYMPTOMS... (4*)

Mo1583. . . . GHRELIN AND MOTILIN DERANGEMENTS DURING WIRELESS... (7*)

Mo1584. . . . EFFECTIVENESS OF LANREOTIDE IN THE TREATMENT... (3*) [This study was sponsored by Ipsen Pharmaceuticals.]

Mo1585. . . . ROLE OF SEX HORMONES AND THEIR... (2*)

Mo1586. . . . OPIOID USE DISORDER IS ASSOCIATED WITH... (5*)

Mo1587. . . . PRUCALOPRIDE VERSUS PLACEBO IN DIABETIC GASTROPARESIS... (3*) [Janssen Inc.]

Mo1588. . . . INCREASED SYMPTOM SEVERITY ASSOCIATED WITH THE... (3*) [Takeda Pharmaceuticals]

Mo1589. . . . GASTRIC RETENTION IN GASTROPARESIS: RELATIONSHIP OF... (2*)

Mo1590. . . . BODY WEIGHT AND BODY WEIGHT CHANGES... (2*)

Mo1591. . . . DOES OTHER END-ORGAN DAMAGE CORRELATE WITH... (2*)

Mo1592. . . . MARIJUANA USE IN PATIENTS WITH SYMPTOMS... (2*)

Mo1593. . . . DOCUMENTATION OF PYLORIC SMOOTH MUSCLE DYSFUNCTION... (5*)

Mo1594. . . . MODELING DELAYED GASTRIC EMPTYING USING WNT1CRE-IDTR... (2*)

Mo1595. . . . THE IMPACT OF RISK FACTORS ON... (5*)

Mo1596. . . . A PILOT CHRONIC ANIMAL STUDY OF... (2*)

Mo1597. . . . THE VIP/PIN BALLOON CATHETER REVEALS A... (4*)

Mo1598. . . . THE DIAGNOSIS AND MANAGEMENT OF GASTROPARESIS... (5*)

Mo1599. . . . COMBINED GASTRIC ELECTRICAL STIMULATION PYLOROPLASTY IMPROVES... (5*)

Mo1600. . . . ASSESSING PYLORUS DISTENSION WITH IMPEDANCE PLANIMETRY... (5*)

Mo1601. . . . GASTROINTESTINAL SYMPTOMS IN CHILDREN DURING GASTRIC... (5*)

Mo1602. . . . SCINTIGRAPHIC METHODOLOGY USING MID-ANTRUM REGIONS OF... (5*)

Mo1603. . . . PREVALENCE AND INCIDENCE OF GASTROPARESIS IN... (3*) [This study was supported by Takeda Pharmaceuticals Intertiol Inc., All authors are employees of Takeda Pharmaceuticals Intertiol Inc.,]

Mo1604. . . . COMPARISON OF SYMPTOM AND QUALITY OF... (3*) [The parent investigation supporting this study was funded by Medtronic (grant MAS01).]

Mo1605. . . . CLINICAL CHARACTERISTICS AND GUT PHYSIOLOGY IN... (4*)

Mo1606. . . . AUTONOMIC AND ENTERIC FUNCTION PROFILING CAN... (5*)

Mo1607. . . . BASELINE PREDICTIVE FACTORS FOR FORE AND... (5*)

Mo1608. . . . ALTERED INTESTINAL PERMEABILITY AND EFFECT OF... (5*)

Mo1609. . . . CAREGIVER BURDEN IN GASTROPARESIS: CORRELATION WITH... (5*)

Mo1610. . . . CHARACTERIZING SYMPTOMS OF BRAIN Fogginess AND... (5*)

Mo1611. . . . SYMPTOMS OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER... (5*)

Mo1612. . . . SYMPTOM VARIABILITY THROUGHOUT THE DAY IN... (5*)

Mo1613. . . . WIRELESS MOTILITY CAPSULE EVALUATION OF REGIONAL... (5*)

Mo1614. . . . COMPARISON OF GASTRIC ACCOMMODATION MEASUREMENTS BY... (5*)

Mo1615. . . . FAT-SOLUBLE VITAMINS, B12, AND IRON DEFICIENCY... (3*) [Progenity, Inc]

Mo1616. . . . CARDIAC SAFETY AND CLINICAL EFFICACY OF... (5*)

Mo1617. . . . DIFFERENCES IN PYLORIC DISTENSIBILITY IN PATIENTS... (5*)

Mo1618. . . . PER-ORAL ENDOCOPIC PYLOROMYOTOMY FOR SEVERE REFRACTORY... (5*)

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Fecal immunochemical tests were...
Mo1739. . . . MOLECULAR MarkERS, MLH1 AND MSI STATUS... (2*)
Mo1740. . . . ALCOHOL AND COLON CANCER: DOES TIME... (2*)
Mo1741. . . . INDUCTION OF WHOLE GENOME DOUBLING WITH... (2*)
Mo1742. . . . PROXIMAL VERSUS DISTAL COLON ADENOCARCINOMA WITH... (5*)
Mo1743. . . . KNOCK-DOWN OF GRANULIN, A NOVEL STAT3-INTERACTING... (5*)
Mo1744. . . . NLRP6 TARGETING SUPPRESSES COLONIC TUMORIGENESIS VIA... (2*)
Mo1745. . . . PATHOLOGICAL IMPACT OF TRANSDURAL COLORECTAL TUBE... (5*)
Mo1746. . . . 12-LIPOXYGENASE PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION THROUGH THE... (2*)
Mo1746A. . . . SERUM N-GLYCOMIC BIOMARKERS PREDICT TREATMENT ESCALATION... (2*)
Mo1746B. . . . REAL-LIFE EXPERIENCE WITH LONG-TERM MAINTENANCE OF... (5*)
Mo1746C. . . . MULTIDISCIPLINARY TEAM CARE AT THE EMERGENCY... (5*)
Mo1747. . . . PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS... (5*)
Mo1748. . . . ELEVATED RISK OF METACHRONOUS NEOPLASIA WITH... (5*)
Mo1749. . . . OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES... (5*)
Mo1750. . . . ADHERENCE TO GUIDELINES REMAINS POOR AMONG... (5*)
Mo1751. . . . THE FACTORS ASSOCIATED WITH THE LEVELS... (7*)
Mo1752. . . . INCREASED HEALTHCARE UTILIZATION BY MEDICAID PATIENTS... (5*)
Mo1753. . . . COST DRIVERS AND TRENDS IN INFLAMMATORY... (6*)[[Funding for this initiative is made possible through a grant from the Leo M. and Harry B. Helmsley Charitable Trust and United Health Group.]
Mo1754. . . . HEALTHCARE UTILISATION COSTS MAY BE REDUCED... (3*)[[This work was supported by a peer reviewed grant from the Gastroenterological Society of Australia funded by Janssen: “Inflammatory Bowel Disease Centre of Excellence Award”.
Mo1755. . . . PREVALENCE OF FINANCIAL CONFLICTS OF INTEREST... (5*)
Mo1756. . . . SUSTAINED IMPROVEMENTS IN FATIGUE AND QUALITY... (3*)[[AMAG Pharmaceuticals, Inc.]
Mo1757. . . . A PROSPECTIVE MULTI-CENTER STUDY ON THE... (4*)
Mo1758. . . . FEMALE GENDER ASSOCIATED WITH LESS-SEVERE CROHN’S... (5*)
Mo1759. . . . TRENDS IN EMERGENCY DEPARTMENT VISITS AND... (3*)[[Sponsorship: Janssen Scientific Affairs, LLC]
Mo1760. . . . GENDER BIAS IN REFERRAL AND DIAGNOSIS... (2*)
Mo1761. . . . ROLE OF G PROTEIN-COUPLED RECEPTOR 15... (4*)
Mo1762. . . . THE ROLE OF CYCLOOXYGENASE IN COLITIS-ASSOCIATED... (2*)
Mo1763. . . . H. PYLORI-INDUCED PRDX2 PROTECTS AGAINST OXIDATIVE... (4*)
Mo1764. . . . THE ROLE OF FOXM1 IN HELICOBACTER... (2*)
Mo1765. . . . CELLULAR SENESCENCE OF CD4+ T CELLS... (5*)
Mo1766. . . . AGE-AND CANCER-ASSOCIATED OPLAH METHYLATION IS... (5*)
Mo1767. . . . THE FUNCTIONAL ROLE OF VEGFR-2 IN... (5*)
Mo1768. . . . PREVALENCE AND RISK FACTORS OF FIRST-EVER... (5*)
Mo1769. . . . INFLAMMATORY REACTION PATTERNS AND MOLECULAR GENETICS... (5*)
Mo1770. . . . MUCOSAL HEALING IS ACHIEVABLE WITH METHOTREXATE... (5*)
Mo1771. . . . BIOLOGIC AND IMMUNOMODULATOR WITHDRAWAL IN PEDIATRIC... (2*)[[This Tobacco Formula grant is under the Commonwealth Universal Research Enhancement (C.U.R.E) program with the grant number SAP # 4100068710.)
Mo1772. . . . SELF-REPORTED DIETARY BEHAVIORS FOR SYMPTOM MANAGEMENT... (4*)
Mo1773. . . . DRIVERS OF HEALTHCARE COST FOR CHILDREN... (5*)
Mo1774. . . . INCREASING TRENDS IN DIAGNOSTIC PREVALENCE AND... (3*)
Mo1775. . . . THREE YEAR OUTCOMES OF A COHORT... (5*)
Mo1776. . . . VEDOLIZUMAB EXPERIENCE IN CHILDREN AND ADOLESCENTS... (5*)
Mo1777. . . . IMPACT OF PREMEDICATION AND OTHER VARIABLES... (5*)
Mo1778. . . . INFLAMMATORY MICROHETEROGENEITY IN UC: IMPLICATIONS FOR... (5*)
Mo1779. . . . UTILITY OF A SIMPLE BLOOD TEST... (5*)[[Testing of patient samples was provided by Prometheus Laboratories Inc.]
Mo1780. . . . A SIMPLE SCORING TOOL PREDICTS EXPOSURE-RESPONSE... (3*)[[Takeda Pharmaceuticals U.S.A., Inc.]
Mo1781. . . . INCORPORATING FECAL CALPROTECTIN IN CLINICAL PRACTICE... (5*)
Mo1782. . . . TRANSMURAL HEALING ASSESSED USING MRI IS... (5*)
Mo1783. . . . THE MODIFIED HARVEY-BRADSHAW INDEX AND PARTIAL... (5*)
Mo1784. . . . THE ROLE OF FECAL CALPROTECTIN IN... (5*)
Mo1785. . . . INFLAMMATORY BOWEL DISEASE PATIENTS WITH ILEAL... (5*)
Mo1786. . . . ENDOSCOPIC POUCH ACTIVITY IN ASYMPTOMATIC PATIENTS... (5*)
Mo1787. . . . MAGNETIC RESONANCE FINGERPRINTING (MRF) IS A... (2*)[[Siemens Health
Mo1788. . . . RAID-MONITOR TEST IS UNAFFECTED BY GEOGRAPHICAL... (2*)
Mo1789. . . . DIAGNOSTIC ACCURACY OF FECAL LACTOFERRIN AND... (4*)[[Repha GmbH biologische Arzneimittel TechLab Inc
Mo1790. . . . FAecal CALPROTECTIN CONCENTRATION IN INFLAMMATORY BOWEL... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1811. . . . RAPID POINT-OF-CARE ANTIDRUG ANTIBODIES MEASUREMENT CORRELATES... (2*) (1)
Mo1812. . . . CONSIDERATION OF SERUM IGA IN PATIENTS... (5*)
Mo1813. . . . BOTH FECAL IMMUNOCHEMICAL BLOOD TEST AND... (3*)
Mo1814. . . . A COMBINED SET OF FOUR SERUM... (5*)
Mo1815. . . . MODIFIED GLASGOW PROGNOSTIC SCORE IS USEFUL... (5*)
Mo1816. . . . PREDICTION OF ENDOSCOPIC ACTIVITY IN PATIENTS... (5*)
Mo1817. . . . RESPONDER DEFINITIONS FOR THE ULCERATIVE COLITIS... (3*) (Nordic Bioscience A/S)
Mo1818. . . . TARGETED LIPOIDOMIC ANALYSIS OF THE PLA... (5*)
Mo1819. . . . PERFORMANCE OF NOVEL MYCOBACTERIAL DETECTION TEST... (5*)
Mo1820. . . . MONITORING INFLAMMATORY ACTIVITY IN CROHN’S DISEASE... (5*)
Mo1821. . . . THE UTILITY OF MONITORING AS... (5*)
Mo1822. . . . ELEVATED ECTODOMAIN OF TYPE 23 COLLAGEN... (5*) (S. Sun, J.H. Mortensen, M.L. Olesen, M.A. Karsdal and T. Manon-Jensen are employed at Nordic Bioscience A/S which is a company involved in discovery and development of biochemical biomarkers. M.A. Karsdal and T. Manon-Jensen owns stocks at Nordic Bioscien)
Mo1823. . . . ENDOSCOPIC PATTERNS AND LOCATION OF POST-OPERATIVE... (2*)
Mo1824. . . . HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES... (5*) (Statistical analyses performed by Robarts Clinical Trials Inc.)
Mo1825. . . . FECAL CALPROTEIN (FCAL) MONITORING IN ASYMPTOMATIC... (5*)
Mo1826. . . . HOLD THE MAYO, ARE ENDOSCOPISTS TAKING... (5*)
Mo1827. . . . CUMULATIVE HISTOLOGIC INFLAMMATION PREDICTS COLORECTAL NEOPLASIA... (5*)
Mo1828. . . . HISTOLOGIC DISEASE ACTIVITY AT SURGICAL RESECTION... (5*)
Mo1829. . . . DEGRADATION AND FORMATION OF TYPE III... (5*)
Mo1830. . . . SEROLOGICAL BIOMARKERS OF TYPE VI COLLAGEN... (3*) (Nordic Bioscience A/S)
Mo1831. . . . MMP-2 AND -8 DEGRADED AND CITRULLINATED-VIMENTIN... (2*) (The assessment of VICM is done by and at the expense of Nordic Bioscience.)
Mo1832. . . . AN INVERSE CORRELATION OF SERUM FIBROBLAST... (4*)
Mo1833. . . . CAPSULE ENDOSCOPY IMPACT ON THERAPEUTIC DECISIONS... (5*)
Mo1834. . . . VALIDATION OF AN INTEGRAL DISEASE INDEX... (4*)
Mo1835. . . . THE DEVELOPMENT OF A NON-INVASIVE ULTRASONOGRAPHIC... (5*)
Mo1836. . . . CAN CROHN’S PATIENTS BE ACCURATELY PHENOTYPED... (2*)
Mo1837. . . . EFFECT OF UPAADICITINIB ON EXTRA-INTESTINAL MANIFESTATIONS... (3*) (The authors and AbbVie scientists designed the study, and aysled and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the study)
Mo1838. . . . CROHN’S DISEASE HAS AN INCREASED RISK... (5*)
Mo1839. . . . RISK FACTORS FOR ACUTE VENOUS THROMBOEMBOLISM... (5*)
Mo1840. . . . INCIDENCE OF ADVERSE PSYCHIATRIC EFFECTS OF... (2*)
Mo1841. . . . SAFETY AND EFFICACY OF ENDOSCOPIC DILATION... (5*)
Mo1842. . . . RELATIVE HAZARD OF CHRONIC KIDNEY DISEASE... (2*)
Mo1843. . . . A SIGNIFICANT DECLINE IN COLECTOMY RATES... (5*)
Mo1844. . . . LONG-TERM FATE OF THE EXCLUDED RECTUM... (5*)
Mo1845. . . . INCREASED RISK OF ADVANCED NEOPLASIA IN... (5*)
Mo1846. . . . ULCERATIVE COLITIS (UC) PATIENTS WITH PRIMARY... (4*)
Mo1847. . . . NUTRITIONAL INDICATORS AND POSTOPERATIVE OUTCOMES IN... (5*)
Mo1848. . . . EXTRAINTESTINAL MANIFESTATIONS AND THEIR IMPACT ON... (3*) (Pfizer Inc)
Mo1849. . . . LONG-TERM OUTCOMES OF STEROID-RESPONSIVE AND NON-RESPONSIVE... (5*)
Mo1850. . . . PREOPERATIVE ANTI-TNFα ARE ASSOCIATED WITH A... (5*)
Mo1851. . . . THE TREATMENT OF PERIANAL FISTULAS BY... (5*)
Mo1852. . . . INVESTIGATION OF CORRELATION BETWEEN POUCH WALL... (5*)
Mo1853. . . . OPPORTUNISTIC INFECTIONS IN INFLAMMATORY BOWEL DISEASE... (5*)
Mo1854. . . . WEEKEND DISCHARGES AND HOSPITAL READMISSIONS FOR... (5*)
Mo1855. . . . HOSPITALIZATION OUTCOMES FOR INFLAMMATORY BOWEL DISEASE... (5*)
Mo1856. . . . BIG DATA ANALYTICS IDENTIFIES ULCERATIVE COLITIS... (2*)
Mo1857. . . . 7ALPHA-HYDROXY-4-CHOLESTEN-3-ONE FOR DIAGNOSIS AND MANAGEMENT OF... (5*)
Mo1858. . . . OUTCOMES OF ACUTE PANCREATITIS IN INFLAMMATORY... (5*)
Mo1859. . . . DOES A POSITIVE CLOSTRIDIODES DIFFICILE RESULT... (6*)
Mo1860. . . . PREGNANT WOMEN WITH IBD HAVE WORSE... (5*)
Mo1861. . . . THE RISK OF ECTOPI... (5*)
Mo1862. . . . NO INCREASED RATES OF ADVERSE IBD-RELATED... (5*)
Mo1863. . . . EXTRAINTESTINAL MANIFESTATIONS AND QUALITY OF LIFE... (3*) (The authors & AbbVie scientists designed the study, & aysled & interpreted the data. AbbVie funded the research & provided writing support. All authors contributed to the development of the content. The authors & AbbVie reviewed & approved the abstract; t)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Mo1915 | . . . LONG-TERM OUTCOMES OF INFLIXIMAB THERAPY FOR... (5*) |
| Mo1916 | . . . EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR... (5*) |
| Mo1917 | . . . USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES... (5*) |
| Mo1918 | . . . CAN WE STOP ANTI-TUMOUR NECROSIS FACTOR... (5*) |
| Mo1919 | . . . USTEKINUMAB EFFICIENCY AS A HIGHER-LINE THERAPY... (5*) |
| Mo1920 | . . . RESULTS OF INTERIM ANALYSIS OF A... (5*) |
| Mo1921 | . . . TNF-α INHIBITORS HAVE SIMILAR EFFECTIVENESS IN... (5*) |
| Mo1922 | . . . SUPPLEMENTATION WITH BUTYRATE PRODUCING BACTERIA REDUCES... (4*) |
| Mo1923 | . . . LONG-TERM SAFETY OF FECAL MICROBIOTA TRANSPLANTATION... (5*) |
| Mo1924 | . . . CLOSTRIDIUM BUTYRICUM PROMOTES LIGANDS RELEASE FROM... (5*) |
| Mo1925 | . . . TRANSGENERATIONAL IMPACTS OF ORAL PROBIOTICS ADMINISTRATION... (5*) |
| Mo1926 | . . . A SINGLE CENTER EXPERIENCE: FECAL MICROBIOTA... (5*) |
| Mo1927 | . . . CITROBACTER RODENTIUM INDUCES CD4+ TISSUE RESIDENT... (4*) |
| Mo1928 | . . . TOLL-LIKE RECEPTOR-2-MEDIATED ACCELERATION OF INTESTINAL MUCOSAL... (2*) |
| Mo1929 | . . . CANDIDA ALBICANS SC5314 INHIBITS NLRP3/NLRP6 INFLAMMASOME... (2*) |
| Mo1930 | . . . HARNESSING ANTI-INFLAMMATORY GUT BIOACTIVES TO MODULATE... (4*) |
| Mo1931 | . . . URINE METABOLOMIC SIGNATURES DIFFERENTIATE PREGNANCY FROM... (5*) |
| Mo1932 | . . . MECHANISTIC INSIGHT INTO BACTERIAL HTPG-HOST INTERACTIONS... (2*) |
| Mo1933 | . . . ASSOCIATION BETWEEN PRENATAL ANTIBIOTICS EXPOSURE AND... (5*) |

Mo1934 . . . UNEXPLAINED CHRONIC ABDOMINAL PAIN IN 50-YEAR-OLD... (5*)
Mo1939 . . . PERIPARTUM CLOSTRIDIOIDES DIFFICILE INFECTION AND ITS... (5*)
Mo1940 . . . CLOSTRIDIUM DIFFICILE INFECTION MIMICS INTESTINAL ACUTE... (5*)
Mo1941 . . . TREATMENT FOR REDUCING RECURRENCE OF C.... (5*)
Mo1942 . . . CLOSTRIDIUM DIFFICILE OF THE IDEAL POUCH... (5*)
Mo1943 . . . COLONOSCOPY-BASED FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY... (5*)
Mo1944 . . . ADHERENCE TO THE TESTING GUIDELINES FOR... (5*)
Mo1945 . . . THE INFLUENCE OF PETS ON RISK... (1*)
Mo1946 . . . RECONSTITUTION OF PREBIOTIC-DRIVEN HOST-MICROBE SYNTROPHY IN... (4*)
Mo1947 . . . TAXONOMIC AND FUNCTIONAL INTESTINAL DYSBIOSIS IN... (7*)
Mo1948 . . . GUT MICROBIOTA COMPOSITION AT DIAGNOSIS PREDICTS... (2*)
Mo1949 . . . DECREASED COMPLEXITY OF SERUM N-GLYCAN STRUCTURES... (4*)
Mo1950 . . . POSITIVE ENZYME IMMUNOASSAY (EIA) TOXIN TESTING... (4*)
Mo1951 . . . FECAL MICROBIOTA TRANSPLANT DECREASES MORTALITY IN... (5*)
Mo1952 . . . EFFICACY OF ORAL VANCOMYCIN PROPHYLAXIS FOR... (5*)
Mo1953 . . . GROWTH INHIBITION OF CLOSTRIDIODES DIFFICILE BY... (4*)
Mo1954 . . . FECAL MICROBIOTA TRANSPLANTATION IS SAFE AND... (5*)
Mo1955 . . . VE303, A LIVE BIOTHERAPEUTIC PRODUCT FOR... (3*) [(Vedanta Biosciences Inc.)]
Mo1956 . . . CONSTIPATION IS A COMPLICATION OF ORAL... (5*)

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1977. . . . THE EFFECT OF ANTI-INFLAMMATORY PROPERTIES OF... (5+)
Mo1978. . . . OUTCOMES OF FECAL MICROBIOTA TRANSPLANTATION FOR... (5+)
Mo1979. . . . HOSPITAL-ONSET CLOSTRIDIUM DIFFICILE INFECTION... (5+)
Mo1980. . . . VOLUME OF FECAL FILTRATE FOR FECAL... (5+)
Mo1981. . . . ETIOLOGIES, TRENDS AND SHORT-TERM OUTCOMES OF... (5+)
Mo1982. . . . GENDER DIFFERENCES IN FECAL BACTERIOME AND... (4+)
Mo1983. . . . THE UTILITY OF IGA BASED SEROLOGIC... (5+)
Mo1984. . . . SYMPTOM PROFILES, GLUTEN FREE DIET ADHERENCE,... (5+)
Mo1985. . . . MINIMALLY-INVASIVE MONITORING OF INTESTINAL VILLOUS HEALTH... (3+)
Mo1986. . . . LATIGLUTENASE IMPROVES QUALITY OF LIFE IN... (3*)|Immunogenics LLC (dba ImmunogenX))
Mo1987. . . . RESPONDER ANALYSIS FOR LATIGLUTENASE REDUCTION IN... (3+)
Mo1988. . . . USE OF CLADIRIBINE FOR UCERATIVE JEJUNITIS... (5+)
Mo1989. . . . ASSESSMENT OF NOVEL CANDIDATE BIOMARKERS OF... (4+)
Mo1990. . . . ADHERENCE TO THE GLUTEN-FREE DIET AND... (3*)|Takeda Pharmaceutical Company
Mo1991. . . . CO-LOCALISATION OF IGA AND IGG ANTI-TISSUE... (4*)
Mo1992. . . . SOLVING THE STAIN DILEMMA: COMPUTATIONAL IMAGE... (4*)
Mo1993. . . . HEALTHCARE UTILIZATION AND COMORBIDITIES AMONG PEOPLE... (5*)
Mo1994. . . . IS THE INCREASE IN CELIAC DISEASE... (5*)
Mo1995. . . . THE POSITIVE AND NEGATIVE RIPPLE-EFFECT OF... (4*)
Mo1996. . . . ASSESSING SEVERITY AND HEALTHCARE RESOURCE UTILIZATION... (3*)|Takeda Pharmaceuticals International Co.
Mo1997. . . . ACUTE PANCREATITIS WITH CELIAC DISEASE: HAS... (5*)
Mo1998. . . . CELIAC AUTOIMMUNITY AND PREGNANCY OUTCOMES... (5*)
Mo1999. . . . PREVALENCE OF CELIAC DISEASE (CD) IN... (5*)
Mo2000. . . . INCIDENCE OF CELIAC DISEASE IS INCREASING... (6*)
Mo2001. . . . EPIDEMIOLOGY OF PATIENTS ADMITTED FOR CELIAC... (5*)
Mo2002. . . . CELIAC DISEASE: ENHANCING EDUCATIONAL SUPPORT FOR... (5*)
Mo2003. . . . COMPARISON OF QUALITY OF CELIAC DISEASE... (5*)
Mo2004. . . . HOW ARE CELIAC DISEASE PATIENTS FOLLOWED... (5*)
Mo2005. . . . ASSESSMENT OF PARENTAL GLUTEN-FREE DIET KNOWLEDGE... (6*)
Mo2006. . . . AN EDUCATIONAL APP TO SUPPORT THE... (6*)
Mo2007. . . . COMPARISON OF CELIAC DISEASE PATIENT SATISFACTION... (5*)
Mo2008. . . . BLENDERIZED DIETS ARE ASSOCIATED WITH IMPROVED... (5*)
Mo2009. . . . ASSOCIATION BETWEEN COLORECTAL ADENOMA AND NONALCOHOLIC... (2*)
Mo2010. . . . THE IMPACT OF ADJUSTABLE INTRAGASTRIC BALLOON... (2*)
Mo2011. . . . SMALL INTESTINAL MICROBIAL SHIFTS TOWARDS BILE-TOLERANT-ASSOCIATED-MICROBIOTA... (2*)|NIDDK r01 21769 NIDDK r01 29867
Mo2012. . . . HIGH-FAT DIET REDUCES BROWN ADIPOSE TISSUE... (2*)
Mo2013. . . . HEPATIC AGO2 IS INDISPENSABLE FOR NASH... (2*)
Mo2014. . . . COMPARATIVE EFFECTS OF BARSO2, A DUAL... (5*)
Mo2015. . . . THE ROLE OF SMALL INTESTINAL BACTERIA... (5*)
Mo2016. . . . THE TGF-β/SMAD3 ADAPTOR SPTBN1 AND ALDH2... (2*)
Mo2017. . . . ANTIMICROBIAL PEPTIDE ELAFIN REVERSES OBESITY, INSULIN... (2*)
Mo2018. . . . HEPATOCYTE-SPECIFIC OVEREXPRESSION OF FADS1 ATTENUATED DIETARY... (2*)
Mo2019. . . . DEFINING CLINICALLY SIGNIFICANT WEIGHT REGAIN AFTER... (5*)
Mo2020. . . . CHARACTERISTICS OF A CASH-PAY GI-BASED MEDICAL... (5*)
Mo2021. . . . NUMBER OF FOLLOW-UP VISITS IS INDEPENDENTLY... (5*)
Mo2022. . . . WEIGHT LOSS ADVICE FOR FATTY LIVER... (5*)
Mo2023. . . . ASSOCIATION BETWEEN OBESITY AND RISK OF... (5*)
Mo2024. . . . OBESITY PROLONGS HOSPITALIZATION IN CHRONIC PANCREATITIS... (5*)
Mo2025. . . . COLORECTAL CANCER SCREENING RATES ARE LOWER... (4*)
Mo2026. . . . EFFECTIVENESS OF ANTI-OBESITY MEDICATIONS IN "REAL... (2*)
Mo2027. . . . HIGH STRESS LEVEL IS ASSOCIATED WITH... (5*)
Mo2028. . . . A STRUCTURED, COMPREHENSIVE LIFESTYLE INTERVENTION PROGRAM... (5*)
Mo2029. . . . OCTREOTIDE AMELIORATES OBESITY-INDUCED PANCREATIC STEATOSIS VIA... (5*)
Mo2030. . . . COST-EFFECTIVENESS OF EARLY INITIATION AND/OR MORE... (4*)
Mo2031. . . . A FUNCTIONAL SCREENING APPROACH FOR ANTI-OBESITY... (4*)
Mo2032. . . . INTESTINAL ELECTRICAL STIMULATION ALTERS HYPOTHALAMIC EXPRESSIONS... (2*)
Mo2041. . . . ARTIFICIAL INTELLIGENCE AUGMENTS REAL-TIME HISTOLOGY OF... (2*)
Mo2042. . . . CHROMOENDOSCOPY Reduces the Subsequent Risk of... (4*)
Mo2043. . . . IMAGE ENHANCED ENDOSCOPY DOES NOT IMPROVE... (5*)
Mo2044. . . . 0.02 VITAMIN C SOLUTION SPRAY FOR... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo2045. . . MACHINE-LEARNING-BASED AUTOMATIC DIAGNOSTIC SYSTEM USING LINKED... (5*)
Mo2046. . . AUTOMATED REAL TIME ENDOSCOPIC SCORING BASED... (5*)
Mo2047. . . AUTOMATED DETECTION OF ABDOMINAL FREE FLUID... (5*)
Mo2048. . . UNSUPERVISED MACHINE LEARNING BASED AUTOMATIC DEMARCATION... (5*)
Mo2049. . . AUGMENTING GASTROINTESTINAL HEALTH: A DEEP LEARNING... (5*)
Mo2050. . . NOVEL COMPUTER-ASSISTED DETECTION SYSTEM OF COLORECTAL... (3*)
Mo2051. . . AUTOMATED COMPUTER DETECTION OF COLONOSCOPY COMPLETION... (5*)
Mo2052. . . APPLICATION OF MACHINE LEARNING AND ARTIFICIAL... (7*)
Mo2053. . . PRE-PROCEDURAL ASSESSMENT OF THE FASTING STATE... (5*) [(The eNose Company, Zutphen, NL, provided Aeionose device for study but no funding.)
Mo2054. . . A SEMI-SUPERVISED BLEEDING DETECTION METHOD IN... (3*)]
Mo2055. . . A NATURAL LANGUAGE BASED TOOL IMPROVES... (5*)
Mo2056. . . PERORAL ENDOSCOPIC MYOTOMY: EFFECTS OF THE... (5*)
Mo2057. . . INITIAL NORTH AMERICAN EXPERIENCE WITH ENDOSCOPIC... (4*)
Tu1000. . . CHRONIC LIVER DISEASE IS ASSOCIATED WITH... (5*)
Tu1001. . . PERFORMANCE OF THE VETERAN'S CHOICE PROGRAM... (5*)
Tu1002. . . WEEKEND ADMISSIONS FOR ACUTE CHOLANGITIS: IMPORTANCE... (5*)
Tu1003. . . CHARACTERIZING LOW-VALUE PPI USE AMONG OLDER... (4*)
Tu1004. . . FRAGMENTED CARE IS PREVALENT AMONG PATIENTS... (5*)
Tu1005. . . ANESTHESIA ROLE IN HOSPITALIZATION FOR PNEUMONIA... (3*) [(Mediators)]
Tu1006. . . DEVELOPMENT OF AN EVIDENCE-BASED STRATEGY INCORPORATING... (4*)
Tu1007. . . PATIENT-INITIATED ELECTRONIC MESSAGING WITH PHYSICIANS IS... (5*)
Tu1008. . . PROXIMAL NEOPLASIA YIELD AMONG SUBJECTS REFERRED... (2*)
Tu1009. . . TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL, NON-INVASIVE,... (2*)
Tu1010. . . VALIDATION OF A STOOL-DERIVED EUKARYOTIC RNA (3*) [(Geneoscopy)]
Tu1011. . . CHARACTERISTICS OF INDIVIDUALS UNDERGOING FIT FOR... (5*)
Tu1012. . . LOW RATES OF METACHRONOUS ADVANCED NEOPLASIA... (4*)
Tu1013. . . ARE OUT-OF-POCKET COSTS UNDER MEDICARE A... (1*)
Tu1014. . . ABERRANT CRYPT FOI PREDICT RISK OF... (5*)
Tu1015. . . MULT-TARGET STOOL DNA TESTING: YIELD AS... (4*)
Tu1016. . . COLORECTAL CANCER SCREENING: HOLES AND HOPE... (5*)
Tu1017. . . PREVALENCE OF COLONIC POLYPS IN END-STAGE... (5*)
Tu1018. . . SHOULD SCREENING FOR COLORECTAL CANCER START... (5*)
Tu1019. . . INCREASING PREVALENCE OF SSSE SERRATED POLYP... (5*)
Tu1020. . . UNDERUTILISATION OF RESOURCES FOR COLORECTAL CANCER... (5*)
Tu1021. . . DISTANCE OF TRAVEL TO THE SITE... (5*)
Tu1022. . . QUALITY OF BOWEL PREPARATION AMONG PATIENTS... (5*)
Tu1023. . . ADDITIONAL INTESTINAL MUCOSAL BIOPSY SAMPLING FOR... (5*)
Tu1024. . . ESOPHAGEAL MANOMETRY COMPETENCY PROGRAM IMPROVES PERFORMANCE... (5*)
Tu1025. . . FACTORS CONTRIBUTING TO ENTRUSTMENT DECISIONS IN... (7*)
Tu1026. . . IMPACT OF SPECIFIC TEACHING STRATEGIES ON... (5*)
Tu1030. . . A LOOK AT HOW ENDCUFF AFFECTS... (5*)
Tu1031. . . BEST PRACTICES IN TEACHING ENDOSCOPY: A... (5*)
Tu1032. . . DOES MENTORSHIP IMPACT TRAINEE PARTICIPATION IN... (5*)
Tu1033. . . A SNAPSHOT OF WOMEN IN GASTROENTEROLOGY... (5*)
Tu1034. . . PROXIMAL SERRATED POLYP DETECTION RATE IS... (5*)
Tu1035. . . IMPACT OF PATIENT EDUCATION ON SWITCH... (1*)
Tu1036. . . ENSURING JUDICIOUS PPI USE THROUGH AN... (5*)
Tu1037. . . ADDRESSING THE GENDER DIVIDE: FEMALE GASTROENTEROLOGISTS... (5*)
Tu1038. . . SOCIAL INFLUENCES ON CAREER CHOICES IN... (4*)
Tu1039. . . WHY NOT BE A LEADER? CHARACTERISTICS... (5*)
Tu1040. . . EXPERIENCED ENDOSCOPY TEACHERS USE TEACHING STRATEGIES... (5*)
Tu1041. . . ELECTRONIC CASE-BASED GI BLEEDING MODULE IMPROVES... (5*)
Tu1042. . . INNOVATIVE INSTRUCTIONAL STRATEGIES FOR INCORPORATING THE... (5*)
Tu1043. . . GASTROENTEROLOGY FELLOWS HAVE SIMILAR POLYP, ADENOMA... (5*)
Tu1044. . . WORK-LIFE CONFLICT AND ITS HEALTH EFFECTS... (4*)
Tu1045. . . TEACHING THE "FOUR-POSITION METHOD" MAKES BEGINNER... (5*)
Tu1046. . . KNOWLEDGE AND PRESCRIBING PATTERNS OF INTERNAL... (5*)
Tu1047. . . FOOD FOR THOUGHT: GASTROENTEROLOGY FELLOW AND... (5*)
Tu1144. . . CELLULAR SIGNALING CASCADES FOR ACTIVATION OF... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIB, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1145. . . . INDUCTION OF LIVER AUTOPHAGY AMELIORATES IMPAIRED... (3) (Tsumura & Co.)
Tu1146. . . . SCHLAFEN 3 KNOCKOUT MICE DISPLAY GENDER-SPECIFIC... (5*)
Tu1147. . . . NPT2B, A TYPE II SODIUM-PHOSPHATE COTRANSPORTER,... (2*)
Tu1148. . . . MICROFLUIDIC ORGANOTYPIC SYSTEM FOR THE ANALYSIS... (4*)
Tu1149. . . . IDENTIFYING FUNCTIONAL PATHWAY ASSOCIATIONS BETWEEN GENE... (2*)
Tu1150. . . . INSULIN PROMOTES THE INVASION AND MIGRATION... (2*)
Tu1151. . . . HUMAN MYOFIBROBLASTS SUPPORT PROLIFERATION OF INTESTINAL... (5*)
Tu1152. . . . CORDYCEPIN INDUCES G2/M PHASE ARREST AND... (2*)
Tu1153. . . . REGULATION OF KETOGENESIS BY WNT/β-CATENIN/PPARY SIGNALING... (2*)
Tu1154. . . . TROP2 UPREGULATION IN MOUSE PRE-NEOPLASTIC STOMACH... (2*)
Tu1155. . . . EXPRESSION OF GCRG213, LINE-1 ENDONUCLEASE VARIANT,... (2*)
Tu1156. . . . EVALUATION OF SERUM TFF3 LEVELS IN... (5*)
Tu1157. . . . ANALYSIS OF GASTRIC POLYPS FROM WESTERN... (5*) (NIL)
Tu1158. . . . GENOME-WIDE ANALYSIS FOR GASTRIC ADENOCARCINOMA-SPECIFIC H.PYLORI... (2*)
Tu1159. . . . BLOOD M QTL EFFECTS ARE CONSISTENT DURING... (6*)
Tu1160. . . . GENE EXPRESSION SIGNATURE OF THE "POINT"... (4*)
Tu1161. . . . A PROTOCOL FOR LIVE-FACS FROM CRYOPRESERVED... (2*)
Tu1162. . . . USING TRANSCRIPTOMICS TO SUBCLASSIFY ULCERATIVE COLITIS... (6*)
Tu1163. . . . HISTONE DESACYTYLASE 2 FAVORS AEC INVASION... (4*)
Tu1164. . . . SHARED GENETIC MUTATIONS ARE FOUND IN... (2*)
Tu1169. . . . SEX MODERATES THE RELATION BETWEEN NAUSEA... (2*)
Tu1170. . . . HOSPITAL ADMISSIONS AND TREATMENT COST OF... (5*)
Tu1171. . . . IS THE CONCLUSIVE EVIDENCE FOR GERD... (5*)
Tu1172. . . . INCOMPLETE RESPONSE OF SYMPTOMS OF GASTROESOPHAGEAL... (2*)
Tu1173. . . . ESOPHAGEAL MUCOSAL INTEGRITY IS UNCHANGED IN... (5*)
Tu1174. . . . RECLASSIFICATION OF PATIENTS WITH GASTROESOPHAGEAL REFUX... (5*)
Tu1175. . . . EVALUATION OF MINIMAL CHANGE LESION USING... (5*)
Tu1176. . . . SHORTER (48-HOUR) BRAVO PH MONITORING MAY... (5*)
Tu1177. . . . ESOPHAGEAL BASELINE IMPEDANCE FROM HIGH RESOLUTION... (5*)
Tu1178. . . . ASSOCIATION BETWEEN GASTROESOPHAGEAL JUNCTION MORPHOLOGY AND... (5*)
Tu1179. . . . A DISTINCT PATTERN OF RUMINATION SYNDROME... (4*)
Tu1180. . . . HIGH RESOLUTION MANOMETRY (HRM) EVALUATION OF... (5*)
Tu1181. . . . PROSPECTIVE STUDY OF A COHORT OF... (1*)
Tu1182. . . . HIGH RESOLUTION ESOPHAGEAL MANOMETRY RESULTS AFFECT... (5*)
Tu1183. . . . MEASUREMENT OF ESOPHAGEAL BASELINE IMPEDANCE: A... (1*)
Tu1184. . . . MUCOSAL IMPEDANCE PREDICTS ABILITY TO DISCONTINUE... (2*)
Tu1185. . . . PROLONGED (96 H) WIRELESS AMBULATORY ESOPHAGEAL... (5*)
Tu1186. . . . E-CADHERIN AND EPIDERMAL GROWTH FACTOR (EGF)... (4*)
Tu1187. . . . SYMPTOM RECOGNITION DURING AMBULATORY PH-IMPEDANCE MONITORING:... (5*)
Tu1188. . . . REFUX PATTERN AND ROLE OF IMPEDANCE-PH... (5*)
Tu1189. . . . A BRIEF MANOMETRIC INDEX FOR COMPREHENSIVE... (5*)
Tu1190. . . . POSTREFUX SWALLOW-INDUCED PERISTALTIC WAVE INDEX INDEPENDENTLY... (5*)
Tu1191. . . . BASELINE IMPEDANCE ON HIGH-RESOLUTION ESOPHAGEAL IMPEDANCE-MANOMETRY... (5*)
Tu1192. . . . CLINICAL UTILITY OF ADVANCED IMPEDANCE METRICS... (5*)
Tu1193. . . . IMPACT OF CHRONIC OPIATES ON ESOPHAGEAL... (5*)
Tu1194. . . . ESOPHAGOESOPHAGEAL JUNCTION DISTENSIBILITY IS NEARLY ALWAYS... (2*)
Tu1195. . . . 3D-PRESSURE TOPOGRAPHY OF THE ESOPHAGOESOPHAGEAL JUNCTION... (2*)
Tu1196. . . . IMPAIRED SWALLOW-INDUCED AXIAL ESOPHAGEAL SHORTENING/ LES... (2*)
Tu1197. . . . ENDOscopic INTRASPHERICTERIC INJECTION OF BOTOX IN... (2*)
Tu1198. . . . INEFFECTIVE ESOPHAGEAL MOTILITY IS ASSOCIATED WITH... (5*)
Tu1199. . . . ENDOSCOPIC MANAGEMENT OF ESOPHAGEAL SOFT FOOD... (5*)
Tu1200. . . . UTILIZING FUNCTIONAL LUMINAL IMAGING PROBE (FLIP)... (2*)
Tu1201. . . . CODEINE INDUCES MAJOR MOTILITY DISORDERS IN... (5*)
Tu1202. . . . KEY PARAMETERS OF ESOPHAGOESOPHAGEAL JUNCTION (EGJ)... (5*)
Tu1203. . . . PHARMACOLOGIC INTERROGATION OF PATIENTS WITH ESOPHAGEAL... (4*)
Tu1204. . . . MUSCLE LAYER FIBROSIS DO NOT REDUCE... (5*)
Tu1205. . . . EOSINOPHILS EXPRESSING TGF-B1 IN THE MUSCLE... (5*)
Tu1206. . . . DYSPHAGIA IS A COMMON CONSEQUENCE OF... (5*)
Tu1207. . . . THE CHICAGO CLASSIFICATION FREQUENTLY IDENTIFIES MANOMETRIC... (5*)
Tu1208. . . NORMAL PARAMETERS OF DISTENSION-INDUCED CONTRACTILITY ASSESSED... (2*)

Tu1209. . . CLINICAL, MANOMETRIC AND PSYCHOLOGICAL PROFILE OF... (5*)

Tu1210. . . ESOPHAGEAL PATHOLOGY IS THE LIKELY ETIOLOGY... (5*)

Tu1211. . . ESOPHAGOGRASTIC JUNCTION MEASURES FOLLOWING PER ORAL... (2*)

Tu1212. . . HIGH PREVALENCE OF DYSPHAGIA AND ASSOCIATED... (2*)

Tu1213. . . ACUTE ADMINISTRATION OF CODEINE HAS NO... (5*)

Tu1214. . . FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY (FLIP)... (5*)

Tu1215. . . COMPARISON OF SAFETY OF TREATMENT OPTIONS... (5*)

Tu1216. . . RAPID SEQUENCE CT SCAN IMAGING TO... (2*)

Tu1217. . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS... (5*)

Tu1218. . . ABERRANT STRIATED MUSCLE CONTRACTILITY IN SYMPTOMATIC... (2*)

Tu1219. . . MONTE CARLO SIMULATION CONFIRMS AGE-RELATED GROUP... (2*)

Tu1220. . . ACID EXPOSURE AND DYSPHAGIA IN SYMPTOMATIC... (5*)

Tu1221. . . LOW CLINICAL RELEVANCE OF CERVICAL INLET... (5*)

Tu1222. . . ESOPHAGEAL DYSPHAGIA OF ASIAN PEOPLE WITH... (5*)

Tu1223. . . EFFECTIVENESS OF N-ACETYLCYSTEINE ON THE TREATMENT... (5*)

Tu1224. . . DEPRESSION OF HYDROGEN SULFIDE SYNTHESIS ENZYMES... (5*)

Tu1225. . . HYPERCONTRACTILE MOTILITY DISORDERS OF THE ESOPHAGUS... (5*)

Tu1226. . . FACTORS ASSOCIATED WITH SPASTIC ESOPHAGEAL DISORDERS... (5*)

Tu1227. . . EFFICACY OF PER-ORAL ENDOSCOPIC MYOTOMY FOR... (5*)

Tu1228. . . ACACHALASIA QUALITY OF LIFE SCORE AND... (5*)

Tu1229. . . IMPAIRED ESOPHAGOGRASTIC JUNCTION RECESSIVE RELAXATION PLAYS... (5*)

Tu1230. . . CLINICAL OUTCOME AFTER SINGLE HYDRAULIC ESOPHAGUS (1*)

Tu1231. . . DIFFERENCES IN TRANSABDOMINAL ULTRASONOGRAPHIC PARAMETERS AMONG... (4*)

Tu1232. . . DISTAL ESOPHAGEAL DYSMOTILITY AND BOLUS CLEARANCE... (5*)

Tu1233. . . RAPID DRINKING CHALLENGE MAY HELP DISTINGUISH... (2*)

Tu1234. . . CROSS-SECTIONAL IMAGING IN PATIENTS WITH ESOPHAGOGRASTIC... (4*)

Tu1235. . . CLINICAL UTILITY OF HIGH-RESOLUTION ESOPHAGEAL MANOMETRY... (5*)

Tu1236. . . PATHOPHYSIOLOGICAL MECHANISMS ASSOCIATED WITH SUPRAGASTRIC BELCHING... (5*)

Tu1237. . . ESOPHAGEAL ACID SENSITIVITY IN PATIENTS WITH... (4*)

Tu1238. . . THE TRANSITION ZONE AND DYSPHAGIA: A... (2*)

Tu1239. . . ESOPHAGEAL HYPERVIGILANCE AND VISCERAL ANXIETY ARE... (2*)

Tu1240. . . ASSESSMENT OF ESOPHAGEAL BOLUS TRANSIT AND... (5*)

Tu1241. . . EFFECTS OF STRENGTH TRAINING ON DEGLUTITITIVE... (2*)

Tu1242. . . DEGLUTITITIVE STRIATED MUSCLE ENSEMBLE CONTRACTILITY INDICES:... (2*)

Tu1243. . . SUSTAINED ESOPHAGEAL CONTRACTIONS ON FUNCTION LUMINAL... (5*)

Tu1244. . . SWALLOWING AGAINST LARYNGEAL RESTRICTION (SLAR) EXERCISE... (2*)

Tu1245. . . INITIAL GAINS BY SWALLOWING AGAINST LARYNGEAL... (2*)

Tu1246. . . HIGH RESIDUAL UPPER ESOPHAGEAL SPHINCTER PRESSURE... (5*)

Tu1247. . . ASSOCIATION OF NON-DYSPHAGIA SYMPTOMS AND UPPER... (5*)

Tu1248. . . THE EFFICACY OF FLUOXETINE FOR TREATMENT... (5*)

Tu1249. . . AUTOLOGOUS HAEMATOPOETIC STEM CELL TRANSPLANT (HSCT)... (5*)

Tu1250. . . TOTAL DAILY OPIOID DOSE IS ASSOCIATED... (2*)

Tu1251. . . EFFECT OF ACUTE ESOPHAGEAL ACID EXPOSURE... (2*)

Tu1252. . . TOPOGRAPHICAL PLOTS OF ESOPHAGEAL DISTENSION AND... (2*)

Tu1253. . . VASCULAR PRESSURE BANDS ON HIGH RESOLUTION... (5*)

Tu1254. . . ASSOCIATION BETWEEN MEDICATION USE AND GERD... (5*)

Tu1255. . . THE EFFICACY OF TOPICAL LIDOCAINE IN... (5*)

Tu1256. . . DEEP LEARNING FOR ESOPHAGEAL MANOMETRY... (5*)

Tu1257. . . ESOPHAGEAL HISTOPATHOLOGIC PATTERNS IN PATIENTS UNDERGOING... (5*)

Tu1258. . . MAST CELL INFLTRATION ASSOCIATED WITH LOSS... (2*)

Tu1259. . . YIELD OF ENDOSCOPIC ULTRASOUND AND COMPUTED... (5*)

Tu1260. . . UPRIGHT AND SUPINE INTEGRATED RESIDUAL PRESSURE... (5*)

Tu1261. . . PHARYNGEAL PRESSURIZATION SEEN ON PHARYNGEAL SCREENING... (5*)

Tu1262. . . THE EFFECT OF AGING ON ESOPHAGO-UES... (2*)

Tu1263. . . VARIATION OF BASAL UES PRESSURE WITHIN... (2*)

Tu1264. . . INTER-OBSERVER AGREEMENT FOR ANALYSIS OF FUNCTIONAL... (2*)

Tu1265. . . COMPARING REAL-TIME VS POST-PROCESSING DATA IN... (5*)

Tu1266. . . PROSPECTIVE EVALUATION OF THE CLINICAL RESPONSE... (5*)

Tu1267. . . RELATIONSHIP BETWEEN UPPER ESOPHAGEAL PRESSESSURES AND... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Tu1268 | ... INCOMPLETE ESOPHAGEAL BOLUS CLEARANCE IS ASSOCIATED... (5*) |
| Tu1269 | ... INCOMPLETE BOLUS CLEARANCE CONTRIBUTES TO SEVERITY... (5*) |
| Tu1270 | ... CONTROL OF ESOPHAGEAL SECONDARY PERISTALSIS BY... (4*) |
| Tu1271 | ... APPLICATION OF A NOVEL LEG ELEVATION... (4*) |
| Tu1272 | ... IMPACT OF GABA-B AGONIST BACLOFEN ON... (4*) |
| Tu1273 | ... ELEVATION OF BASAL EGJ PRESSURE IS... (5*) |
| Tu1274 | ... IMPACT OF PATIENT POSITION ON ESOPHAGEAL... (5*) |
| Tu1275 | ... HEMATOLOGICAL INDICES IN ACHALASIA PATIENTS AND... (4*) |
| Tu1276 | ... DIAGNOSTIC ACCURACY OF AN ESOPHAGEAL SWEEP... (5*) |
| Tu1277 | ... ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION: DETERMINATION OF... (4*) |
| Tu1278 | ... UTILITY OF ESOPHAGEAL DUAL PH SENSORS-IMPEDE... (1*) |
| Tu1279 | ... CORRELATION OF NOVEL INFLAMMATORY-NUTRITIONAL BIOMARKERS WITH... (5*) |
| Tu1280 | ... PERFORMING MORE THAN TEN SWALLOWS DURING... (5*) |
| Tu1281 | ... UPPER ESOPHAGEAL SPHINCTER IS HYPTENSIVE IN... (5*) |
| Tu1282 | ... CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF... (5*) |
| Tu1283 | ... ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION ASSOCIATED WITH... (5*) |
| Tu1284 | ... SWALLOW-TO-SWALLOW VARIATION IN ESOPHAGEAL MOTOR PATTERNS... (5*) |
| Tu1285 | ... MANOMETRIC CHARACTERISTICS OF UPPER ESOPHAGEAL SPHINCTER... (2*) |
| Tu1286 | ... DURATION OF SYMPTOMS AND MANOMETRIC PARAMETERS... (5*) |
| Tu1287 | ... ESOPHAGEAL MOTILITY AND ANTI-REFLUX BARRIER FUNCTION... (5*) |
| Tu1288 | ... THE PREVALENCE OF DISACCHARIDASE DEFICIENCY IN... (5*) |
| Tu1289 | ... PILL ESOPHAGRAM CAN IDENTIFY PEDIATRIC PATIENTS... (5*) |
| Tu1290 | ... RELATIONSHIPS BETWEEN CLINICAL CHARACTERISTICS, TREATMENT, AND... (5*) |
| Tu1291 | ... VARIATIONS IN PRACTICE PATTERNS IN THE... (2*) |
| Tu1292 | ... ABNORMAL 24-HOUR PH-IMPEDE TESTING IS NOT... (4*) |
| Tu1305 | ... ASSOCIATION OF PHENOTYPES OF LOW MUCOSAL... (5*) |
| Tu1306 | ... PREVALENCE OF CANNABINOID USE DISORDER HAS... (5*) |
| Tu1307 | ... PHYSICAL ACTIVITY AND ITS IMPACT ON... (5*) |
| Tu1308 | ... POOR SLEEP QUALITY AND DYSPEPSIA: IT'S NOT... (5*) |
| Tu1309 | ... EFFECT OF RIKKUNSHTO ON GASTROINTESTINAL MOTILITY... (3*) |
| Tu1310 | ... EFFICACY AND SAFETY OF SOYO-SAN FOR... (2*) |
| Tu1311 | ... ENDOCOSCOPIC GASTRIC FUNCTION TEST: THE RELATIONSHIP... (4*) |
| Tu1312 | ... CAMOSTAT MESILATE, PANCRELIPASE AND RABEPRAZOLE COMBINATION... (1*) |
| Tu1313 | ... EATING AND PSYCHIATRIC DISORDERS ARE INDEPENDENT... (5*) |
| Tu1314 | ... CLASSIFYING FUNCTIONAL DYSPEPSIA USING A NOVEL... (5*) |
| Tu1315 | ... ACYLATED GHRELIN LEVELS WERE ASSOCIATED WITH... (1*) |
| Tu1316 | ... DOES MEASUREMENT OF SYMPTOMS DURING A... (5*) |
| Tu1317 | ... TOOSENADIN EXERTS ANTITUMOR ACTIVITY IN GASTRIC... (2*) |
| Tu1318 | ... PREDICTIVE FACTORS OF LYMPH NODE METASTASIS... (5*) |

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1651. . . TELEPHONE COUNSELING INTERVENTION IMPROVES UPTAKE OF... (4*)
Tu1652. . . COLORECTAL CANCER SCREENING AND PATIENT NAVIGATION:... (2*)
Tu1653. . . ACCURACY OF INITIAL RECOMMENDED COLONOSCOPY SURVEILLANCE... (2*)
Tu1654. . . THE EFFECT OF GENDER AND RACE... (5*)
Tu1655. . . THE LONG TERM IMPACT OF ROUX-EN-Y... (5*)
Tu1656. . . GASTRIC CANCER AND GEOGRAPHICAL/ETHNIC SHIFTS IN... (5*)
Tu1657. . . REGIONAL AND RACIAL DISPARITIES IN GASTRIC... (4*)
Tu1658. . . MECKEL’S DIVERTICULUM- A NIDUS FOR ILEAL... (4*)
Tu1659. . . ENDOMETRIAL POLYPS ARE MORE LIKELY TO... (2*)
Tu1660. . . INCREASING INPATIENT ADMISSIONS, COSTS, AND MORTALITY... (5*)
Tu1661. . . PREVALENCE, IN-HOSPITAL OUTCOMES AND RESOURCE UTILIZATION... (5*)
Tu1662. . . THE EPIDEMIOLOGY OF GASTRIC CANCER IN... (5*)
Tu1663. . . ANATOMICAL DISTRIBUTION OF GASTRIC CANCER IN... (5*)
Tu1664. . . DOES THE GEOGRAPHIC DISTRIBUTION OF THE... (5*)
Tu1665. . . TRISOMY 21 DOES NOT INCREASE THE... (5*)
Tu1666. . . ANALYSIS OF THE ASSOCIATION BETWEEN POVERTY... (5*)
Tu1667. . . RACIAL/ETHNIC DISPARITIES IN GASTRIC CANCER INCIDENCE,... (5*)
Tu1668. . . WHAT IS THE PREVALENCE OF SERRATED... (2*)
Tu1669. . . CHROMOENDOSCOPY LEADS TO A HIGHER INSIGHT-STAGE... (4*)
Tu1670. . . EXOGENOUS AND ENDOGENOUS ASSOCIATED FACTORS TO... (5*)

Tu1671. . . SMALL BOWEL NEOPLASIA DETECTION IN LYCH... (5*)
Tu1672. . . PREVALENCE OF GENE MUTATIONS IN PATIENTS... (4*)
Tu1673. . . SINGLE-GENE VS. MULTI-GENE PANEL TESTING IN... (5*)
Tu1674. . . POTENTIATION OF CALCIUM-ACTIVATED CHLORIDE SECRETION AND... (4*)
Tu1675. . . CLINICAL FEATURES OF RITUXIMAB-INDUCED GASTROINTESTINAL TOXICITIES... (5*)
Tu1676. . . NEUTROPENIC COLITIS - CLINICAL FEATURES, TREATMENT... (5*)
Tu1677. . . COMPARISON OF RISK FACTORS BETWEEN INTESTINAL... (5*)
Tu1678. . . FLUOROPYRIMIDINE-INDUCED INTESTINAL MUCOSAL INJURY IS ASSOCIATED... (1*)
Tu1679. . . BIFIDOBACTERIUM ANIMALIS SUBSPECIES LACTIS ENGINEERED TO... (5*)
Tu1680. . . ANTI-INFLAMMATORY AND ANTI-OXIDATIVE EFFECTS OF 17-β... (5*)
Tu1681. . . EFFECTS OF 17 β-ESTRADIOL ON COLORECTAL CANCER... (5*)
Tu1682. . . ELEVATED O-GLCNACYLATION INCREASES FOXM1 PROTEIN VIA... (4*)
Tu1683. . . CYSTATHIIONINE-GAMMA-LYASE EXPRESSING BONE MARROW-DERIVED CELLS INHIBIT... (2*)
Tu1684. . . THE PREVELANCE OF PRIMARY MALIGNANT NEOPLASM... (5*)
Tu1685. . . COLONOSCOPY IS INDICATED AFTER AN EPISODE... (5*)
Tu1686. . . EARLY ENDOSCOPIC EVALUATION ASSOCIATED WITH SHORTER... (5*)
Tu1687. . . PATIENT REPORTED MEASURES OF HEALTH STATUS... (3*) (This study was conducted with unrestricted funding from Celgene Corporation.)

Tu16708. . . EARLY CHILDHOOD INFLAMMATORY BOWEL DISEASE IS... (2*)
Tu1710. . . USTEKINUMAB TO TREAT PEDIATRIC PATIENTS WITH... (2*)
Tu1711. . . EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS... (3*) ([Eli Lilly and Company])
Tu1712. . . REDUCTION IN INFLAMMATORY BIOMARKERS IN A... (3*) ([Eli Lilly and Company])
Tu1714. . . IMPACT OF UPADACITINIB ON THE GENERAL... (3*) ([AbbVie funded the study, contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl])
Tu1715. . . A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB)... (3*)
Tu1716. . . HIGHLY BIOAVAILABLE CURCUMIN (THERACURMIN®) FOR CROHN’S... (5*)
Tu1717. . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE... (3*) ([Pfizer Inc])
Tu1718. . . IMMUNOGENICITY OF USTEKINUMAB IN PATIENTS WITH... (3*) ([This study was funded by Janssen Research & Development, LLC])
Tu1719. . . CLINICAL REMISSION BY LEGACY VERSUS FDA... (3*) ([This study was funded by Janssen Research & Development, LLC])
Tu1720. . . EFFICACY OF TOFACITINIB MAINTENANCE THERAPY FOR... (3*) ([Pfizer Inc])
Tu1721. . . MAINTENANCE OF EFFICACY FOLLOWING TOFACITINIB DOSE... (3*) ([Pfizer Inc])
Tu1722. . . DARVADASTROCEL TREATMENT OUTCOMES IN CROHN'S DISEASE... (3*) ([Takeda Pharmaceutical Company])
Tu1723. . . IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH... (3*) ([This study was funded by Janssen Research & Development, LLC])

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1724. . . . ASSOCIATION OF USTEKINUMAB SERUM CONCENTRATIONS AND... (3*)|Janssen Research & Development, LLC funded this study.)

Tu1725. . . . CHARACTERIZATION OF PATIENTS WITH DELAYED RESPONSE... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1726. . . . THE IMPACT OF EARLY DISEASE CONTROL... (3*)|(Takeda)

Tu1727. . . . RAPIDITY OF SYMPTOMATIC AND INFLAMMATORY BIOMARKER... (3*)|(The authors and AbbVie scientists designed the study, and alysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the)

Tu1728. . . . LONG-TERM EFFICACY AND PHARMACODYNAMICS OF THE... (3*)|(The OPERA II study was funded by Pfizer. These alyses were funded by Pfizer and Shire. Medical writing support was provided by Emma Saxon PhD of PharmaGenesis London and funded by Shire.)

Tu1729. . . . LONG-TERM EFFICACY OF TOFACITINIB IN PATIENTS... (3*)|(Pfizer Inc)

Tu1730. . . . IMPROVEMENT IN PATIENT-REPORTED INFLAMMATORY BOWEL DISEASE... (3*)|(Pfizer Inc)

Tu1731. . . . EARLY HISTOLOGIC IMPROVEMENT DEMONSTRATED WITH ORAL... (3*)|(This study is sponsored by Celgene Corporation.)

Tu1732. . . . CHANGES IN SIMPLIFIED ENDOSCOPIC SCORE FOR... (3*)|(AbbVie funded the study, contributed to its design, and was involved in the collection, alysis, and interpretation of the data, and in the writing, review, and approval of the publication. Medical writing support was provided by Maria Hovenden, PhD, Compl)

Tu1733. . . . CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMID... (3*)|(This study is sponsored by Celgene Corporation.)

Tu1734. . . . EFFECT OF VEDOLIZUMAB ON SURGICAL RATES... (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)

Tu1735. . . . EFFECTS OF USTEKINUMAB INDUCTION THERAPY ON... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1736. . . . MOLECULAR RESPONSE TO USTEKINUMAB IN MODERATE-TO-SEVERE... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1737. . . . EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL... (3*)|(The TURANDOT II study was funded by Pfizer and Shire. These alyses were funded by Shire. Medical writing support was provided by PharmaGenesis London and funded by Shire.)

Tu1738. . . . EFFICACY AND SAFETY OF USTEKINUMAB THROUGH... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1739. . . . EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH MODERATE... (3*)|(The study was funded by Janssen Research & Development, LLC)

Tu1740. . . . SUSTAINED REMISSION IN PATIENTS WITH MODERATE... (3*)|(The study was funded by Janssen Research & Development, LLC)

Tu1741. . . . A NOVEL ORAL FORMULATION OF BUDESONIDE... (3*)|(Dr. Falk Pharma GmbH)

Tu1742. . . . LONG-TERM IMMUNOGENICITY OF INTRAVENOUS VEDOLIZUMAB IN... (3*)|(Takeda)

Tu1743. . . . IV ORTMENT OF IRON DEFICIENCY... (3*)|(AMAG Pharmaceuticals, Inc.)

Tu1744. . . . TARGETED RELEASE ORAL CYCLOSPORINE (ST-0529) AS... (3*)

Tu1745. . . . CORRELATION OF FECAL CALPROTECTIN AND C-REACTIVE... (3*)|(Are Pharmaceuticals, Inc.)

Tu1746. . . . A PHASE 3 STUDY OF VEDOLIZUMAB... (3*)|(Takeda Pharmaceutical Company, Ltd.)

Tu1747. . . . EFFECT OF TELEMEDICINE FOR THE... (2*)|(This research was supported by the Agency for Healthcare Research and Quality (1R01HS018975-01A1) and the University of Maryland General Clinical Research Centers Program. Zaid Bilgrami was supported by the Program for Research Initiated by Students and)

Tu1748. . . . ORAL CURCUMIN IS NOT MORE EFFECTIVE... (2*)

Tu1749. . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF INTRAVENOUSLY... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1750. . . . NOVEL RIFAMYCIN SV MULTI-MATRIX FORMULATION FOR... (3*)|(Clinical study was funded by Dr. Falk Pharma GmbH.)

Tu1751. . . . THE EFFECT OF REMOTE ISCHEMIC CONDITIONING... (3*)|(Novo Nordisk Foundation)

Tu1752. . . . ANALYSIS OF HEMATOLOGICAL CHANGES IN TOFACITINIB-TREATED... (3*)|(Pfizer Inc)

Tu1753. . . . ANALYSIS OF THE IMPACT OF BODY... (3*)|(Pfizer Inc)

Tu1754. . . . SAFETY AND TOLERABILITY OF BT-11, A... (3*)|(Study was funded by Landos Biopharma, Inc.)

Tu1755. . . . EFFICACY OF COMBINATION THERAPY OF FECAL... (2*)

Tu1756. . . . THE TREATMENT NAIVE RECTAL TRANSCRIPTOME IDENTIFIES... (2*)

Tu1757. . . . FUNCTIONAL REGULATORY ANNOTATION OF FINE-MAPPED IBD... (2*)

Tu1758. . . . INFLAMMATORY BOWEL DISEASE TRANSCRIPTOMES REVEAL REDUCED... (4*)

Tu1759. . . . NEW METHYLATION BIOMARKER PANEL OF INFLAMMATORY... (5*)

Tu1760. . . . ALTERATIONS IN EXPRESSION QUANTITATIVE TRAIT LOCI... (2*)

Tu1761. . . . POLYGENIC RISK SCORES ARE ASSOCIATED WITH... (2*)

Tu1762. . . . GENETIC BACKGROUND OF THIOPURINE-INDUCED PANCREATITIS IN... (2*)

Tu1763. . . . SYSTEMIC AND TISSUE MODULATION OF IL-23... (3*)|(Boehringer Ingelheim and AbbVie funded the study and research. AbbVie provided medical writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the abstract. The authors maintained control over)}
Tu1815. . . . CONCENTRATION OF INFliximab in the Non-Inflamed... (2*) [(This study was partly supported by AMED (Japan Agency for Medical Research and Development) (160705148).]

Tu1816. . . . COMBINATION OF BIOMARKERS REFLECTING TYPE IV... (5*)

Tu1817. . . . INCREASING SUBCUTANEOUS FAT AND WEIGHT ARE... (2*)

Tu1818. . . . ULTRA-PROACTIVE THERAPEUTIC DRUG MONITORING INCORPORATING INFliximab... (5*) [(Mundipharma)

Tu1819. . . . SERUM MARKER PANEL FOR DETECTION OF... (3*) [(Kepler Diagnostics, Inc. purchased all analyzed ELISA kits)

Tu1820. . . . PROACTIVE INFliximab DRUG MONITORING IS SUPERIOR... (5*)

Tu1821. . . . PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF RADILOGICAL... (5*)

Tu1822. . . . IFX SERUM LEVELS AT TROUGH DO... (5*)

Tu1823. . . . THERAPEUTIC DRUG MONITORING-BASED OPTIMIZATION SHOULD BE... (5*)

Tu1824. . . . TROUGH LEVELS OF INFliximab BETTER CORRELATE... (5*)

Tu1825. . . . USTEKINUMAB THERAPEUTIC DRUG MONITORING IN CROHN’S... (5*)

Tu1826. . . . EVALUATION OF PREDICTORS OF DURABLE CLINICAL... (5*)

Tu1827. . . . MAINTENANCE LEVELS OF VEDOLIZUMAB DO NOT... (4*) [(Prometheus Laboratories)]

Tu1828. . . . ENHANCING UTILIZATION OF THERAPEUTIC DRUG MONITORING... [2]*)

Tu1829. . . . COMPARISON OF SERUM CONCENTRATIONS OF USTEKINUMAB... (5*)

Tu1830. . . . INFliximab AND ADAlimumab CONCENTRATIONS MAY VARY... (3*) [(This study was funded by Inform Diagnostics.)

Tu1831. . . . USE OF DRUG-TOLERANT ASSAYS IN INFLAMMATORY... (3*) [(Prometheus Laboratories who performed the drug/antibody assays)]

Tu1832. . . . ASSOCIATION OF VEDOLIZUMAB LEVELS WITH CLINICAL... (5*)

Tu1833. . . . WEEK 2 ADAlimumab LEVEL PREDICTS SHORT-TERM... (5*)

Tu1834. . . . A PROTOCOL FOR SAFE REINTRODUCTION OF... (5*)

Tu1835. . . . ASSOCIATION BETWEEN VEDOLIZUMAB TROUGH CONCENTRATION AND... (5*)

Tu1836. . . . INFliximab TROUGH LEVELS ARE NOT PREDICTIVE... (2*)

Tu1837. . . . DEVELOPING A NOVEL MEDICATION ADHERENCE INDEX... (5*)

Tu1838. . . . DOES SWITCHING BETWEEN 5-AMINOSALICYLATES AFFECT THIOPURINE... (5*)

Tu1839. . . . IMPACT OF USTEKINUMAB TDM ON CLINICAL... (3*)

Tu1840. . . . LOW DRUG LEVELS DURING INFliximab MAINTENANCE... (5*)

Tu1841. . . . COMPARATIVE ANALYSIS OF BLOOD AND MUCOSAL... (4*)

Tu1842. . . . NOVEL POPULATION SUBSETS OF TCRβH TH17... (5*)

Tu1843. . . . ACETYLCHOLINE SECRETING T-CELLS CONTRIBUTE TO INNATE... (3*) [(Galvani Bioelectronics unrestricted research grant)]

Tu1844. . . . DETERMINING PREDICTORS OF GASTROINTESTINAL DISEASE IN... (5*)

Tu1845. . . . IDENTIFICATION OF A UNIQUE POPULATION OF... (4*) [(This work was supported by the Gatorade Trust through funds distributed by the University of Florida, Department of Medicine.)

Tu1846. . . . HIGHER TNFα AND MIP-1β EXPRESSION IN... (4*)

Tu1847. . . . UREA-POSITIVE PROTEOBACTERIA IN CROHN’S DISEASE IDENTIFIED... (6*)

Tu1848. . . . ESCHERICHIA COLI SIDEROPHORE PRODUCTION INDUCES INTESTINAL... (2*)

Tu1849. . . . ROSEBURIA INTESTINALIS FLAGELLIN ALLEVIATES EXPERIMENTAL COLITIS... (2*)

Tu1850. . . . ADHERENT-INVASIVE ESCHERICHIA COLI IN INFLAMMATORY BOWEL... (2*)

Tu1851. . . . STUDY ON THE INFLAMMATORY MECHANISMS OF... (2*)

Tu1852. . . . METFORMIN AMELIORATES INFLAMMATORY BOWEL DISEASE BY... (2*)

Tu1853. . . . FAECALIBACTERIUM PRASUNITZII PRODUCES BUTYRATE TO DECREASE... (2*)

Tu1854. . . . ASSOCIATION BETWEEN QPCR ASSAYS TARGETING FIMS/FIMH... (3*) [(Enterome was the sponsor of the study)

Tu1855. . . . MICROBIOTA EXPOSURE IN EARLY LIFE IMPACTS... (2*)

Tu1856. . . . THE SIDEROPHORE YERSINIABACTIN POTENTIATES INFLAMMATORY BOWEL... (4*)

Tu1857. . . . NEONATAL SUPPLEMENTATION WITH A LACTOBACILLUS RHAMNOSUS... (2*)

Tu1858. . . . SEGMENTED FILAMENTOUS BACTERIA INDUCE ALTERNATIVE TH17... (2*)

Tu1859. . . . ALTERING DIETARY FERMENTABLE CARBOHYDRATE (FODMAP) CONTENT... (2*)

Tu1860. . . . THE OCCURRENCE OF UPPER GASTROINTESTINAL DISEASE... (5*)

Tu1861. . . . UNIDENTIFIED COCCOID BACTERIA (UCB) ARE ASSOCIATED... (5*)

Tu1862. . . . HISTAMINE IS IMPORTANT FOR MACROPHAGES ACTIVITIES... (2*)

Tu1863. . . . DIFFERENCES AMONG LUMINAL AND MUCOSAL MICROBIOTA... (4*)

Tu1867. . . . LNCRNAs TARGETED BY ENTERIC BACTERIAL INFECTION... (2*)

Tu1868. . . . THERAPEUTIC FECAL MICROBIOTA TRANSPLANTATION CONTROLS INTESTINAL... (6*)

Tu1869. . . . CHARACTERIZATION OF CROHN’S DISEASE MUCOSA-ASSOCIATED MICROBIOTA... (6*)

Tu1870. . . . ENDOBARRIER® IMPLANTATION IS ASSOCIATED WITH MARKED... (2*) [(NIDDK rO1 21769 NIDDK rO1 29867)]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Tu1871 | . . . THE ASSOCIATION BETWEEN ANTIBIOTICS EXPOSURE DURING APPENDECTOMY HAVE SIGNIFICANTLY MODULATE BIOPRODUCTS CONTRIBUTE TO (SELECTIVE MICROBIOTA) PROCTITIS TRANSPLANTATION INDUCES RADIATION REDUCE BACTERIAL DENSITY (CLOSTRIDIUM DIFFICILE INFECTION) KONG Medicine, The Chinese University of Hong Kong Research Center provided by the Faculty of Medicine, The Chinese University of Hong Kong | Tu1888 | . . . THE UTILITY OF MULTIPLEX GI PCR... (5*) | Tu1907 | . . . LIVER FIBROSIS STAGE AT BASELINE PREDICTS... (2*) |
| Tu1872 | . . . THE HUMAN INTESTINAL PROTEOME IN CHILDREN... (7*) | Tu1889 | . . . THE PROTECTIVE ANTIMICROBIAL ACTIVITY OF VSL#3... (5*) | Tu1908 | . . . EFFICACY OF PHARMACOTHERAPY IN THE TREATMENT... (5*) |
| Tu1873 | . . . BOWEL CLEANSING MAY AFFECT DIAGNOSTIC YIELD... (5*) | Tu1890 | . . . GASTRIC MICROBIOTA IN HELICOBACTER PYLORI-NEGATIVE AND... (2*) | Tu1909 | . . . ROUX-EN-Y GASTRIC BYPASS IMPROVES ESOPHAGEAL SYMPTOMS... (5*) |
| Tu1874 | . . . DETECTION OF ENTERIC INFECTIONS IN THE... (5*) | Tu1891 | . . . AUTOMATED MOLECULAR DETECTION OF HELICOBACTER PYLORI... (3*) [(This study was funded by AutoGenomics inc.)] | Tu1910 | . . . ESOPHAGITIS AFTER BARIATRIC SURGERY: LARGE CROSS-SECTIONAL... (4*) |
| Tu1875 | . . . CHRONIC ANTIBIOTIC USE AND SUBSEQUENT DEVELOPMENT... (2*) | Tu1892 | . . . COMPARISON OF HIGH AND LOW MOLECULAR... (2*) [(Small Grant Exploratory Research, Korea)] | Tu1911 | . . . BARIATRIC SURGERY IS ASSOCIATED WITH REDUCED... (5*) |
| Tu1876 | . . . FECAL MICROBIOTA TRANSPLANTATION FOR IMMUNE CHECKPOINT... (4*) | Tu1893 | . . . SPANISH SPECIALIST CARE SURVEY ON THE... (3*) [(Laboratories Casen Recordati, Spain.)] | Tu1912 | . . . WEIGHT LOSS AND METABOLIC IMPROVEMENTS ONE... (2*) [(GI Dymics provided training for the clinical staff.)] |
| Tu1877 | . . . FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR IRritable... (5*) | Tu1894 | . . . COLONIC MUCOSAL MICROBIOME IS ASSOCIATED WITH... (4*) | Tu1913 | . . . ‘TO DELAY OR NOT TO DELAY... (5*) |
| Tu1878 | . . . FECAL MICROBIOTA TRANSPLANTATION (FMT) IN IRritable... (5*) | Tu1895 | . . . COLONIC MUCOSAL MICROBIOME CORRELATES WITH DIETARY... (2*) | Tu1914 | . . . BODY COMPOSITION AS FOLLOW UP OF... (5*) |
| Tu1879 | . . . RAPID AND DURABLE ENGRAFTMENT OF DONOR... (4*) [(the funding source from Gut Microbiome Research Center provided by the Faculty of Medicine, The Chinese University of Hong Kong)] | Tu1896 | . . . ASTAXANTHIN ATTENUATED INTESTINAL HYPERMOTILITY INDUCED BY... (2*) | Tu1915 | . . . FEASIBILITY OF SERUM LIPIDOMICS AND FECAL... (2*) |
| Tu1880 | . . . DURABLE FREEDOM FROM CLOSTRIUM DIFFICILE INFECTION... (3*) [(This alysis was funded by Rebiotox Inc., Roseville, MN, USA.)] | Tu1897 | . . . ENTERIC METHANE OR HYDROGEN PRODUCTION IN... (2*) | Tu1916 | . . . ASSESSMENT OF NOVEL Plication Technique IN... (5*) |
| Tu1881 | . . . ECONOMIC EVALUATION OF A FECAL MICROBIOTA... (4*) | Tu1898 | . . . A COMPARISON OF PATIENTS WITH UNEXPLAINED... (2*) | Tu1917 | . . . IMPACTS OF LIRAGLUTIDE USE IN WEIGHT... (5*) |
| Tu1882 | . . . FECAL VIRUS-LIKE PARTICLES REDUCE BACTERIAL DENSITY... (6*) | Tu1899 | . . . MICROBIAL FECALIZATION OF THE SMALL INTESTINE... (2*) [(NIDDK r01 21769 NIDDK r01 29867)] | Tu1918 | . . . SEVERE NUTRITIONAL COMPLICATIONS AFTER BARIATRIC SURGERY... (4*) |
| Tu1883 | . . . SELECTIVE MICROBIOTA TRANSPLANTATION INDUCES RADIATION PROCTITIS... (1*)] | Tu1900 | . . . DOSE RESPONSE FOR ARGON PLASMA COAGULATION... (5*) | Tu1919 | . . . COMPLIANCE WITH EARLY POST-OPERATIVE FOLLOW-UP REDUCES... (4*) |
| Tu1884 | . . . PRE-TREAT WITH FAEAUBACTERIUM PRAUSNITZII PREVENT... THE... (2*) | Tu1901 | . . . LOW FREQUENCY VAGAL NERVE STIMULATION USING... (2*) | Tu1920 | . . . CHANGES IN QUALITY OF LIFE, BODY... (5*) |
| Tu1885 | . . . PROTECTIVE EFFECT OF SMT (SELECTIVE MICROBIOTA... (2*) | Tu1902 | . . . PROSPECTIVE STUDY INVESTIGATING CHANGES IN GASTRIC... (2*) | Tu2026 | . . . MIR-23B-3P PROMOTES CARCINOGENICITY THROUGH PETN/P3K/AKT PATHWAY... (2*) |
| Tu1886 | . . . COMMENSAL Derived BIOPRODUCTS CONTRIBUTE TO MODULATE... (2*) | Tu1903 | . . . A COMPARISON OF GASTRIC Plication ALONE... (5*) | Tu2027 | . . . GREATER LINE-1 HYPMETHYLATION IN TUBULAR ADENOMAS... (4*) |
| Tu1887 | . . . PATIENTS WITH APPENDECTOMY HAVE SIGNIFICANTLY LESS... (4*) | Tu1904 | . . . BARIATRIC SURGERY IS ASSOCIATED WITH INCREASED... (5*) | Tu2028 | . . . IDENTIFICATION OF 5-FUOROURACIL (5-FU) RESISTANCE-RELATED MICRORN... (4*) [(5)] |
| Tu1888 | . . . THE UTILITY OF MULTIPLEX GI PCR... (5*) | Tu1905 | . . . CHANGES IN METABOLIC AND INFLAMMATORY BIOMARKERS... (5*) | Tu2029 | . . . ESOPHAGEAL ADENOCARCINOMA WITH INTESTINAL METAPLASIA PHENOTYPE... (5*) |
| Tu1889 | . . . THE PROTECTIVE ANTIMICROBIAL ACTIVITY OF VSL#3... (5*) | Tu1906 | . . . 30 DAY READMISSION AFTER ROUX-EN Y... (5*) | Tu2030 | . . . NOVEL CIRCULAR RNA NF1 ACTS AS... (2*) |

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu2031. . . ITGBL1 PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION VIA THE... (4*)

Tu2032. . . ADDITION OF PRESERVATIVE BUFFER IMPROVES DNA... (4*) (Exact Sciences The Champions for Hope Foundation Florida Pancreatic Cancer Coalition)

Tu2033. . . QUANTITATION OF METHYLATION LOAD OF TUMOR... (2*)

Tu2034. . . FACTORS ASSOCIATED WITH PATHOLOGICAL COMPLETE RESPONSE... (4*)

Tu2035. . . NEUROTENSIN PROMOTES EPITHELIAL-MESENCHYMAL TRANSFORMATION VIA ERK... (2*)

Tu2036. . . A PATIENT SELF-MADE ONE STEP QUICK... (5*)

Tu2037. . . NOVEL GENOMIC ANALYSIS OF CENTRAL AMERICA... (2*)

Tu2038. . . LAPAROSCOPY-ASSISTED VERSUS ENTEROSCOPY-ASSISTED ENDOCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY... (5*)

Tu2039. . . GASTRIC PERORAL ENDOCOPIC PYLOROMYOTOMY (G-POEM) FOR... (5*)

Tu2040. . . PROSPECTIVE ASSESSMENT OF THE USE OF... (5*)

Tu2041. . . THE OUTCOME OF ENDOCOPIC MUCOSAL RESECTION... (5*)

Tu2042. . . INVESTIGATION OF POLYETHYLENE GLYCOL RECOVERY RATE... (5*)

Tu2043. . . EFFICACY AND SAFETY OF PERCUTANEOUS RENDEZ-VOUS... (5*)

Tu2044. . . SMALL BOWEL PREPARATION PRIOR TO VIDEO... (5*)

Tu2045. . . EFFICACY AND SAFETY OF NOVEL, DISPOSABLE... (5*)

Tu2046. . . CHOLEDOCHOSCOPE WITH STENT PLACEMENT FOR TREATMENT... (5*)

Tu2047. . . A TRANSNASAL IMAGING TUBE FOR UNSEDATED... (4*)

Tu2051. . . CANDIDATE AND EXPLORATORY GENETIC ASSOCIATION STUDY... (2*)

Tu2052. . . POTENTIAL NOVEL SEROLOGICAL MICRO-RNA MARKERS OF... (4*)

Tu2053. . . INFLAMMATORY BOWEL DISEASE IN CYSTIC FIBROSIS... (5*)

Tu2054. . . ACUTE PANCREATITIS IN PATIENTS WITH DOWN... (4*) (5)

Tu2055. . . CHARACTERIZATION OF GASTROINTESTINAL SYMPTOMS IN FABRY... (3*) (Sanofi Genzyme)

Tu2056. . . THE IMPACT OF METABOLIC SYNDROME (MS)... (5*)

---

Abstract Funding Source Key

* = Primary Source

- (1) = Clinical Practice Funds
- (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)
- (3) = Industry or Commercial Entity
- (4) = Institutional Funds
- (5) = No Study Funding
- (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)
- (7) = Professional Organization (e.g. AGA, AASLD, etc.)